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INTRODUCTION
Because of the complexity, plasticity and heterogeneity of malignant brain tumors 
such as glioblastoma and medulloblastoma, successful treatment of patients remains 
a challenge. While the 5-years’ survival of medulloblastoma is around 60% in adults 
and 75% in children, these patients do suffer from treatment-related side effects (1). 
Glioblastoma patients usually die within 18 months after diagnosis, despite optimal 
surgery, followed by chemoradiation therapy (2). 
In order to improve the treatment of brain tumors, we need to improve our understanding 
of their basic biology and to identify the molecular mechanisms that underlie brain tumor 
formation and initiation. Functional bioluminescence imaging is a tool that is able to study 
molecular regulatory processes in cells (3). We aimed to adapt this tool to image and 
quantify tumor heterogeneity and brain tumor cells in order to discover novel molecular 
pathways. In addition, we explored the possibility of using this method for the imaging of 
normal stem cell regeneration, using an explant model of spinal degeneration.
BRAIN TUMORS
Gl ioblastoma mult i forme
In The Netherlands, almost 1000 patients per year present themselves with a malignant 
glioma. Until now, gliomas where classified according to a World Health Organization 
(WHO) classification system based on classical phenotypic characteristics as observed 
in microscopic Hematoxilin-Eosin stained tissue sections (4). Adult gliomas have an 
incidence of 1000-1200 patients per year in The Netherlands of which glioblastoma 
multiforme (GBM), a WHO grade IV glioma, is the most common type (60% of gliomas). 
Glioblastoma therapy consists of surgery followed by radiotherapy and temozolomide 
chemotherapy, and increases life expectancy with 2-3 months (2) to a median survival 
of approximately 14.6 months and a two-years’ survival of 30% (2). Glioblastomas 
also arise in children, be it far less frequently, and are histologically indistinguishable 
from their adult counterparts, although they tend to do better than adults with a five-
years’ survival of 25%. Despite this histological similarity, the genetic background of 
pediatric glioblastoma is often very different (5).
In recent years, molecular classification has become more important as tumors are 
increasingly being classified by their genetic profile. Using genetic profiling, it has become 
clear that glioblastoma multiforme can be classified into four subtypes: The classical, 
mesenchymal, proneural and neural subtype (6). This has led to targeted therapies arising 
from functional analysis of cellular gene expression and protein contents (7–10). 
The molecular heterogeneity of glioblastoma may be the result of the transformation 
of aberrant neural precursor cells that function as brain cancer stem cells (11) or of 
dedifferentiation of cancerous glial cells or neurons (12). The clonal evolution of these 
mutated neural stem cells results in heterogeneous glioblastomas in which cells of 
all subtypes of GBM can arise (13).  Despite recent advances in our knowledge of 
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the molecular mechanisms of glioblastoma and its oncogenesis, there is still a need 
for tools to study functional and molecular tumor biology. Increased molecular 
understanding of glioblastoma can provide us with better treatment modalities.
Medul loblastoma
While glioblastoma is the most common brain malignancy in adults, medulloblastoma 
tops the ranking of most common malignant brain tumor in children with a five-years’ 
survival rate between 50% and 80%, depending on the subtype (14). This tumor 
originates in the cerebellum, often near the fourth ventricle. Common treatment 
includes surgery, radiotherapy and chemotherapy, but the relatively hopeful survival 
rates are overshadowed by complications and long-term sequelae which significantly 
reduce the quality of life (15). Currently medulloblastomas are classified based on their 
morphology and histopathology, such as desmoplastic or nodular medulloblastoma, 
MBEN (medulloblastoma with extensive nodularity) or classic, large cell and anaplastic 
medulloblastoma (1). However recently, molecular investigations of medulloblastoma 
have resulted in a molecular classification into four subgroups: a Wnt gene pathway 
associated subgroup (Wnt group), a Sonic Hedge hock gene (Shh) pathway associated 
subgroup (Shh group), a subgroup containing MYC gene amplifications and 
photoreceptor/GABAergic gene expression (group 3), and a subgroup which has MYCN/
CDK6 gene amplifications and neuronal or glutamatergic gene expression (group 4)
(1). These molecular subgroups have different clinical outcomes and react distinctively 
different to current treatment modalities. It is therefore, a necessity to further analyze 
these subgroups independently to improve outcome. As with glioblastoma, it is currently 
unknown whether these subgroups also arise from distinct subsets of progenitor cells.
STEM CELLS AND TISSUE REGENERATION
Stem ce l l s
Stem cells are undifferentiated cells that have the capability to divide limitless and to 
self-renew while the undifferentiated state is maintained (16). Stem cells therefore, play 
a role in development and in tissue repair and regeneration, and are invaluable for the 
maintenance of life. The most fundamental stem cells are totipotent zygotes and have 
the capacity to eventually differentiate into all types of cells that are necessary for the 
embryonic development. These stem cells are often referred to as embryonic stem 
cells. When pluripotent stem cells further differentiate, they form multipotent stem cells 
that are dedicated to form cells that are derived of one germ layer. When multipotent 
cells lose the capacity of unlimited growth, they are referred to as progenitor cells (17). 
Multipotent progenitor cells are often referred to as adult or somatic stem cells and 
their function is to replenish dying cells or to regenerate damaged tissues. 
Stem cells can either divide symmetrically, for self-renewal and maintenance of the 
stem cell pool, or divide asymmetrically to form a daughter cell that can differentiate 
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into a more specialized precursor of tissues. The bone marrow is an important source 
of stem cells. It contains hematopoietic stem cells that are the progenitor cells of all 
types of blood cells and it contains mesenchymal stem cells that have the potential to 
differentiate in chondrocytes, adipocytes or osteoblasts. There are many indications 
that a population of these bone marrow-derived mesenchymal stem cells may be able 
to replenish many types of cells after damage, such as muscle tissue, liver hepatocytes, 
lung tissue and neural cells (18). 
Stem ce l l  t i ssue regenerat ion
As mentioned previously, stem cells have the ability to self renew and differentiate to 
regenerate damaged tissues. Depending on the stem cell origin, they can differentiate 
into a specific cell type. Embryonic stem cell transplantation in rats has shown to assist 
in repair of spinal cord injuries (19)(20). With the identification of adult stem cells, the 
use of embryonic stem cells, which are difficult to obtain, was circumvented. Adult 
stem cells are populations of multipotent stem cells that can be found in almost all 
tissues, and mesenchymal stem cells can be easily obtained from adipose tissue and 
bone marrow (21, 22). Adipose-derived mesenchymal stem cells have been shown to 
restore heart function, to form osteoid tissue, the precursor tissue of bone formation, 
and to produce cartilage matrix molecules, suggesting potential restoration of 
cartilage tissue, making it a promising novel therapy for chronic low back pain due to 
age-related intervertebral disc degeneration (23)(24)(25)(26).
Cancer  stem ce l l s
Accumulation of genetic aberrations in differentiated cells does not result in tumor 
formation unless the cells regain their self-renewal potential. One strategy to obtain this 
capacity is to transform towards a more stem-like type of cell: the cancer stem cell. After 
consecutive genetic aberrations, epithelial cells can transform towards a mesenchymal 
cell genotype and phenotype showing expression of stem cell markers (Mani et al., 
2008). In essence, tumor cells have the potential to revert from differentiated, more 
specialized cells towards a more primordial cancer stem cell type with unlimited renewal 
capacity and a more dynamic, adaptable genotype and phenotype. 
Cancer stem cells have been identified in multiple types of tumors and recently it 
has become clearer that they contribute to increased drug and radiation resistance, and 
tumor progression and recurrence after surgical resection (28). It has been proposed 
that gliomas arise from dedifferentiation of glia cells, or from undifferentiated neural 
progenitor cells (12, 29). Early glioblastoma development analysis suggests that they 
arise in the subventricular zone, where the neural progenitors reside.  
There is still debate about the actual existence of cancer stem cells or about the 
specifications, differences and similarities between cancer stem cells and other cancer 
cells (30). Despite this debate recent research reveals that also in tumors, like in other 
tissues, differentiated cells can regain stem cell markers and properties such as self-
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renewal. Only recently it has been shown that tumor cells can switch between the 
epithelial state and the stem-like mesenchymal state (31).There are also indications that 
the cancer stem cell population that resides in a tumor could contain a drug-resistant 
stem cell that repopulates the tumor after initial drug-mediated tumor regression. It is 
not yet resolved whether resistant cells are present in heterogeneous tumors or whether 
stem cells acquire resistance after drug treatment but it is speculated that stem cells are 
more quiescent and therefore less affected by growth-inhibiting drugs (32).
FUNCTIONAL MOLECULAR IMAGING 
Bio luminescence and f luorescence
Molecular imaging techniques such as bioluminescence or fluorescence provide 
scientists with quantitative methods for functional cell studies, and many adaptations 
of these methods in functional molecular biology assays have been developed (3)(33). 
Figure 1. Tumor heterogeneity can be the result of individual cells obtaining mutations and aberrations 
of time or of different cancer stem cells, each producing different tumor cells. a: Clonal selection theory: 
A cell obtains mutations and aberrations and proliferates (1.). Over time, each individual cell obtains 
more, exclusive aberrations (2.) providing a selection advantage for certain cells and resulting in a 
heterogeneous tumor that contains many different tumor cells (3.). b: Cancer stem cell theory: Self 
renewing stem cells might obtain aberrations (1.) resulting in cell tumorigenic stem cells (2.). The cancer 
stem cells proliferate and each cancer stem cell provides bulk tumor cells of a single type, resulting in 
heterogeneous tumors (3.). Tumorigenesis is most like a result of a combination of both theories.
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In order to study stem cells and cancer cells, imaging methods to study the behavior 
and cellular properties of these cells are indispensible to obtain more insight into their 
molecular mechanisms. Molecular imaging involves the localization and quantification 
of biomarkers or bioreporters using electromagnetic wave detection such as light, radio 
waves and radioactivity. In the clinical setting, tumors are often imaged using magnetic 
resonance imaging (MRI), single photon emission computed tomography (SPECT) 
or positron emission tomography (PET). For patient safety, these methods may only 
use transient, biomarker-targeted contrast agents to image tissue-specific or process-
specific markers. These biomarkers can be radiolabelled molecules such as antibodies, 
peptides or aptamers (34, 35). SPECT and PET use radioactive probes for imaging. 
In preclinical research, target-specific probes, such as antibodies or complementary 
DNA, can be fused to fluorophores in order to detect their location within cells and 
follow molecular movement. Genetic reporters are proteins that are expressed in cells 
to detect the cells in their environment and to distinguish them from other cells. These 
bioreporter proteins can be fluorescent or luminescent. Green fluorescent protein 
(GFP) was the first fluorescent protein used as a bioreporter (36) and its importance for 
molecular imaging and biology has been acknowledged by awarding its discoverers 
the 2008 Nobel price for chemistry (37)(38). Since then, many derivatives with different 
colors have been developed (39) and named accordingly, such as cyan or cerulean 
fluorescent protein, yellow fluorescent protein and red fluorescent protein (40).
Bioluminescent proteins are luciferase enzymes that degrade a substrate into 
products and thereby produce detectable photons. Examples of bioluminescent 
reporters are Firefly luciferase (41), Renilla luciferase (42) and the cell-secreted Gaussia 
luciferase (43). Recently, a new firefly luciferase, Luciola italica, was discovered, 
Figure 2. Luciferase enzymes are derived from organisms that use light production to communicate 
or as a mechanism of defense to distract predators. a: Photinus pyralis, the common eastern or big 
dipper firefly, uses light flashes to attract a mate. b: Gaussia princeps is an ocean dwelling copepod 
that uses bioluminescence as a defense mechanism against predators.
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increasing the range of reporter luciferases with varying properties(44). One property 
of luciferases is their ability to degrade substrates. Firefly luciferases degrade luciferin, 
while Gaussia luciferase and Renilla luciferase degrade coelenterazine. The wavelength 
of the emitted photon also varies, depending on the luciferase type. 
Funct iona l  b ioreporters
Bioreporters are artificial genes that can be expressed constitutively active or under 
regulation of a specific promoter to make transcriptionally conditional. Also, the gene 
can be equipped with post-transcriptional or post-translational regulatory elements 
such as a 3’-UTR for microRNA degradation, a protease cleavage site or a localization 
domain. Using these methods (and combinations of these methods), different 
cellular mechanisms can be studied. When the firefly luciferase (Fluc) bioluminescent 
reporter under control of the constitutively active cytomegalovirus (CMV) promoter, is 
transplanted into tumor cells, they can be followed in vivo over time and viability or 
growth can be quantified (45) after injection of the Fluc substrate d-luciferin using a 
cooled charged-coupled device (CCD) camera. An alternative for the Fluc bioreporter 
is the secreted Gaussia luciferase (Gluc) bioreporter, that eliminates the need for an in 
vivo CCD camera and only requires a luminometer to detect gli36 human glioma cells 
in mice, since the reporter can be detected in collected mouse blood or urine (46). The 
obtained bioluminescent signal is representative for tumor growth and can be used 
to ex vivo determine in vivo processes. Gaussia luciferase is actively secreted out of 
the cells via the endoplasmic reticulum (ER)-related secretory pathways and therefore 
Figure 3. Fluorescence and luminescence are distinct processes. a: Fluorescent proteins such as green 
fluorescent protein (GFP) require light excitation from its ground state to enable it so return to its ground 
state and thereby emit a photon with lower wavelength. B: Luciferases such as Gaussia or Firefly luciferase 
(Gluc or Fluc) are enzymes that require a substrate to catalyse the reaction into a product and photons. 
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constitutive Gluc expression is used as a secretory pathway reporter (47). Upon induced 
ER stress, Gluc secretion from cells is considerably decreased, making Gluc a suitable 
reporter to study secretory pathway-related diseases. Fluc is located within the cell, 
making it ideal to visualize tumors. When a tumor is not contained in a well-defined 
bulk, is of a more diffuse nature, or when the bulk tumor is surgically removed but small 
number of residual cells are left over or metastasized to other locations in the body, it 
can be difficult to determine cancer cell load and to determine treatment effects. In the 
pre-clinical experimental setting Gluc may be a good option to measure tumor load 
since it is released into the blood and therefore small metastasis of breast cancers can be 
detected, even when the location cannot be determined using a CCD camera (48). Also, 
Gluc blood monitoring may reveal a more specific quantification of viable tumor burden 
as compared to localized reporters, such as Fluc, since the total viable tumor secretes 
Gluc into the blood while Fluc can become confined, also in a less viable tumor mass. 
The Gluc reporter is used in glioma high-throughput drug screens to identify potential 
new drugs. For example, lanatoside C has been shown to sensitize glioblastoma cells to 
TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis (49) and only recently 
Gluc has also been used to identify inhibitors of Marburg and Ebola virus. Bioreporters 
under a conditional promoter can provide insight into transcriptional activity of genes 
or transcription factors. Transcription factors bind the double stranded DNA of a gene 
promoter in the genome and thereby positively or negatively regulate gene expression. 
Transcription factors have preferred DNA sequences to which they bind and these 
consensus sequences can be used to construct transcription factor activity bioreporters 
Figure 4. Functional bioluminescent reporters can be designed in to report different properties. a: 
The Gluc reporter is under control of a constitutively active cytomegalovirus (CMV) promoter to report 
cell viability and proliferation. b: The Gluc reporter is under control of a transcription recognition 
element (TRE) to report specific transcription factor activity. C: The Gluc reporter is under control 
of a CMV promoter but contains a specific 3’-UTR region downstream so it can be recognized and 
postranslationally repressed by a specific microRNA. d: The Gluc reporter is under control of a specific 
gene promoter region to report (tissue specific) gene expression. e: A constitutively active promoter 
drives a fusion gene of intracellular GFP linked to Gluc by a protease cleavage sequence (DEVD). When 
a protease is active, Gluc is released from the intracellular GFP, allowing detectable Gluc secretion.
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that regulate reporter gene activity (50). In another study microRNA 23a (miR-23a) 
maturation and activity was assessed, by using the Fluc reporter under transcriptional 
control of the miR-23a promoter and the Gluc reporter, fused to miR-23a 3’-UTR target 
sequences, to quantify miR-23a post-transcriptional activity (51). Since Fluc and Gluc 
use the luciferase substrate luciferin and coelenterazine respectively, this dual reporter 
system can be used to simultaneously study primary miR-23a expression by detection of 
miR-23a promoter activity represented by the Fluc reporter and mature miR-23a silencing 
activity by binding of the miRNA to the Gluc-3’-UTR fusion reporter. In order to analyze 
cell apoptosis and caspase proteolytic activity, Niers et al. (52) designed a caspase 3 
activity reporter. Therefore, they fused the recreated Gluc reporter to intracellular GFP 
with a caspase 3 cleavage site (DEVD). The intracellular GFP prohibited Gluc to exit the 
cell. When caspase 3 becomes active, it cleaved the DEVD linker between GFP and 
Gluc, allowing detectable Gluc secretion outside the cell.
Funct iona l  molecular  imaging of  stem ce l l s
Stem cells have been often studied using bioluminescent reporters (53). These methods 
have been extensively used to reveal the temporal behavior and spatial localization of 
stem cells, but also for functional research and even therapeutic modalities. There are 
many studies that have used bioluminescent reporters based on luciferases. The most 
widely used luciferase is the cell localized Fluc. 
For example, Fluc imaging can follow neural progenitor cells after injection into 
mouse ventricles and they have been proposed to migrate towards sites of brain 
infarction (54). Also using Fluc, systemically injected neural precursor cells, modified 
to express therapeutic molecules such as TRAIL, have been shown to selectively 
deliver these molecules to gliomas, inflicting tumor regression (55). Similar results 
were obtained by using the Gluc reporter blood-based assay and treatment combined 
with the previously mentioned TRAIL-sensitizing compound lanatoside C (56). 
In another example, to study glioma-initiating stem cells the Fluc reporter was put 
under control of the plagl1 gene promoter to correlate Sox11 expression with neural 
differentiation. It was shown that upon loss of Sox11 expression plagl1 was overexpressed, 
resulting in loss of neural differentiation commitment and tumorigenesis in vivo (57). 
The construction of a RTVP-1 3’-UTR reporter, a target of microRNA-137, which is 
down-regulated in glioblastoma by promoter hypermethylation, resulted in decreased 
degradation of RTVP-1 and increase of self-renewal potential of glioma stem cells (58). 
To study rat intervertebral disc degeneration, Fluc has been used to image 
mesenchymal stem cell fate and viability (59). The use of Gluc in regenerative medicine, 
and specifically in intervertebral disc regeneration, is still limited and the functionality 
of Gluc in this research is largely unexplored. In a study on mesenchymal stem cell 
biodistribution in mice, the stem cells were equipped with Fluc using non-viral sleeping 
beauty transposons. After injection of these stem cells the mice developed increasing 
Fluc signal, suggesting an increase in transplanted mesenchymal stem cells and post-
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mortem analysis of the mice revealed sarcomas in the lungs and the researchers were 
able to grow malignant lesions in secondary mouse recipients (60). 
The secreted Gluc is a relatively new ‘kid on the block’ (43) and therefore is less 
well-known and used. This also accounts for even more recently discovered luciferases. 
The secreted luciferases have certain advantages such as the relative ease of use 
without CCD equipment, the possibility to measure cell viability without the need to 
know a near location and the ability to measure relatively diffuse cells in tissues and 
organisms. Downsides may be that cell secretion might lead to higher background 
signals in organisms when using CCD imaging to localize cells or the relative stability 
of Gluc in vitro, although efforts are made to identify mutants that harbor other 
specifications. There is no better or worse luciferase; the luciferase of choice depends 
on the application and therefore the options available should always be considered. 
AIMS AND OUTLINE OF THIS THESIS 
The aim of this thesis is to develop a novel application of Gaussia luciferase 
bioluminescence imaging and to apply bioluminescent imaging to discover functional 
molecular mechanisms in nervous system pathologies. Functional bioluminescent 
imaging is a tool that can be adapted for many types of research in many diseases. In 
our research we mainly focused on malignant brain tumors but in chapter six we also 
explored spine intervertebral disc stem cell regeneration imaging as another example 
of functional bioluminescent imaging in the nervous system. In Chapter 2 we aim to 
develop a novel multiplex bioluminescence assay, based on the secreted Gluc fused 
to an epitope tag. This method would enable us to identify and functionally analyze 
multiple types cells, each expressing Gluc with a different epitope tag, and to follow the 
performance of each type of cell within a heterogeneous tumor cell population in vitro 
and in vivo. This opens up the possibility to study a variety of cell subpopulations in 
heterogeneous tumors and tissues. In Chapter 3 we provide an extensive protocol, with 
tips & tricks and troubleshooting, for the multiplex reporter assay described in chapter 2. 
In Chapter 4 we conduct a comprehensive meta-analysis of gene expression studies of 
mouse and human medulloblastoma to identify novel mechanisms in medulloblastoma 
development. Chapter 5 also aims at identifying novel tumor suppressor genes by an 
in silico analysis of GBM gene expression data. In Chapter 6 we explore luciferase-
mediated bioluminescence imaging of adipose-derived mesenchymal stem cells in an 
intervertebral disc model in order to study stem cell regenerative biology. A general 
discussion and future considerations are presented in Chapter 7, followed by an English 
summary in Chapter 8 and a Dutch summary in Chapter 9.
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ABSTRACT
We have developed a multiplex reporter system to monitor multiple biological 
variables in real-time. The secreted Gaussia luciferase was fused to ten different 
epitope tags (Gluctag), each expressed in different tumor cells. By immunobinding 
of the tags followed by Gluctag detection, this system allowed the independent and 
real-time monitoring of mixed cell cultures in vitro and of mixed subcutaneous and 
intracranial tumor subpopulations in vivo.
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INTRODUCTION
To study complex processes in systems biology, tools are needed that give insight into 
multiple molecular and cellular interactions simultaneously and in real-time1longitudinal 
studies of dynamic biological processes in vivo. The most common reporters include 
firefly luciferase (bioluminescence imaging,2. Several cellular reporter systems are in 
use to shed light on biological processes, many based on luciferase enzymes and their 
photon production upon luciferin substrate addition, including Firefly luciferase (Fluc)3, 
Renilla luciferase (Rluc)4, and Gaussia luciferase (Gluc)5nontoxic, and novel reporters can 
serve to expand this potential. Here we describe the properties of a luciferase from the 
copepod marine organism Gaussia princeps. It is a monomeric protein composed of 185 
aa (19.9 kDa,6. These bioluminescent reporters have been used to monitor biological 
processes such as cellular proliferation and differentiation7, transcription factor activity8, 
translational repression by miRNA9,10, and intercellular interactions11, reviewed in12. 
Other commonly used reporters are based on the green fluorescent protein (GFP), the 
red fluorescent protein (RFP) and, more recently, near infra-red fluorescent proteins13,14 
which can be multiplexed together to monitor several processes simultaneously using 
spectral unmixing in conjunction with fluorescence molecular tomography15. These 
reporters have several disadvantages including low sensitivity due to autofluorescence, 
complexity, and the requirement of expensive instrumentation. Further, similar to 
bioluminescence, limited numbers of variables can be monitored simultaneously, limiting 
their use in multiplex screening assays and cellular heterogeneity studies. Here, we 
developed a multiplex bioluminescence assay that allows monitoring of many variables 
in real-time within the same biological system. This assay is based on Gluc since this 
reporter is highly sensitive, naturally secreted, and can be detected in the conditioned 
medium of cells in culture as well as in the blood of animals ex vivo, allowing real-time 
monitoring of cellular variables5nontoxic, and novel reporters can serve to expand this 
potential. Here we describe the properties of a luciferase from the copepod marine 
organism Gaussia princeps. It is a monomeric protein composed of 185 aa (19.9 kDa,6.
RESULTS
We constructed a library of lentiviral vectors consisting of the Gluc cDNA fused to ten 
different epitope tags at its C-terminus, under the constitutively active cytomegalovirus 
(CMV) promoter resulting in GlucFlag, GlucHis, GlucHA, GlucAcV5, GlucV5, GlucGlu, GlucMyc, 
GlucKt3, GlucAu1, GlucE2, and the control reporter construct without tag, GlucCtrl. These 
lentiviral vectors also express cerulean fluorescent protein (CFP) separated from Gluctag 
by an internal ribosomal entry site (IRES) element as a marker for transduction efficiency 
(Fig. 1a and Methods section). We employed human U87 glioblastoma cells stably 
expressing Fluc and the mCherry fluorescent protein6 (U87-FM) for validation of the 
Gluctag multiplex system. These cells were transduced with each of the lentiviral vectors 
to produce ten different cell lines, each stably expressing a different Gluctag and CFP 
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(U87-FM-Gluctag-CFP). Fluorescent microscopy analysis for mCherry and CFP showed 
that these cells were nearly 100% transduced with the reporter vectors (Fig. 1b). We 
first demonstrated that all of the individual U87-FM-Gluctag-CFP cells expressed the 
corresponding tags by immunostaining using specific antibodies, except for GlucAu1 
that was not detectable by immunostaining attributed to anti-Au1 antibody properties 
(Fig. 1c). As a control we stained cells expressing Glucctrl with the different tag 
antibodies, which did not show any staining (data not shown). We confirmed Gluctag 
expression by Western blot using anti-tag antibodies (Sup. Fig. 1a) and RT-PCR of the 
tag region (Sup. Fig. 1b and c). Next, we determined the effect of the tags on Gluc 
by measuring luciferase activity at different time points in an aliquot of conditioned 
medium from U87-FM cells expressing each Gluctag reporter construct using the 
Gluc substrate coelenterazine. We demonstrated that fusion of epitope tags to Gluc 
does not dramatically affect the expression, secretion or activity of Gluc (Fig. 1d and 
supplemental Fig. 1a-c). We then used the conditioned media containing the different 
Gluctag constructs to optimize antibody-tag immunobinding in a 96-well plate format 
(Methods). Plates were first coated with monoclonal antibodies against the different 
tags and incubated with different amounts of conditioned medium allowing Gluctag 
immunobinding. Subsequently, the wells were washed to remove unbound Gluctag 
and subjected to the Gluc assay by direct addition of coelenterazine to the wells 
and measuring photon counts using a plate luminometer. As a control, an aliquot of 
conditioned medium was assayed directly for total Gluc activity. We determined that 
six of the ten individual Gluctag constructs, i.e. GlucFlag, GlucHis, GlucHA, GlucAcV5, GlucV5, 
GlucGlu, reported with high-efficiency after immunobinding in the antibody-coated 
wells, as compared to total Gluctag activity (Fig. 1e). The GlucMyc, GlucKt3, GlucAu1, and 
GlucE2 reporters showed lower activity upon immunobinding, attributed to suboptimal 
antibody-tag interactions. In order to demonstrate the use of the Gluctag system for 
multiplex applications, we mixed equal numbers of the ten different U87-FM-Gluctag-
Figure 1. Gluctag multiplex assay development and validation in vitro. (a) Schematic of the lentiviral 
vector constructs encoding the luciferase reporters. (b) Fluorescence microscopy analysis of 
a representative U87-FM-Gluctag-CFP cells (using GlucFlag reporter) showing mCherry levels (in 
red; marker for tumor cells) and CFP expression (in blue; marker for transduction efficiency). (c) 
Immunostaining against the various tags in U87-FM cells expressing different Gluctag. (d) Gluc 
activity in U87 cells expressing different Gluctag with respect to cell proliferation over time and cell 
number. The dashed line represents GlucCtrl activity. (e) Gluctag immunobinding assay versus total 
Gluc activity using serial dilutions of the conditioned medium from a 1-day culture of U87-FM 
cell lines expressing the individual Gluctag reporters. . (f-g) Equal mixture of ten cell lines each 
expressing a different Gluctag reporter. (f) Immunobinding assay of Gluctag from a mixed population. 
(g) Immunostaining for the ten different tags expression in the mixed population of U87-FM cell 
culture. (h-i) U87-FM cells expressing all ten different Gluctag reporters. (h) Immunostaining for 
the ten different tags in one cell line. The insert panels show staining of control parental cells. 
Percentages of positively stained cells are indicated. (i) Immunobinding assay of all ten Gluctag 
reporters in one cell line after TMZ treatment (black bars) compared to untreated control (white 
bars). (j) CFP fluorescence microscopy of cells in (h-i) with or without 600 µM TMZ.  Size bar (in b,c, 
g and h) = 200 µm. Size bar (i) = 400 µm. N.d. = not detectable.
◀
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CFP cells and plated them in a single well. One, three and five days later, we measured 
the total Gluc level in aliquots of the conditioned medium. The levels of the individual 
Gluctag reporters in the mixed culture medium were analyzed by immunobinding with 
the different tag specific antibodies. We were able to monitor in real-time the growth 
of the individual U87-FM-Gluctag-CFP cell populations in the mixed culture (Fig. 1f). 
Immunostaining confirmed the expression of each tag in the corresponding cells in the 
mixed culture, again except for GlucAu1 (Fig. 1g). In order to determine whether we can 
measure the activity of ten different Gluctag constructs in the same cell, we transduced 
U87-FM cells with all ten different lentiviral gluctag reporters. Immunostaining of the 
U87-FM-Gluc10x tagCFP glioblastoma cells with tag specific antibodies showed that 
almost all cells expressed all ten different Gluctag constructs (Fig. 1h). The tag expression 
as demonstrated by immunostaining is less intens in Fig. 1h as compared to Fig. 1c, 
which we attribute to the transduction pool of ten different lentivectors used in Fig. 
1h. We used these cells to monitor cell viability in the presence and absence of the 
alkylating agent temozolomide (TMZ), the standard chemotherapy for glioblastoma 
patients. Gluctag immunobinding assays were used to determine the expression of all 
ten reporters in the presence or absence of TMZ. We treated the U87-FM-Gluc10x tagCFP 
cells with TMZ and measured Gluctag activity after six days (Fig. 1i). Precipitation of 
all ten different Gluctag reporters showed a ~75% decrease in Gluc bioluminescence 
signal after TMZ treatment, similar to the total Gluc signal and confirmed by CFP 
immunofluorescence analysis (Fig. 1j). Altogether, these results demonstrate that we 
can measure biologically relevant differences using our multiplex Gluctag system. 
In order to determine the in vivo applicability of the Gluctag reporter assay, we 
injected the ten individual U87-FM cell cultures expressing either one of the Gluctag or 
GlucCtrl reporters subcutaneously in nude mice for singleplex application. In another 
set, we injected mice with PBS as a negative control (12 groups; n=3/group). Tumor 
growth was monitored over time by calliper measurement, and Fluc bioluminescence 
imaging (Fig. 2a,b). Blood was collected from mice at different time points and 
5 µl of whole blood (optimum amount for Gluc blood assay16) was assayed for total 
Gluc activity.  At the same time, 25 µl of blood was analyzed for Gluc activity after 
immunobinding on wells coated with the corresponding tag antibody (Fig. 2b). All of 
the Gluctag reporters, except GlucE2, allowed blood monitoring of tumor growth over 
time in a singleplex assay. We compared the tumor growth as measured by calliper, 
Fluc imaging and Gluc blood assay to signals obtained from the ten different Gluctag 
reporters after immunobinding (Fig. 2b). The six Gluctag reporters GlucFlag, GlucHis, 
GlucHA, GlucAcV5, GlucV5, GlucGlu were more sensitive in detecting tumor growth than the 
others, possibly due to a higher affinity of the antibodies to these tags. To demonstrate 
the use of the Gluctag system for multiplex applications, we mixed equal numbers of 
U87-FM cells expressing the ten different Gluctag and implanted the heterogeneous 
cell pool subcutaneously in nude mice (n=5). We monitored tumor growth by Fluc 
bioluminescence imaging and total Gluc blood assay (Fig. 2c,d). Importantly, we were 
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Figure 2. Gluctag multiplex assay in vivo. (a) U87-FM cells expressing different Gluctag were 
implanted subcutaneously in nude mice (n=3) and tumor growth was monitored overtime. Shown 
are representative Fluc bioluminescence images of the U87-FM-Gluctag-CFP tumors expressing 
the GlucFlag reporter. (b), Quantitation of the different U87-FM tumors expressing different Gluctag 
reporters; Fluc activity (black), calliper measurement (green), total Gluctag activity in the blood 
(red), and bound Gluctag activity after immunobinding (blue). (c-d) U87-FM cells expressing the 
different Gluctag reporters were mixed in equal amounts and injected subcutaneously in the same 
mouse (n=5). Tumor growth was monitored using Fluc imaging and total Gluc blood assay as in 
(a-b). Individual cells subpopulation within the same tumor were monitored using the multiplex 
Gluctag immunobinding assay. (e) Immunostaining for the ten different tags expression in the 
mixed U87-FM-Gluctag-CFP tumor. Black arrows indicate positive staining for cells expressing the 
corresponding Gluctag. Size bar = 200 µm. N.d. = not detectable. (f-g) Mixed population of U87-FM 
cells expressing all ten different tags were implanted intracranially in the brain of nude mice (n=5). 
Tumor growth was monitored with Fluc imaging and Gluc total blood assay, and different tumor cell 
subpopulations were monitored using the multiplex Gluctag assay as in (c-d). Fluc bioluminescence 
imaging of a representative mouse is shown in (f). Data shown in (b,d, and g) as average relative 
light units (RLU) ± standard deviation. Heatscales in (a, c and f) indicate relative photon levels 
(photons/sec) as measured by the CCD camera.
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able to efficiently monitor the growth of the individual subpopulation of the U87-FM 
cells expressing the different high-efficiency Gluctag reporters (GlucFlag, GlucHis, GlucHA, 
GlucAcV5, GlucV5, GlucGlu) in the same tumor over time (Fig. 2d). We confirmed the 
expression of all tags (except for GlucAu1) in the same tumor by immunostaining (Fig. 
2e). To determine the applicability of the Gluctag multiplex system in deep tissues, the 
mixture of the ten different U87-FM-Gluctag-CFP cells were implanted orthotopically in 
the brain of nude mice (n=5). We monitored tumor growth by Fluc bioluminescence 
imaging and total Gluc blood assay (Fig. 2f,g). Again, we were able to monitor the 
intracranial growth of the individual subpopulations of U87-FM cells expressing the 
high-efficiency Gluctag reporters within the same brain tumor in real-time, by blood 
sampling and the application of the Gluctag multiplex reporter system (Fig. 2g).
DISCUSSION
Here we demonstrated the functionality of the Gluctag multiplex reporter system by 
the parallel monitoring of mixed cell cultures in vitro, and of subpopulations in mixed 
subcutaneous and intracranial tumors ex vivo. The individual epitope tags could 
also be employed to localize expression by immunostaining. We used ten different 
Gluctag reporters, but this tag library can be readily extended allowing for increased 
multiplexing. In addition, antibody binding of the low-efficiency tags in the Gluctag 
immunobinding assay might be further optimized to achieve higher sensitivity since 
these tags, except for GlucAU1, were efficiently detected by immunostaining. Real-time 
monitoring of individual cells in a heterogeneous mixture may allow, for instance, 
multiplexed RNAi screening or measurement of drug responses of multiple cell 
populations in parallel. The Gluctag multiplex system might be extended to monitor 
different variables in a single cell type. For instance, engineering each individual 
Gluctag under the control of different transcription response elements for multiplex 
transcription factor activity measurements7, constructing microRNA (miRNA)-binding 
sequences in the 3’-UTR of the Gluctag constructs for multiplex monitoring of miRNA 
activity10 or by inserting different protease cleavage sites into the Gluctag gene for 
multiplex protease activity measurement17. This reporter assay provides a versatile 
tool to study complex processes with different variables in systems biology.
METHODS
Cells. For in vitro and in vivo validation, we used the glioblastoma cell line U87, stably co-
expressing Firefly luciferase and mCherry fluorescent protein. Cell lines were maintained in 
DMEM high glucose complemented with sodium pyruvate, stable glutamine, 10% FBS and 
pen/strep (all PAA), incubated under standard cell culture conditions of 37ºC and 5% CO2.
Lentivirus vector construction and transduction. First, we amplified Gluc by PCR using 
Accuprime Pfx DNA polymerase (Life Technologies) from CSCW-Gluc-IRES-CFP6 
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with specific primers that incorporate an XbaI site downstream of the Gluc cDNA 
(Forward primer: 5’- GCGTGTACGGTGGGAGGTCT-3’, reverse primer: 5’-TCTCGA 
GTAGAGATCTGTCACCACCGGCCCCCTT-3’). The reverse primer also covers the 
original stop-codon that is thereby removed. The Gluc cDNA, now containing a 
unique XbaI site, was ligated back into the CSCW-Gluc-IRES-CFP vector with T4 DNA 
ligase (Life Technologies), after removal of the wild-type Gluc using NheI and XhoI 
(Life Technologies). Plasmid DNA was transformed in XL-10 Gold ultracompetent cells 
(Agilent Technologies), cultured overnight in LB agar containing 50 µg/ml Ampicillin. 
We isolated DNA using a DNA plasmid mini kit (Qiagen) and verified successful 
transformation by XbaI restriction analysis. The Gluc construct was then digested with 
XbaI and XhoI to insert the different epitope tags. The epitope tags were designed 
with an XbaI site upstream, a stop codon and XhoI site downstream. A total of 20 µM 
of both single strand oligonucleotides of the acquired tag DNA (Life Technologies, see 
Table S1 for sequences) was annealed in annealing buffer (100 mM Tris-HCl pH 7.5, 1 
M NaCl and 10 mM EDTA) by heating to 65ºC for 10 minutes and slow cooling to room 
temperature. The epitope tag was then inserted into the vector using T4 DNA ligase 
and transformed in XL-10 Gold ultracompetent cells. Bacteria were cultured and DNA 
was isolated. We verified the Gluctag constructs by sequencing using BigDye Terminator 
v3.1 Cycle Sequencing kit (Life Technologies, primer: 5’-GCCAACGTGCAGTGTTC-3’). 
The Gluctag construct was co-transfected with a third generation lentiviral packaging 
mix (pMDLg/pRRE, pRSV-Rev and pMD2.G, Addgene) in HEK293T cells using 
Lipofectamine 2000 (Life Technologies). Virus was harvested two and three days after 
transfection and cell debris was spun down for five minutes at 1,000 x g. U87 cells were 
transduced overnight with lentivirus using a multiplicity of infection of 100 transducing 
units per cell in the presence of 8 µg/ml polybrene in standard culture conditions.
Fluorescence microscopy. Successful transduction was verified by visualizing CFP (co-
expressed with the Gluctag construct) and mCherry fluorescent protein (co-expressed 
with Fluc) using fluorescent microscopy (Leica).
Immunostaining and antibodies. For in vitro immunostaining, cells were fixed in 3.7% 
formaldehyde for 20 minutes, washed with PBS and permeabilized with PBS containing 
0.1% Triton X-100. Cells were then washed three times in PBS containing 5% FBS and 
blocked with PBS containing 5% FBS. Primary mouse-anti-tag monoclonal antibody 
(10 µg/ml in 100 µl of PBS, Table S1) was added and incubated for one hour at room 
temperature. Cells were washed again and incubated with 1:100 goat-anti-mouse 
horseradish peroxidase (HRP) conjugate (Dako) for one hour. After washing, cells 
were stained with DAB+ (Life Technologies). For mouse tissue staining, tumors were 
removed and embedded in paraffin. Microtome sections of 5 micron on glass slides 
were deparaffinized in xylene and rehydrated in ethanol series of 100%, 96%, and 70% 
ethanol. Endogenous peroxide was blocked with 0.3% H2O2 in methanol for 30 minutes. 
After rinsing with water, antigens were retrieved with citrate buffer (pH 6) with 0.05% 
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Tween 20 using a microwave (Bosch, five minutes 900 watt, 10 minutes 360 watt). After 
slowly cooling, tissues were washed three times with PBS and incubated with primary 
antibody (10 µg/ml), for one hour at room temperature. After washing three times again, 
tissues were incubated with REAL Envision Rabbit anti-mouse (Dako and REAL DAB+ 
stained (Dako). Tissue sections were dehydrated with ethanol series as before and fixed 
in xylene. Cells and sections were imaged and photographed by light microscopy (Leica).
Western blot. U87-FM-Gluctag-CFP cells were lysed in RIPA buffer and mixed with Laemli 
buffer containing ß-mecaptoethanol (80µl/ml). The samples were separated using a 10% 
SDS-PAGE gel and the XCell-II blot module (Invitrogen). Primary antibodies (Table S1) were 
used in a 1:3,000 dilutions and  goat-anti-mouse HRP immunoglobuline (Dako) secondary 
antibody was used in a 1:2,000 dilution. Incubation times were 1 hour at room temperature.
RT-PCR. U87-FM-Gluctag-CFP RNA was isolated using Trizol (Invitrogen) according to 
manufacturer’s guidelines. cDNA was generated using Omniscript RT kit (Qiagen) and PCR 
was performed in triplo using FastStart SYBR Green Master (Rox) mix (Roche). As a forward 
primer we used 5’- GCCAACGTGCAGTGTTC-‘3, which is located in the Gluc gene. We 
used the tag antisense oligonucleotides as tag specific reverse primers (Table S1).
In vitro Gluc activity assay. For Gluctag activity measurement over time, 50,000 cells 
were plated in a 24-well plate and incubated overnight. A total of 10 µl conditioned 
medium was harvested from cells and Gluc activity was measured by adding 50 µl 
(5 µg/ml) coelenterazine (Nanolight Technologies) in PBS and 0.1% Triton X-100). 
Before addition to the sample, the substrate was incubated at room temperature for 
30 minutes for stabilization. Photon counts were determined over 10 seconds in a 
luminometer (Berthold Technologies). For the measurement of Gluctag activity with 
respect to cell number, indicated numbers of cells were plated in a 24-well plate and 
incubated overnight. Gluctag activity in medium was determined as described above.
Gluctag immunobinding assay. White goat-anti-mouse-coated 96-well plates (Thermo 
Scientific) were washed three times with PBS containing 0.05% Tween 20 and incubated 
with 50 µl (10 µg/ml) of each of the mouse monoclonal antibody directed against the 
specific epitope tags (Table S1). Incubation time was two hours while centrifuging at 500 
x g at 4ºC. Wells were washed and blocked three times with PBS containing 5% FBS and 
0.05% Tween 20 on a plate shaker at 65-75 rpm. A total of 30 µl of Gluctag conditioned 
medium or Gluctag mouse blood was added to the well and incubated for two hours at 
room temperature on a microplate shaker at 65-75 rpm. Wells were washed five times 
for five minutes on a plate shaker at 65-75 rpm. A total of 50 µl Gluc substrate (5 µg/ml 
coelenterazine in PBS and 0.1% Triton X-100) was added to the well and photon counts 
were determined in a microplate luminometer (Tecan) at 0.1 second per well. For the 
comparison of the bound Gluc to the total Gluc activity, aliquots of conditioned medium 
or 5 µl mouse blood were transferred to a white 96-wells microplate and assayed using 
50 µl (5 µg/ml) coelenterazine in PBS and 0.1% Triton X-100. 
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In vivo experiments. All in vivo experiments were subject to ethical committee 
approval and are in accordance with VU University Medical Center and national 
regulations. For subcutaneous tumor xenograft model, six weeks old athymic Nude-
Foxn1nu mice (Harlan) were implanted with 5 x 105 U87-FM-Gluctag-CFP cells in 50 µl 
DMEM and 50 µl Matrigel (BD Biosciences). For intracranial tumor implantation, a 
stereotactic frame (Harvard Biosciences) was used to inject cells vertically into the 
right hemisphere. General anesthesia was induced by subcutaneous injection of 
buprenorphine hydrochloride (0.1 mg/kg). The mice were further anesthetized with 
oxygen containing 2.5% isofluorane. After skin incision, lidocaine drops (5 mg/ml in 
PBS) were administered topically. A small drill was used to drill a hole into the skull. 
Coordinates used for injection were X = 0.5 mm, Y = 2 mm, Z = -2 mm from the 
bregma. A total of 2 x 105 cells in 5 µl of DMEM was injected vertically. On indicated 
days after injection, tumor size was monitored using a calliper (for subcutaneous) 
and bioluminescence in vivo Fluc imaging, by injecting D-luciferin (100 mg/kg) 
intraperitoneally. Imaging was performed with an IVIS CCD camera and analyzed 
with Living Image software (Caliper Life Sciences). We collected 300 µl mouse blood 
aliquots from the tail vein in Microvette CB300 EDTA capillary tubes (Sarstedt) for ex 
vivo whole Gluc measurements and Gluc immunobinding assays. 
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Fig. S1. Gluctag expression in the ten U87-FM-GluctagCFP. (a) Western blot, * = not detected. (b)
RT-PCR. (c) RT-qPCR.
Fl
ag
 (1
9,
5 
kD
a)
 
M
yc
 (1
8,
4 
kD
a)
 
H
is
 (1
8,
0 
kD
a)
 
H
a 
(1
8,
3 
kD
a)
 
K
t3
 (1
8,
5 
kD
a)
 
A
u1
 (1
8,
0 
kD
a)
 
A
cV
5 
(1
8,
3 
kD
a)
 
V
5 
(1
8,
8 
kD
a)
 
E
2 
(1
8,
4 
kD
a)
 
G
lu
 (1
8,
4 
kD
a)
 
GlucTag 
Β-Actin 
a 
M
yc
 (1
56
 b
p.
) 
Fl
ag
 (1
92
 b
p.
) 
H
is
 (1
44
 b
p.
) 
H
a 
(1
53
 b
p.
) 
K
t3
 (1
59
 b
p.
) 
A
u1
 (1
44
 b
p.
) 
A
cV
5 
(1
53
 b
p.
) 
V
5 
(1
68
 b
p.
) 
E
2 
(1
56
 b
p.
) 
G
lu
 (1
56
 b
p.
) 
H
2O
	  
GAPDH 
GlucTag 
10 
0 
100 
M
yc
 
Fl
ag
 
H
is
 
H
a 
K
t3
 
A
u1
 
A
cV
5 
V
5 E
2 
G
lu
 
b 
c 
G
lu
c T
ag
 e
xp
re
ss
io
n 
(C
t-v
al
ue
) 
Fig. S1. Gluctag expression in the ten U87-FM-GluctagCFP. (a) Western blot, * = not detected. (b) 
RT-PCR. (c) RT-qPCR. 
*	  
36
Fl
ag
 (1
9,
5 
kD
a)
 
M
yc
 (1
8,
4 
kD
a)
 
H
is
 (1
8,
0 
kD
a)
 
H
a 
(1
8,
3 
kD
a)
 
K
t3
 (1
8,
5 
kD
a)
 
A
u1
 (1
8,
0 
kD
a)
 
A
cV
5 
(1
8,
3 
kD
a)
 
V
5 
(1
8,
8 
kD
a)
 
E
2 
(1
8,
4 
kD
a)
 
G
lu
 (1
8,
4 
kD
a)
 
GlucTag 
Β-Actin 
a 
M
yc
 (1
56
 b
p.
) 
Fl
ag
 (1
92
 b
p.
) 
H
is
 (1
44
 b
p.
) 
H
a 
(1
53
 b
p.
) 
K
t3
 (1
59
 b
p.
) 
A
u1
 (1
44
 b
p.
) 
A
cV
5 
(1
53
 b
p.
) 
V
5 
(1
68
 b
p.
) 
E
2 
(1
56
 b
p.
) 
G
lu
 (1
56
 b
p.
) 
H
2O
	  
GAPDH 
GlucTag 
10 
0 
100 
M
yc
 
Fl
ag
 
H
is
 
H
a 
K
t3
 
A
u1
 
A
cV
5 
V
5 E
2 
G
lu
 
b 
c 
G
lu
c T
ag
 e
xp
re
ss
io
n 
(C
t-v
al
ue
) 
Fig. S1. Gluctag expression in the ten U87-FM-GluctagCFP. (a) Western blot, * = not detected. (b) 
RT-PCR. (c) RT-qPCR. 
*	  

Sjoerd van Rijn, Thomas Würdinger and Jonas Nilsson
Methods in Molecular Biology 1098, 231-47 (2014)
3MULTIPLEX FUNCTIONAL BIOLUMINESCENT REPORTERS USING GAUSSIA LUCIFERASE FUSED TO EPITOPE TAGS IN AN IMMUNOBINDING ASSAY
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SUMMARY/ABSTRACT
The use of Gaussia luciferase in a multiplex assay can have several advantages over 
the singleplex method for an experimental setup. Issues such as intersample variability, 
screening purposes, efficiency and in vivo applications can be addressed using a 
multiplex assay. Here we describe a functional reporter multiplex method using Gaussia 
luciferase fused to epitope tags to identify the different reporters that are expressed. 
Tag specific antibodies are used to bind and separate the tagged luciferase reporters.   
Key words: Gaussia luciferase, optical imaging, bioluminescent imaging, multiplex 
assay, epitope tag, antibody binding assay
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INTRODUCTION
Bioluminescent reporters can be used to non-invasively detect and quantify biological 
processes in vitro and in vivo1. By engineering the reporter gene under the control of 
genetic promoters or other gene regulatory elements, the resulting reporter protein 
reflects the regulation of these elements. Examples of these regulatory elements can 
be constitutively active promoters to analyse cell survival and proliferation (e.g. CMV 
promoter) or specific promoters containing transcription factor regulatory elements 
(TREs) to analyse transcription factor activities2,3. Other examples are 3’-UTR regions 
to analyse miRNA activities4 and protease cleavage sites (PCSs) to analyse protease 
activities5. Regularly used bioluminescent reporter genes are Firefly luciferase6 (Fluc) 
and Renilla luciferase7 (Rluc). After translation these luciferases are localised inside 
the cell’s cytoplasm and ex vivo detection can therefore be a challenge. The enzyme 
Gaussia luciferase8 (Gluc) is secreted into the extracellular fluids such as culture 
medium, animal blood and urine and can therefore be readily non-invasively detected 
in these fluids enabling serial sampling over time in a single experiment. 
One major disadvantage of luciferase reporters is the difficulty to use a multiplicity of 
luciferase reporters in combination in a single experiment. This limits the use of luciferase 
reporters in multiplex assays. Attempts are made to use a range of reporters using modified 
luciferases, each producing light with a different wavelength in order to discriminate 
between the different parameters they represent. The downside of this strategy is the need 
for sophisticated equipment to separate the different signals. Also, overlap in the light 
spectra might make signal separation a challenge and the number of reporters limited. 
Another strategy to analyse multiple reporters in a single assay is to use luciferases 
that need different enzyme substrates to produce light9. A regularly used example is 
firefly luciferase, which needs D-luciferin as a substrate, in combination with Renilla 
luciferase, which needs coelenterazine. The disadvantage of this method is the limited 
number of luciferase substrate combinations currently known. 
We aimed to develop an easily adaptable method for multiplexing a secreted 
luciferase reporter in order to perform broad range screening of biologically relevant 
processes in vitro or in vivo. Therefore, we engineered a range of fusion gene 
reporters consisting of the Gluc gene, each coupled to a different epitope tag10 (see 
figure 1). By this method we engineered the ten GlucTag reporters GlucFlag, GlucHis, 
GlucHA, GlucAcV5, GlucV5 and GlucGlu, GlucMyc, GlucKt3, GlucAu1 and GlucE2. Epitope tags
11 
are peptide sequences usually derived from viral or bacterial genes, giving them a 
high affinity to mammalian antibodies. Coupling the Gluc gene to a range of different 
epitope tags enables us to design a large number of different GlucTag reporters. Using 
the corresponding tag specific antibodies to selectively immunobind the different 
GlucTag makes it possible to separate the different GlucTag reporters and individually 
quantify them by reading out the light production after addition of substrate10(see 
figure 3). As a proof of concept we designed ten different GlucTag based reporters, 
each coupled to a different epitope tag, under the control of the constitutively active 
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cytomegalovirus (CMV) promoter. After lentiviral transduction12 we produced ten U87 
glioma cell lines, each stably expressing one GlucTag reporter and used these cells to 
collect GlucTag conditioned cell culture medium or mouse blood to monitor in vitro 
and in vivo tumor cell growth by measuring GlucTag activity ex situ, after tag specific 
antibody immunobinding (see figure 3). In this chapter the proof of concept of the 
multiplex Gaussia luciferase-based functional reporter assays in vivo is described10. 
MATERIALS
Construct ion and development of  GlucTag reporter cel l  l ines
1. The CSCW-Gluc-IRES-CFP lentiviral vector DNA (see note 1). This lentiviral vector 
co-expresses the Gluc bioluminescent reporter and the cerulean fluorescent 
protein (CFP) control. The internal ribosomal entry site (IRES) allows co-expression 
of both proteins using the same cytomegalovirus (CMV) promoter. The vector is 
designated CSCW-Gluc-CFP in this protocol.
2. AccuPrime Pfx DNA polymerase (Life Technologies, see note 2). It is provided with 
a 10 x AccuPrime reaction mix and separate MgSO4 (50 mM).
3. PCR amplification primer oligonucleotides (10 µM, see note 1):
 - Forward: 5’-GCG TGT ACG GTG GGA GGT CT-3’ 
 - Reverse: 5’-T CTC GAG TAG TCT AGA GTC ACC ACC GGC CCC CTT-3’.
4. PCR thermocycler.
5. Restriction enzymes NheI, XbaI and XhoI (New England Biolabs, see note 3). 
6. Heat block.
7. DNA gel electroforesis system.
8. 0.5 % agarose (v/w) DNA gel with ethidium bromide (10 µg/ml final concentration). The 
total volume depends on the DNA gel electroforesis system used (7.). Add e.g. 0.5 g 
agarose to 100 ml TAE buffer (9.) and cook it in a microwave for 2 minutes at the highest 
power (~900 watts). Be careful to make sure that the agarose has melted completely. 
Cool down the gel to ~65˚C, add ethidium bromide (10 µg/ml final concentration, see 
note 4) and swirl gel well. Pour gel in a DNA gel cast with a DNA gel slot comb and let 
it solidify for 30 minutes. Remove the DNA gel slot comb carefully. 
9. 1 x TAE buffer (40 mM Tris, 20 mM acetic acid and 1 mM EDTA in dH2O). Make a 
50 x TAE stock solution by dissolving 242 g Tris base in dH2O. Add 57.1 ml glacial 
Figure 1. Overview of the GlucTag construct. We constructed ten GlucTag constructs, each with a 
different tag: GlucFlag, GlucHis, GlucHA, GlucAcV5, GlucV5 and GlucGlu, GlucMyc, GlucKt3, GlucAu1 and GlucE2.
CMV Gluc TagU87‐GlucTag
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acetic acid and add 100 ml 0.5 M EDTA (pH 8.0). Add the volume up to 900 ml with 
dH2O and set the pH to 8.5 using HCl or NaOH. Bring the total volume to 1000 ml 
with distilled H2O and autoclave the TAE buffer for 20 minutes at 121˚C. Dilute 20 
ml 50 x TAE stock solution in 980 ml distilled H2O to prepare 1000 ml 1 x TAE buffer.
10. DNA gel loading dye and a broad range (100 bp – 10.000 bp) DNA gel molecular 
weight marker. Use the loading dye and the weight marker according to the 
manufacturers guidelines. 
11. DNA gel extraction kit (Qiagen).
12. T4 DNA ligase (Life Technologies).
13. XL10-Gold ultracompetent cells (Agilent Technologies) for large or ligated DNA.
14. LB + ampicillin (50 µg/ml) bacteria selection and propagation plates. To make LB, 
measure 10 g of peptone, 5 g yeast extract and 10 g NaCl and suspend in 1000 ml 
distilled H2O and autoclave the suspension for 20 minutes at 121˚C. Let the LB cool 
down to ~65˚C and add ampicillin to a final concentration of 50 µg/ml and briefly 
swirl. Pour 20 ml of LB + ampicillin per plate (Ø 100 mm).
15. 37˚C bacteria incubator.
16. QIAfilter plasmid kit.
17. Epitope tag sense and antisense oligonucleotides with appropriate ligation 
overhangs (See table 1 and note 1) in a concentration of 100 µM.
18. 10 x Oligonucleotide annealing buffer. To prepare a 50 ml stock solution, mix 5 ml 1 M 
Tris-HCl (pH 7.5, final concentration 100 mM) with 10 ml 5 M NaCl (final concentration 
1 M) and 1 ml 0.5 M EDTA (final concentration 10 mM) and add 34 ml ultrapure H2O.
19. Human embryonic kidney cell line HEK293T.
20. Human glioblastoma cell line U87.
21. Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 g/l glucose, 110 mg/l 
sodium pyruvate and 584 mg/l L-glutamine. To make DMEM complete culture 
medium, add 10% Fetal bovine serum and penicillin/streptomycin.
22. Phosphate buffered saline (PBS). 
23. Trypsin (0.5 mg/ml) + EDTA (0.22 mg/ml) in PBS.
24. A cell culture incubator at 37˚C and with 5% CO2.
25. Third generation lentiviral packaging plasmid pRRE, packaging plasmid pRSV/Rev 
and envelope plasmid pMD2.G (Addgene).
26. 3 M Calcium chloride (CaCl). to make 100 ml of 3 M CaCl solution, dissolve 33.3 
g CaCl x 2H2O in 95 ml ultrapure H2O. Set the pH to 7.2 and fill the solution up to 
100 ml. Sterile filter the 3 M CaCl solution. 
27. 2x HEPES buffered saline (HEBS). Dissolve 8 g NaCl (final concentration 273.7 
mM), 0.37 g KCl (final concentration 9.9 mM), 1 g Na2HPO4 (1.4 mM), 1 g dextrose 
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(final concentration 11.1 mM) and 5 g HEPES (42 mM) in 450 ml ultrapure H2O. Set 
the pH to 7.2 and then fill up the solution to 500 ml with ultrapure H2O. Autoclave 
the 2x HEBS for 15 minutes at 121˚C.
Gluc Tag-CFP mult ip lex assay appl icat ion
Gluc Tag immunobinding assay  in  v i t ro
1. 6-well cell culture plates.
2. A cell culture incubator at 37˚C and with 5% CO2.
3. Wash buffer. Add 0.5 ml Tween-20 (0.05%) to 1 l of phosphate buffered saline (PBS) 
to make the PBS + 0.05% Tween-20 wash buffer solution.
4. White goat anti-mouse IgG coated 96-well microplates (Thermo Scientific, see note 5).
5. Mouse monoclonal anti-Tag IgG (see Table 1, see note 6). 
6. Microplate centrifuge.
7. Microplate shaker.
8. Block buffer. Add 0.5 ml Tween-20 (0.05%) and 10 g bovine serum albumin (BSA, 
1% v/w) in 1 l of phosphate buffered saline (PBS) to make the PBS + 0.05% Tween-20 
+ 1% BSA block buffer solution.
9. Coelenterazine Gluc substrate. Dilute coelenterazine in methanol (5 mg/ml) to 
make a stock solution. Before use, dilute the stock solution coelenterazine 1 µl 
per 1000 µl PBS + Triton X-100. Incubate the final user solution coelenterazine 
(5 µg/ml) 30 minutes at room temperature.
10. Microplate luminometer. 
Gluc Tag immunosta in ing in  v i t ro
1. 24-well plates.
2. Phosphate buffered saline (PBS).
3. 3.7% formaldehyde fixative solution.
4. Block buffer. Add 10 g bovine serum albumin (BSA) to 1 L of PBS to make a PBS + 
1% BSA block buffer solution.
5. Permeabilization buffer. Add 1 ml Triton X-100 to 1 l of PBS to make a PBS + 0.1% 
Triton X-100 permeabilization buffer solution.
6. Mouse monoclonal anti-Tag IgG (see Table 1, see note 6). 
7. Goat polyclonal anti-mouse-HRP Ig (Dako).
8. DAB substrate kit.
9. Light microscope.
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Gluc Tag immunobinding assay  in  v ivo
1. Athymic nude-foxn1nu mice.
2. Isoflurane anaesthesia system.
3. Temgesic (Buprenorfinehydrochloride) analgesia in PBS.
4. Small animal stereotaxic frame.
5. Surgical scalpel.
6. Microsyringe (Hamilton).
7. Microdrill 0.8 mm.
8. Capillary collection and sample container (Sarstedt, see note 7).
9. Blood dilution buffer. Add 0.8 g EDTA (0.8% v/w) to 100 ml PBS to make PBS + 
0.8% EDTA blood dilution buffer solution.
10. White goat anti-mouse IgG coated 96-well microplates (Thermo Scientific, see note 5).
11. Wash buffer. Add 0.5 ml Tween-20 (0.05%) to 1 l of phosphate buffered saline (PBS) 
to make the PBS + 0.05% Tween-20 wash buffer solution.
12. Mouse monoclonal anti-Tag IgG (see Table 1, see note 6). 
13. Microplate centrifuge.
14. Block buffer. Add 0.5 ml Tween-20 (0.05%) and 10 g bovine serum albumin (BSA, 
1% v/w) in 1 l of phosphate buffered saline (PBS) to make the PBS + 0.05% Tween-20 
+ 1% BSA block buffer solution.
15. Microplate shaker.
16. Coelenterazine Gluc substrate. Dilute coelenterazine in methanol (5 mg/ml) to 
make a stock solution. Before use, dilute the stock solution coelenterazine 1 µl per 
1000 µl PBS + Triton X-100. Incubate the final user solution coelenterazine (5 µg/
ml) 30 minutes at room temperature.
17. Microplate luminometer. 
Gluc Tag immunosta in ing in  v ivo
1. Formaldehyde 3.7% in PBS. To make 100 ml of 3.7% formaldehyde in PBS, add 
10 ml of 37% stock solution formaldehyde to 90 ml of phosphate buffered saline 
(PBS) and mix.
2. Microtome.
3. Glass microscope slides.
4. Xylene.
5. Ethanol series. Make 3 ethanol solutions of 100%, 97% and 75% ethanol in H2O. 
To make 100 ml of 97% ethanol solution, add 97 ml ethanol in 3 ml H2O and mix. 
To make 100 ml of 75% ethanol solution, add 75 ml ethanol to 25 ml H2O and mix.
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6. 0.3% H2O2 in methanol. To make a 0.3% hydrogen peroxide (H2O2) in methanol 
solution, add 1 ml of 30% H2O2 stock solution to 100 ml of methanol and mix.
7. Antigen retrieval citrate buffer. To make the antigen retrieval citrate buffer, add 1.92 
g anhydrous citric acid (final concentration 10 mM) to 950 ml of H2O and mix. Set the 
pH to 6 and fill up the solution to 1 l. Finally, add 0.5 ml of Tween-20 and mix well.
8. Microwave.
9. Mouse monoclonal anti-Tag IgG (see Table 1, see note 6). 
10. Antibody diluent (Dako).
11. Phosphate buffered saline (PBS).
12. Goat polyclonal anti-mouse-HRP Ig (Dako).
13. DAB substrate kit.
14. Haematoxyline staining solution.
15. Light microscope.
3 METHODS
Construct ion and development of  GlucTag reporter cel l  l ines
1. Construct the Glucmodified gene by amplifying the Glucparental gene from lentiviral 
vector CSCW-Gluc-CFP (see figure 2 and note 1) making a PCR reaction mix of 
20 µl using primers that exclude the STOP codon and add the unique restriction 
site XbaI downstream. Use a high fidelity proof reading DNA polymerase and 
follow the manufacturer’s guidelines to amplify the Glucmodified gene (633 bp) in 
thermal cycler by 1: denature the plasmid DNA for 2 minutes at 95˚C. Then 2: 
denature for 30 seconds at 95˚C, 3: anneal primers for 30 seconds at 62˚C and 4: 
elongate DNA for 1 minute at 72˚C and cycle sequence 2, 3, 4 for 35 times. Allow 
5: final elongation of DNA for 2 minutes at 72˚C. 
2. To form sticky ends to the Glucmodified gene in order to clone it back into the CSCW 
lentiviral backbone to replace the Glucparental gene, restrict the Glucmodified gene 
with restriction enzyme NheI upstream, and restriction enzyme XhoI downstream. 
Restrict the total volume of the PCR reaction from (1.) by making a double digestion 
using high fidelity enzymes (see note 3), according to the manufacturer’s guidelines 
in a total volume of 50 µl. Incubate the restriction mix for 2 hours at 37˚C to ensure 
complete restriction. Also, create the CSCW lentiviral backbone by restricting 2 µg 
of the parental CSCW-Gluc-CFP lentiviral vector with NheI and XhoI as described 
to restrict out the Glucparental gene.
3. Isolate and purify the Glucmodified gene from (2.) and the CSCW lentiviral backbone from 
(2.) on a 0.5% (w/v) agarose DNA gel. Add DNA loading buffer (final concentration 
is 1x DNA loading buffer) to the Glucmodified gene and CSCW lentiviral backbone 
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restriction mixtures from (2.) and load both the samples into a separate gel well. Also 
load a separate well with a DNA molecular weight marker to identify the product and 
confirm product sizes. Run the gel in 1 x TAE buffer at 100 volts until the Glucparental 
gene (718 bp) has separated properly from the CSCW lentiviral backbone (9408 bp). 
4. Extract the Glucmodified gene construct (570 bp) and the CSCW lentiviral backbone 
(9408 bp) using a DNA gel extraction kit according to manufacturer’s protocol. 
After elution with 50 µl elution buffer, heat both the DNA extractions in an open 
tube to 60˚C for 5 minutes to completely evaporate any residual ethanol. 
5. To clone the Glucmodified gene into the CSCW lentiviral backbone, ligate 100 ng 
CSCW lentiviral backbone from (4.) with 57 ng Glucmodified gene from (4.) ((Glucmodified 
gene):(CSCW lentiviral backbone) is 10:1 molar ratio, see note 8) using a T4 DNA 
ligase according to the manufacturer’s guidelines. Use a total reaction volume of 20 µl.
6. Transform the resulting ligation product CSCW-Glucmodified-CFP lentiviral vector in 
ultracompetent bacterial cells for ligated DNA according to the manufacturer’s 
guidelines in order to make bacterial clones for CSCW-Glucmodified-CFP lentiviral 
vector production. Plate the bacterial cells on a LB + ampicillin (50 µg/ml) bacteria 
selection and propagation plate and grow the bacterial colonies overnight at 37˚C.
7. Amplify and isolate the CSCW-Glucmodified-CFP lentiviral vector using a DNA plasmid 
kit following the manufacturer’s guidelines. 
8. Construct epitope tag inserts by annealing the corresponding epitope tag sense 
and antisense oligonucleotides (see Table 1). Mix 50 µl of H2O with 10 µl of the 
10x annealing buffer, 20 µl of the sense oligonucleotide (100 µM) and 20 µl of the 
antisense oligonucleotide (100 µM). Heat the annealing mixture in a heat block for 
10 minutes at 65˚C, then take out the metal heat block insert to very slowly cool 
down the annealing mixture to room temperature. 
9. Restrict 2 µg of the CSCW-Glucmodified-CFP using restriction enzymes XbaI and XhoI 
to open up the CSCW lentiviral backbone in order to insert the epitope tag from 
(8.). Make a 20 µl double digestion using high fidelity restriction enzymes and 
follow manufacturer’s guidelines. 
10. Isolate and purify the CSCW lentiviral backbone as described in (3.) and clone 
the epitope tag insert into the CSCW lentiviral backbone as described in (5.). Use 
a molar ratio (epitope insert):(CSCW lentiviral vector, see note 8) of 10:1 and a 
total volume of 20 µl. Transform the resulting CSCW-GlucTag-CFP lentiviral vector 
ligation product as described in (6.) and amplify the vector as described in (7.).
11. HEK293T and U87 cells are cultured in DMEM complete culture medium at 37˚C and 
5% CO2.  The cells are diluted 1/10 when the culture vessel is ~90% confluent. To 
dilute, aspirate the culture medium and was attached cells with PBS. Shake culture 
vessel gently and aspirate PBS. Detach the cells by adding 1x Trypsin + EDTA, 
enough to just cover the surface of the culture vessel. Incubate the cells 5 minutes at 
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37˚C for 5 minutes. Resuspend the cells in DMEM complete culture medium (>5x the 
Trypsin + EDTA volume) and aspirate 9/10 of the total volume to discard or collect 
the suspended cells. Add DMEM complete culture medium to the 1/10 leftover cell 
suspension up to the final culture volume. Make sure the surface of the culture vessel 
is covered with ~0.5 cm culture medium. Use room temperature reagents.
12. Produce the lentiviral particles as described in (Ref. Dull et al.). Transiently transfect 
5.5 x 106 HEK293T cells in a 10 cm2 culture dish with 3 µg pMD2.G envelope plasmid, 
5 µg pMDLg/pRRE and 2.5 µg pRSV/Rev packaging plasmids and 10 µg CSCW-
GlucTag-CFP lentiviral vector using the calcium phosphate transfection method (Ref, 
see note 9). Harvest the virus-containing medium and spin at 1000 x G for 5 minutes 
to remove residual cells and debris. Aliquote and store the virus-containing medium 
at 4˚C for use within a week or at -80˚C for longer periods of time. 
13. Make U87 cell lines (see note 10) stably expressing GlucTag-CFP by lentiviral 
transduction as described in (Dull et al.). Transduce 2 x 105 U87 cells in a 6 well plate 
with CSCW-GlucTag-CFP lentivirus (MOI of 5, see note 11) overnight. The following 
day, replace the virus-containing medium with 2 ml fresh DMEM complete culture 
medium. Expand and culture the cells as described in (11.). Transduction efficiency 
can be determined by fluorescence microscopy of CFP (455-480 nm).
Gluc Tag-CFP mult ip lex assay appl icat ion
Gluc Tag immunobinding assay  in  v i t ro
1. Plate U87-Gluc6x Tag-CFP cells (see note 10) in a 6-well plate in DMEM complete 
culture medium and culture the cells in 37˚C and 5% CO2. For a triplo experiment, 
plate 3 wells of a 6-well plate.
2. At predetermined time points, collect 180 µl (30 µl x 6 Tags) of the Gluc6x Tag 
conditioned culture medium of the 3 wells and store the culture medium at 4˚C 
(see figure 2). 
3. After the final time point collection, Wash 18 wells (6 Tags in triplo) per time point of a 
goat anti-mouse IgG coated 96-well microplate 3 x with 200 µl wash buffer (see note 5). 
4. Per timepoint, prepare 150 µl wash buffer with mouse anti-Tag monoclonal IgG 
(10 µg/ml, see Table 1, see note 6) for all 6 Tags. Coat the wells with 50 µl anti-Tag 
monoclonal mixture per well (see figure 2) and incubate for 1 hour at 4˚C spinning 
at 500 x G followed by 1 hour of incubation at room temperature on a microplate 
shaker at 65-75 RPM (to create a gentle swirl in the wells). 
5. Then, aspirate anti-Tag monoclonal mixture and the wash the wells 3 x with 200 µl 
of block buffer for 5 minutes on a microplate shaker at 65-75 RPM (to create a 
gentle swirl in the wells).
6. To bind the GlucTag from the conditioned culture medium, add 30 µl of the Gluc6x Tag 
conditioned culture medium to a mouse anti-tag coated well and incubate at room 
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Figure 2. GlucTag cloning strategy. The Gluc gene is amplified from the parental vector using primers 
that amplify Gluc without the tata-box and adding an XbaI and XhoI restriction site downstream. 
This modified Gluc gene then replaces the original Gluc gene in the parental vector to construct 
the Glucmodified vector. Then, the vector is restricted with XbaI and XhoI to insert an epitope tag of 
choice. This GlucTag is the final construct.
temperature for 2 hours on a microplate shaker with 65-75 RPM (to create a gentle 
swirl in the wells).
7. After this, aspirate the culture medium and wash the wells 5 x for 5 minutes with 200 µl 
wash buffer on a microplate shaker at 65-75 RPM (creating a gentle swirl in the wells).
8. To measure the bound GlucTag in the mouse anti-Tag coated wells, aspirate the 
wash buffer completely and just before measurement add 50 µl coelenterazine 
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Gluc substrate per well using a multichannel pipette. Immediately insert the plate 
in the microplate luminometer (see note 11), shake the plate briefly and read out 
the wells for 0.1 second per well (see figure 3).
Gluc Tag Immunosta in ing in  v i t ro
1. Plate 105 of the U87-Gluctag cell lines (see note 10) in a 24 well plate overnight in 
500 µl DMEM complete culture medium at 37˚C and 5% CO2.
2. The next day, wash the cells with 200 µl PBS and fix with 100 µl 3.7% formaldehyde 
fixative solution for 20 minutes.
3. Then, wash and block the cells 3 x 5 minutes with 200 µl block buffer and 
permeabilize the cells with 100 µl permeabilization buffer for 15 minutes.
4. Next, wash and block the cells 2 x 5 minutes with 200 µl block buffer.
5. Add 100 µl primary mouse anti-tag IgG (2 µg/ml, see note 6) in block buffer to the 
cells and incubate for 1 hour at room temperature.
6. Subsequently, wash and block the cells 3 x 5 minutes with 200 µl block buffer.
7. Add 100 µl secondary goat anti-mouse-HRP antibody (5 µg/ml, see note 12) in 
block buffer to the cells and incubate for 1 hour at room temperature.
8. Then, wash the cells 3 x for 5 minutes with 200 µl block buffer and stain the cells 
with the DAB reagent set according to the manufacturers guidelines. Analyse the 
immunostaining using light microscopy (see figure 4).
1. Coat eachwells with a different tag 
Specific antibodies (in triplo)
10 x GlucTag expressing cells mixed in vitro or in vivo
2. Specifically immunobind GlucTag
from the extracellular fluids
3. Read out the Gluc activity for every Specifically 
bound GlucTag using a luminometer
Figure 3. Immunobinding assay. A white 96-well microplate is coated with anti-tag antibodies. Every 
well contains one antibody specific for one GlucTag. Cell culture medium or animal blood containing 
a mix of all ten different GlucTags is added to the well to immunobind a specific GlucTag reporter. After 
washing the bioluminescent activity of every specific GlucTag reporter is determined using a luminometer.
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Gluc Tag immunobinding assay  in  v ivo
1. Culture and collect the U87-GlucTag-CFP cells as described before. Collect 5 x 10
5 
U87-GlucTag-CFP cells per orthotopical injection in athymic nude-foxn1
nu mouse. 
For a triplo experiment inject 3 mice.
2. 30 minutes before surgery of the mouse, subcutaneously administer Temgesic 
(Buprenorfinehydrochloride, 0.1 mg/kg) in PBS analgesia and anesthetize 
the mouse using an isoflurane anaesthesia and fix the mouse in a small animal 
stereotaxic frame. 
3. Incise the head skin with a surgical scalpel and locate the injection site x = 2 mm 
and y = 0.5 mm from bregma. Drill a hole in the skull and slowly inject the U87-
GlucTag-CFP cell suspension into the brain. Then, cover up the skull with the head 
skin and stitch the wound.
4. At predetermined time points, collect 100 µl of the GlucTag conditioned mouse 
blood of all the mice using a capillary collection and sample container containing 
EDTA to prevent blood clotting and store the blood at 4˚C (see note 7).
5. After the final blood sample collection, dilute the blood 1:1 with blood dilution 
buffer to increase the sample volume to 180 µl.
6. Wash 18 wells (6 Tags in triplo) per time point of a goat anti-mouse IgG coated 
96-well microplate (see note 5) 3 x with 200 µl wash buffer. 
7. Per timepoint, prepare 150 µl wash buffer with mouse anti-Tag monoclonal IgG 
(10 µg/ml, see Table 1) for all 6 Tags (see note 13). Coat the wells with 50 µl 
anti-Tag monoclonal mixture per well and incubate for 1 hour at 4˚C spinning at 
500 x G followed by 1 hour of incubation at room temperature. 
8. Then, aspirate anti-Tag monoclonal mixture and the wash the wells 3 x with 200 µl 
of block buffer for 5 minutes on a microplate shaker at 65-75 RPM (to create a 
gentle swirl in the well).
9. To bind the GlucTag from the conditioned mouse blood, add 30 µl of the diluted Gluc6x Tag 
blood samples to a mouse anti-tag coated well and incubate at room temperature for 
2 hours on a microplate shaker with 65-75 RPM (to create a gentle swirl in the well).
10. After this, aspirate the diluted Gluc6x Tag blood samples and wash the wells 5 x for 
5 minutes with 200 µl wash buffer on a microplate shaker at 65-75 RPM (creating 
a gentle swirl).
11. To measure the bound GlucTag in the mouse anti-Tag coated wells, aspirate the 
wash buffer completely and just before measurement add 50 µl coelenterazine 
Gluc substrate per well using a multichannel pipette. Immediately insert the plate 
in the microplate luminometer plate reader, shake the plate briefly and read out 
the wells for 0.1 second per well (see figure 3 and note 11).
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Gluc Tag Immunosta in ing in  v ivo
1. After the in vivo GlucTag assay, collect and fix the mouse brains containing the 
tumor in 3.7% formaldehyde for at least 48 hours. Then, dehydrate and embed the 
tissue samples in paraffin.
2. Using a microtome, section the paraffin embedded tissue samples in 5 µm slices 
and mount the slices on glass slides.
3. Deparaffinise the tissue slices in xylene and rehydrate in a series of 100% ethanol, 
96% ethanol and 75% ethanol.
4. Block the endogenous peroxidase with fresh 0.3% H2O2 in methanol for 30 minutes 
at room temperature and rinse the slices with H2O.
5. Perform antigen retrieval by cooking the slices in citrate buffer (pH 6) using a 
microwave. Cook the samples 5 minutes at 100% power and 10 minutes at 50% 
power. Cool the slices down to room temperature in 20 minutes and rinse the slices 
3 x 5 minutes with PBS.
6. Incubate the slices with mouse anti-Tag monoclonal IgG (final concentration is 
2 µg/ml, see note 6) diluted in in antibody diluent for 1 hour at room temperature. 
After IgG incubation, rinse the slices 3 x 5 minutes with PBS.
7. Incubate the slices with anti-mouse-HRP (1 in 200) diluted in antibody diluent for 
30 minutes at room temperature and rinse the slices 3 x 5 minutes in PBS.
8. Incubate the slices with DAB for 5 to 10 minutes and rinse the slices with H2O. 
9. Counterstain the cell nuclei of the tissue slices with haematoxyline for 30 to 60 
seconds and rinse the slices with PBS.
10. Dehydrate the slices in the ethanol series of 75% ethanol, 96% ethanol and 100% 
ethanol and incubate the slices in xylene for 5 minutes. Let the tissue slices dry and 
analyse them using a light microscope (see figure 4).
NOTES
1. In the assay described here, we use the CSCW-Gluc-IRES-CFP lentiviral vector DNA 
as a template to amplify the Gluc reporter gene and to religate our GlucTag reporter 
constructs in. When using other template vectors or reporters, it is necessary do 
redesign primers, restriction sites and oligonucleotide sequences and PCR programs 
should be optimised in order to fit the alternative vector DNA or reporter gene. 
2. We advise to use a high fidelity proof reading DNA polymerase for the amplification 
of the Gluc reporter gene. This minimizes optimization and the risk of copy errors 
due to incorrect basepairing. 
3. We advise to use high fidelity restriction enzymes for restriction of the DNA 
vectors. This increases restriction efficiency and user simplicity since most high 
fidelity enzymes are optimised in the same restriction reaction buffer. Also, most 
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high fidelity restriction enzymes are optimised to have less star activity, increasing 
ligation efficiency in later steps of the protocol.
4. There are less hazardous alternatives available for ethidium bromide, such as SYBR 
safe DNA gel stain (Life Technologies). Besides being less hazardous, these stains 
can also be used to visualize DNA with non-UV-light, decreasing damage of the 
DNA due to UV exposure.
5. For luciferase assays it is best to use white microplates to prevent crossover 
detection of photons between wells. The white goat anti-mouse IgG coated 
microplates (Thermo Scientific) are pre-coated to improve assay stability but it is 
also possible to manually coat microplates (e.g. ELISA microplates). 
6. The antibodies we used are all mouse monoclonal IgG antibodies. The coated 
microplates used (see note 5) are optimised to use with mouse IgG antibodies. 
Using monoclonal antibodies over polyclonal antibodies improves assay stability. 
We were able to  optimize 6 glucTag antibody combinations for high performance 
binding capacity while for GlucTag antibody combinations showed low binding 
capacity due to a lower affinity of the antibody to the epitope tag. When using 
new antibodes, you should optimize the immunobinding assay by validating the 
antibody binding capacity to the GlucTag.
7. The capillary collection and sample container (Sarstedt) we used combines a 
capillary blood collector with an EDTA coated sample container. This enables fast 
and easy sample collection and storage. If you collect mouse blood using other 
methods, make sure you add EDTA to the blood sample to prevent clotting.
Figure 4. GlucTag Immunostaining. Representative immunostaining of ten mixed U87-GlucTag-CFP 
cell lines in a mouse xenograft, each expressing another GlucTag. In this example, an immunostaining 
against GlucV5 was performed using an anti-V5 mouse immunoglobulin. The GlucV5 expressing U87 
cells can be clearly distinguished from the other cells in the tumor. 
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8. To quantify the concentration of the DNA gel extracts, we do not recommend the 
use of spectrophotometry (Nanodrop) since the concentration will usually be low 
(<100 ng/µl). We advise to quantify the concentrations of the DNA gel extracts 
by loading a small amount of DNA sample on a gel and quantify the resulting 
bands by comparing to the molecular marker. We used ImageJ to quantify the 
DNA sample concentrations and calculate the ligation conditions.
9. Generally, higher virus titers are obtained using other methods of transfection of 
the plasmids and vectors. Using Lipofectamine 2000 (Life Technologies) or Fugene 
(Promega) can be beneficial for virus production titres.
10. It is possible to transduce other cell lines of your interest but not all cell lines are 
equally resistant to lentiviral transduction and therefore the transduction conditions 
need to be optimized for every cell line. To increase transduction efficiency, it might 
be beneficial to culture the cells with polybrene (2-10 µg/ml) before transduction. Also 
using polybrene requires optimization, depending on the cell line of use. Expression of 
the reporters is also cell line dependent since the CMV promoter is not equally active 
in all cell lines and therefore also the promoter might be an issue for optimization.
11. Since the Gluc photon signal is degrading over time (~10% per minute), the 
most stable method of measuring would be to measure Gluc signal directly after 
coelenterazine substrate addition. A plate reader with a substrate injector would 
be optimal but it is also an option to use a multichannel pipette. Measuring a 
96-well microplate for 0.1 second per well would take about 10 seconds, so the 
time difference as a result of measuring the first well and the last well would be well 
within 10% deviation as a result of the Gluc signal degradation.
12. For this assay we used goat anti-mouse secondary Ig. It would also be possible to 
use other anti-mouse Ig antibodies but optimisation is required.
13. As a negative control for the immunobinding assays and the stainings it is possible 
to use the CSCW-Glucctrl-CFP vector. This vector contains the Gaussia luciferase 
not fused with an epitope tag. 
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4EZH2-REGULATED DAB2IP IS A MEDULLOBLASTOMA TUMOR SUPPRESSOR AND A POSITIVE MARKER FOR SURVIVAL 
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ABSTRACT
Purpose: Medulloblastoma is the most common malignant brain tumor in children. 
Despite recent improvements, the molecular mechanisms driving medulloblastoma 
are not fully understood and further elucidation could provide cues to improve 
outcome prediction and therapeutic approaches.
Experimental Design: Here, we performed a meta-analysis of mouse and human 
medulloblastoma gene expression datasets, in order to identify potential 
medulloblastoma tumor suppressor genes.
Results: We identified DAB2IP, a member of the RAS-GTPase activating protein family 
(RAS GAP), and demonstrated that DAB2IP expression is repressed in medulloblastoma 
by EZH2-induced trimethylation. Moreover, we observed that reduced DAB2IP 
expression correlates significantly with a poor overall survival of medulloblastoma 
patients, independent of metastatic stage. Finally, we demonstrated that ectopic 
DAB2IP expression enhances stress-induced apoptotis in medulloblastoma cells and 
that reduced expression of DAB2IP in medulloblastoma cells conveys resistance to 
irradiation-induced cell death.
Conclusion: These results suggest that repression of DAB2IP may at least partly protect 
medulloblastoma cells from apoptotic cell death. Moreover, DAB2IP may represent a 
molecular marker to distinguish medulloblastoma patients at high risk from those with 
a longer survival prognosis.    
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INTRODUCTION
Brain tumors are the most common form of solid tumors in children of which medulloblastoma 
is the most frequent malignant variant, accounting for 20% of cases 1. Treatment modalities 
consist of surgery, radiotherapy and chemotherapy and result in a 5-year survival rate of 
40% in high risk patients and 80-90% in low risk patients 2. Approximately 30% of patients 
however remain incurable and current intensive treatment protocols cause significant 
adverse long term effects 3. Medulloblastomas comprise four subtypes: WNT, SHH, Group 
3 and Group 4 which differ regarding histology and clinical outcome 4 and are believed to 
derive from the deregulation of various signalling pathways in brain development, such 
as the WNT-pathway and sonic hedgehog (SHH) signalling pathways. Over activation of 
these pathways leads to a loss of cell cycle control and a dysfunctional apoptosis program, 
allowing for continued growth and tumorigenesis, predominantly in the cerebellum 5.
DAB2IP - disabled homolog 2-interacting protein, located at chromosome 9q33.1-
q33.3 - is a member of the RAS-GTPase activating protein family (RAS GAP) that 
inactivates RAS by promoting conversion of GTP into GDP 6. DAB2IP acts as a putative 
tumor suppressor gene and is down-regulated by epigenetic modification in multiple 
aggressive cancers. In prostate cancer DAB2IP expression was shown to be repressed 
by promoter methylation and histone modification 7, while in breast cancer 8, lung cancer 
9, and gastrointestinal tumors 10, aberrant promoter hypermethylation was shown to 
down-regulate DAB2IP. Moreover, it was shown in prostate cancer that down-regulation 
of DAB2IP expression results in resistance to ionizing radiation 11, it initiates epithelial-
to-mesenchymal transition 12 and promotes tumor growth and metastasis 13. In addition, 
DAB2IP is involved in TNFα-induced apoptosis in prostate cancer cells by suppressing the 
ASK1-JNK and PI3-AKT pathway 14, and in endothelial cells via the ASK1-JNK pathway 15. 
Apoptosis is a programmed variant of cell death common to all human cells. Defects 
in the apoptosis program result in an imbalance in the rate of cell proliferation and 
the rate of cell death thereby contributing to tumor growth and treatment resistance. 
Essential steps in the apoptotic mechanism are inactivated in medulloblastoma cells, 
resulting in resistance to apoptosis. A recent in vivo study showed that cerebellar 
stem cells can give rise to medulloblastomas when having acquired an impaired 
apoptosis mechanism 16. Consequently, many of the apoptosis mediators are generally 
considered tumor suppressors 17. 
Here, we describe a comprehensive meta-analysis of gene expression studies 
of mouse and human medulloblastoma 18-23 identifying multiple medulloblastoma 
tumor suppressor candidates, including DAB2IP. We found DAB2IP expression to 
be strongly down-regulated in human medulloblastoma cells and in primary human 
medulloblastoma tissues. We demonstrate that DAB2IP down-regulation is - at 
least partially - caused by EZH2-mediated repression through histone methylation, 
conveying apoptosis resistance in immortalized neural precursor and medulloblastoma 
cells. Furthermore, we show that DAB2IP expression correlates significantly with the 
overall survival of medulloblastoma patients, independent of metastatic stage.
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RESULTS
Meta-ana lys is  of  candidate tumor suppressor  genes  
in  medul loblastoma 
In order to identify candidate tumor suppressor genes in medulloblastoma, we 
determined transcripts that were down-regulated in medulloblastoma as compared 
to normal cerebellar precursor cells in seven data sets comparing gene expression of 
normal cerebellar precursor cells and medulloblastoma in mice. We used mouse studies 
since that allowed for a comparison between medulloblastoma cells and proliferating 
progenitor cells. All data sets employed mouse models that mimic the SHH-
medulloblastoma subgroup (Supplemental Table S1A, GSE9299, GSE2426, GSE7212, 
GSE11859, GSE6463) 18-22. This analysis yielded 56 genes that were significantly down-
regulated (>2-fold) in at least five out of the seven mouse medulloblastoma datasets. 
Subsequently, to increase the relevance of our screen for human medulloblastoma, we 
compared the expression of the significantly down-regulated mouse genes to a human 
medulloblastoma gene expression dataset (GSE10327) 23 and an independent gene 
expression dataset of normal human cerebellum (GSE3526) 24. We established that 37 
genes out of our set of 56 genes were significantly down-regulated in both mouse and 
human medulloblastoma (Supplemental Table S2A). In addition, we compared genes 
that were significantly down-regulated in both mouse and human medulloblastoma 
to a composed list of designated tumor suppressor genes. This resulted in two 
candidate gene sets, one set of 37 highly deregulated genes that have not before 
been designated as tumor suppressors (Fig. 1A and Supplemental Table S2A), and 
one set of 26 genes that have been reported as a tumor suppressor before – mostly in 
cancers other than medulloblastoma (Fig. 1B and Supplemental Table S2B). 
DAB2IP is  down-regulated in  medul loblastoma  
and is  assoc iated with  poor  c l in ica l  outcome
We focused on the down-regulated medulloblastoma genes with designated tumor 
suppressor function (Fig. 1B)  and analyzed by literature search to which of these 
genes a pro-apoptotic function could be attributed. This resulted in the emergence 
of DAB2IP as a potential pro-apoptotic tumor suppressor gene in medulloblastoma, 
since DAB2IP is the third most differentially expressed transcript in our analysis and 
literature search suggests its function in apoptosis regulation 14, 15, 25. To confirm 
that DAB2IP is down-regulated in medulloblastoma, we first analyzed the DAB2IP 
expression levels in medulloblastoma cells. qRT-PCR revealed that DAB2IP mRNA 
expression was down-regulated in medulloblastoma cells D283-med, D556-med, Daoy 
and in primary human medulloblastoma cells (Fig. 2A), as compared to normal human 
cerebellar tissue. This was confirmed on protein level by DAB2IP Western blot analysis 
(Fig. 2B). In order to determine the correlation of DAB2IP down-regulation to clinical 
outcome, DAB2IP expression was evaluated in mRNA expression datasets of human 
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Figure 1. Meta-analysis of potential tumor suppressor genes in medulloblastoma. (A) Down-
regulated genes in medulloblastoma versus normal cerebellar precursor cells in at least five out 
of seven mouse medulloblastoma datasets. The heatmap only represents transcripts that are 
also down-regulated in human medulloblastoma versus normal cerebellum. (B) Representation 
of putative tumor suppressor genes down-regulated in at least three out of seven mouse 
medulloblastoma datasets. The heatmap only represents transcripts that are also down-regulated 
in human medulloblastoma versus normal cerebellum.
medulloblastoma 23, 26, and was correlated to survival (Fig. 2C). The clinical characteristics 
of the tumors/patients used in the survival analysis are summarized in Table 1A. Kaplan-
Meier analysis demonstrates that low DAB2IP mRNA expression correlates significantly 
with a poor prognosis, as measured by a lower overall survival probability (p=0.010). 
Multivariate Cox proportional-hazards analysis shows that DAB2IP expression can 
predict prognosis (Hazard ratio: 3.0, CI 95% = 1.1 – 8.6, p = 0.036), independently 
of clinical variables such as age, metastatic stage and histology. Medulloblastoma 
is known to comprise four subtypes: WNT, SHH, Group 3 and Group 4 which differ 
regarding histology, molecular biology, genetics and clinical outcome 4. However, 
we did not find a significant correlation between DAB2IP expression and any specific 
subtype in our patient series (Supplemental Fig. S1). We also investigated the relation 
between DAB2IP expression and metastatic stage in our patient group. However we 
did not find a significant correlation (Fig. 2D). Finally, to further analyze the effects of 
DAB2IP expression and metastatic stage on prognosis, patients were stratified based 
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on metastatic stage (Fig. 2D, Supplemental Fig. S2A and S2B). Again Kaplan-Meier 
analysis demonstrated that low DAB2IP expression correlated with a poor prognosis 
(p=0.055) both in the metastatic patient and non-metastatic patient groups.
DAB2IP and EZH2 are inversely expressed in medulloblastoma 
Previously it was described that DAB2IP expression is epigenetically suppressed 
by EZH2, a member of the polycomb complex and a histone methylating enzyme 
27. Therefore we determined the EZH2 expression levels in medulloblastoma cells 
and tissues and compared these to DAB2IP expression. First, DAB2IP and EZH2 
expression levels were evaluated in the mRNA expression dataset of 62 human 
medulloblastoma (9 WNT, 15 SHH, 11 Group 3 and 27 Group 4) 23 and nine normal 
cerebellum samples 24. As expected the DAB2IP mRNA levels were significantly down-
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Figure 2. DAB2IP is down-regulated in medulloblastoma and is associated with poor clinical outcome. 
(A) RNA, extracted from various medulloblastoma cell lines (D283-med, D556-med, Daoy) and non-
neoplastic brain cell lines (left panel), and from two primary human medulloblastoma samples and one 
normal human cerebellum tissue sample (right panel) were analyzed by qRT-PCR for expression levels 
of DAB2IP. The data were normalized to the levels of GAPDH mRNA in each sample. Error bars indicate 
s.d. *p<0.05, ***p<0.001, t-test. (B) Protein expression analysis of DAB2IP in various medulloblastoma 
and non-neoplastic brain cell lines. Numbers indicate relative DAB2IP protein expression normalized 
against β-Actin expression. (C) Kaplan-Meier analysis shows that individuals with medulloblastoma 
that have lower expression of DAB2IP have a significantly lower overall survival probability (p= 0.010). 
Cut-off for high and low expression is based on maximum likelihood. (D) Scatterplot of DAB2IP mRNA 
expression levels (arbitrary units) in patients based on metastatic stage M0/M1/M2-3-4 shows that 
average DAB2IP expression does not correlate with metastatic stage in medulloblastoma. (left panel). 
Kaplan-Meier survival curves of (C) further stratified based on metastatic stage (right panel).
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regulated in the medulloblastoma samples as compared to normal human cerebellum 
(Fig. 3A). In contrast, EZH2 mRNA levels were significantly up-regulated in the 
medulloblastoma samples as compared to normal human cerebellum (Fig. 3A). There 
was no significant difference in the expression of DAB2IP between the four subgroups 
of medulloblastoma, while the expression of EZH2 demonstrated an increasing trend 
from the WNT and SHH subgroups to Group 3 and 4 (Fig. 3A). In addition we compared 
DAB2IP and EZH2 expression in individual samples and found a negative correlation 
between DAB2IP and EZH2 mRNA expression (Supplemental Fig. S3A). This negative 
correlation was also found on protein level (Supplemental Fig. S3B). In parallel to the 
DAB2IP expression analysis in medulloblastoma cell lines and primary tissues (Fig. 2A), 
EZH2 expression analysis was performed using the same samples. This demonstrated 
an increased EZH2 expression in medulloblastoma cells as compared to normal 
cerebellum (Fig. 3B), again correlating inversely with DAB2IP expression in these 
samples. Finally, immunohistochemical analysis on tissue microarrays, composed of 
276 pediatric medulloblastoma tissues from 87 patients, showed that EZH2 expression 
was significantly overexpressed in 30 out of 87 samples. In contrast, DAB2IP protein 
expression was not detectable in medulloblastoma samples (Fig. 3C). However, in one 
Table 1A. Patient/tumor characteristics of medulloblastoma series used for survival analysis.
DAB2IP low, M0 DAB2IP low, M+ DAB2IP high, M0 DAB2IP high, M+
Total no cases 57 24 20 7
Gender
Male 39 16 11 5
Female 18 8 9 2
Age at diagnosis
Average age 8.0 7.3 8.4 7.8
Median age 7.0 7.6 6.6 8.1
Age range 1.0 - 35.3 2.0 - 16.6 0.8 - 25.6 2.8 - 13.5
Age groups
Infants (<4) 16 6 2 2
Children (4 - 16) 37 18 17 5
Adults (>16) 4 0 1 0
Histology
Classic 37 21 16 5
Desmoplastic 13 3 2 2
LCA 4 0 2 0
ND 3 0 0 0
Molecular subgroups
WNT 4 0 6 0
SHH 21 1 1 0
Group 3 12 10 5 2
Group 4 20 13 8 5
65
4 D
A
P
2
IP
 IS
 A
 M
E
D
U
LLO
B
LA
S
T
O
M
A
 T
U
M
O
R
 S
U
P
P
R
E
S
S
O
R
Table 1B: Patient/tumor characteristics of medulloblastoma series on tissue micro array (TMA).
Total no cases 87
Gender
Male 27
Female 12
Unknown 48
Age at diagnosis
Average age 14.2
Median age 7.0
Age range 1 - 53
Age groups
Infants (<4) 7
Children (4 - 16) 19
Adults (>16) 15
Unknown 46
Histology
Classic 23
LCA 3
ND 8
Unknown 53
Molecular subgroups
WNT 7
SHH 18
Group 3 14
Group 4 33
Unknown 15
Metastatic Stage
M0 35
M+ 6
Unknown 46
Survival
Alive 61
Diseased 26
patient sample that included adjacent normal cerebellar tissue, the adjacent tissue 
stained negatively for EZH2 and positively for DAB2IP (Fig. 3C, bottom panel). The 
clinical characteristics of the tumors/patients are summarized in Table 1B. 
Epigenetic modulation of DAB2IP expression in medulloblastoma
In order to determine whether DAB2IP expression in medulloblastoma is regulated 
by EZH2-mediated epigenetic histone modulation we transfected medulloblastoma 
cells with siRNAs directed against EZH2 (siEZH2). At 96 h after transfection we 
observed significantly reduced EZH2 levels by Western blot in medulloblastoma cells 
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Figure 4. Epigenetic modulation of DAB2IP expression in medulloblastoma cells. (A) D556-med and 
D283-med protein expression analysis of DAB2IP and EZH2 and H3K27me3 at 48 and 96 h after 
transfection with EZH2 siRNA, or non-related siRNAs. β-Actin expression was used as normalization 
control. (B) D556-med and D283-med protein expression analysis of DAB2IP and EZH2 at 48 and 96 
h after treatment with DZNep. (C) Effect of 5-aza-2'-deoxycytidine (DAC) treatment on DAB2IP mRNA 
expression in D556-med cells. (D) Effect of combined DAC and trichostatin-A (DAC-TSA) treatment 
on DAB2IP mRNA expression in D556-med cells. Error bars indicate s.d. *p<0.05, ***p<0.001, t-test. 
transfected with siEZH2 (Fig. 4A). In addition, EZH2-mediated histone 3 methylation at 
lysine 27 was reduced and DAB2IP protein levels increased in the siEZH2 transfected 
medulloblastoma cells. We also analyzed lysates from medulloblastoma cells treated 
with the S-adenosylhomocysteine hydrolase inhibitor DZNep, a potent inhibitor of 
EZH2 histone methyltransferase activity 28-30. Again a reduction in EZH2 protein levels 
was observed with a delayed increase in DAB2IP levels (Fig. 4B). Besides histone 
methylation DAB2IP expression can be altered by histone acetylation 7 and promoter 
DNA hypermethylation 7-10. It was previously shown that in various cancer types 
DAB2IP expression could be restored by treatment with the DNA hypomethylation 
agent 5-aza-2'-deoxycytidine (DAC). In the medulloblastoma cells used here we could 
not detect an increase in DAB2IP expression following DAC treatment (Fig. 4C). 
However, additional treatment with the histone deacetylase inhibitor trichostatin A 
(TSA) did significantly increase DAB2IP expression (Fig. 4D). This suggests that histone 
modifications may play a more significant role in suppressing DAB2IP expression in 
medulloblastoma, as was described also in prostate cancer 7.
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DAB2IP promotes stress-induced apoptosis in medulloblastoma
To assess the functional role of DAB2IP in medulloblastoma, we examined the effects 
of DAB2IP modulation in human medulloblastoma cells and mouse neuronal precursor 
cells. Since DAB2IP was reported to enhance TNFα-induced apoptotic cell death 
in endothelial cells 15 and prostate cancer cells 14, we analyzed the effect of DAB2IP 
overexpression on TNFα-induced apoptotic cell death in medulloblastoma cells. 
Lentiviral vectors encoding for DAB2IP or LacZ were used to stably transduce Daoy 
medulloblastoma cells. Treatment with TNFα (100 ng/ml) resulted in a 2-fold increase 
in caspase activity in Daoy cells overexpressing DAB2IP, as compared to LacZ control 
cells. This increase was neutralized by simultaneous treatment with the caspase inhibitor 
z-VAD (20 µM) (Fig. 5A). In addition we measured the cell proliferation rate of Daoy cells 
overexpressing DAB2IP or LacZ control. Daoy-DAB2IP cells showed a lower proliferation 
rate as compared to their controls. This result was confirmed in D283-med cells (data 
not shown). Treatment with a low dose of TNFα (10 ng/ml) - to induce mild cellular stress 
- impaired proliferation of the DAB2IP-overexpressing cells even further, whereas the 
proliferation rate of control cells was not significantly inhibited (Fig. 5B). Furthermore, 
DAB2IP overexpression also inhibited anchorage independent growth following 
treatment with a low dose of TNFα (10 ng/ml) in Daoy cells (Supplemental Fig. S4). 
Since ionizing radiation (IR) is an important treatment modality in medulloblastoma and 
down-regulation of DAB2IP gene expression was related to resistance to IR in prostate 
cancer cells 11, we studied the effect of DAB2IP modulation on the clonogenic growth of 
medulloblastoma cells after IR. Daoy-DAB2IP and Daoy-LacZ cells were irradiated with 
doses of 0, 1, 2, 3, 4 and 5 Gy. DAB2IP overexpression showed an IR dose-dependent 
reduction in clonogenic survival as compared to LacZ control cells (Fig. 5C). Finally, 
in order to further study the effect of DAB2IP on TNFα-induced apoptosis, we used 
a shDAB2IP construct to transiently knock down DAB2IP expression in C17.2 murine 
cerebellar progenitor cells immortalized by v-myc 31. Moderate knock down of DAB2IP 
was confirmed by Western blot analysis. DAB2IP knock down in these immortalized 
neural precursor cells significantly reduced TNFα-induced caspase activation (Fig. 5D), 
suggesting that DAB2IP has a pro-apoptotic function in these stressed neural precursor 
cells. In the absence of TNFα induced stress, caspase activation was similar as was 
observed for DAB2IP knock down and C17.2 shCTRL cells (Fig. 5D).
DISCUSSION
We performed a meta-analysis of publicly available medulloblastoma gene expression 
datasets in order to identify potential medulloblastoma tumor suppressor genes. We 
identified DAB2IP to be strongly down-regulated in medulloblastoma cells and in primary 
medulloblastoma tissues. Reduced DAB2IP expression was shown to correlate significantly 
with poor overall survival of medulloblastoma patients, independent of clinical variables 
such as age, metastatic stage and histology. Moreover DAB2IP was shown to be regulated 
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Figure 5. DAB2IP promotes stress-induced apoptosis in medulloblastoma cells. (A) DAB2IP 
overexpression increased caspase activation in Daoy cells treated with TNFα 6 h after treatment. 
Overexpression of DAB2IP in Daoy cells was confirmed by Western blot. (B) Acumen proliferation 
assay of Daoy cells overexpressing DAB2IP following treatment with or without a low dose of TNFα. 
(C) Colony formation of DAB2IP overexpressing Daoy cells, following exposure to increasing doses 
of IR. (D) DAB2IP knock down decreased caspase activation in C17.2 neural precursor cells treated 
with TNFα 6 h after treatment. Knockdown of DAB2IP in C17.2 cells was confirmed by Western 
blot. Error bars indicate s.d. *p<0.05, ***p<0.001, t test.
by histone modifications, including histone acetylation, and histone methylation by the 
polycomb group member EZH2. Finally, we demonstrated that ectopic DAB2IP expression 
enhances stress-induced apoptotis in medulloblastoma cells, and that reduced expression 
of DAB2IP in medulloblastoma conveys resistance to irradiation-induced cell death. 
Medulloblastomas are known to comprise four subtypes: WNT, SHH, Group 3 and 
Group 4 which differ regarding histology, molecular biology, genetics and clinical 
outcome 4. The studies used in our meta-analysis all employed mouse models that 
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mimic SHH-subgroup medulloblastoma (Supplemental Table S1A). While this article 
was being revised, the first MYC-based medulloblastoma mouse models that mimic 
Group 3 were generated 32, 33. The medulloblastomas generated by one of these 
MYC models 32 demonstrate a reduced DAB2IP expression in line with our results 
(Supplemental Fig. S5A). However the medulloblastomas generated by the other 
model 33 do not show differential DAB2IP expression compared to the control tissue 
used in that study (Supplemental Fig. S5B). Recently a mouse model that mimics WNT 
subgroup medulloblastoma was also described 34. However the small number (three) 
of samples and the strong variation in their DAB2IP expression preclude making any 
meaningful comments on DAB2IP expression in this model (Supplemental Fig. S5C). 
Finally, our human medulloblastoma dataset demonstrates that DAB2IP expression is 
significantly reduced in all subgroups (Fig. 3A, Supplemental Fig. S1).  
To increase the likelihood of identifying tumor suppressors in medulloblastoma 
we compared the deregulated mRNA transcripts with a composed list of tumor 
suppressor genes. This list was established by interrogating publicly available 
gene ontology databases that included transcripts that have been tied to a tumor 
suppressor function. A number of well-known tumor suppressors in the context of 
medulloblastoma such as PTCH1, SUFU, APC, AXIN and TP53 35-41 are not included in 
our candidate gene sets. This is likely to be caused by our stringent threshold and the 
various medulloblastoma mouse models used to gather the datasets. For instance, 
PTCH1 is down-regulated >2-fold in two out of seven medulloblastoma mouse model 
datasets, thereby not reaching our cut-off of deregulation in at least three out of seven 
datasets. However in two additional datasets PTCH1 is down-regulated ~1.8 fold. 
Another well known tumor suppressor, TP53, is down-regulated >2-fold in three out of 
seven different mouse models datasets. However, TP53 is not differentially expressed 
between the human medulloblastoma and normal cerebellum dataset, supporting 
reports that TP53 down-regulating mutations in sporadic human medulloblastoma are 
not very common 37. In addition, transcripts can have inactivating mutations without 
being down-regulated at mRNA level, and are therefore not detected using mRNA 
expression analysis. Similar observations have also been reported for PTCH1, AXIN2 
and TP53 in various subgroups of medulloblastoma 23.
It was previously shown that DAB2IP expression can be silenced by promoter 
methylation and histone modification 7-10. Other reported mechanisms for DAB2IP 
inactivation include one case of a translocation that disrupts DAB2IP expression in 
acute myeloid leukemia 42, and a single nucleotide polymorphism in the DAB2IP 
gene in aggressive prostate cancer 43. LOH at DAB2IP was demonstrated in 20% of 
cases in hepatocellular carcinoma 44. In addition, a common sequence variant within 
DAB2IP associates with the risk of abdominal aortic aneurysm 45 and recently a genetic 
variant of DAB2IP was also shown to be an independent risk factor for early onset of 
lung cancer 46. However, as far as we know in medulloblastoma no such mechanisms 
of DAB2IP deregulation have been reported yet. Here we show a significant 
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negative correlation between overexpressed EZH2 and down-regulated DAB2IP in 
human medulloblastoma samples. Moreover, we show that DAB2IP suppression in 
medulloblastoma cells can be at least partly reversed by EZH2 inhibition. Treatment with 
the DNA hypomethylation agent 5-aza-2'-deoxycytidine (DAC) did not affect DAB2IP 
expression in medulloblastoma cells. However, additional treatment with the histone 
deacetylase inhibitor trichostatin A (TSA) did significantly increase DAB2IP expression. 
This may suggest that histone modifications play a significant role in suppressing 
DAB2IP expression in medulloblastoma cells, however, we do not rule out that DAB2IP 
expression in medulloblastoma cells may also be impaired by additional mechanisms. 
Other transcripts in our list of potential medulloblastoma tumor suppressor genes may 
also be EZH2 targets, this is however only confirmed for CDH1 47.
We found DAB2IP mRNA expression was reduced in medulloblastoma cell lines 
and primary tissues. DAB2IP protein levels were also reduced in medulloblastoma cell 
lines. Immunohistochemistry on the medulloblastoma tissue micro array did not reveal 
DAB2IP expression in these samples. However, this does not necessarily mean that 
no protein is present at all. It may well be that small traces of DAB2IP are present in 
some of the medulloblastoma tissue samples, although undetectable by us in these 
experiments. Another explanation may be that post-transcriptional events account for 
the discrepancy between mRNA and protein levels.  
Recently, two publications have related the loss of DAB2IP expression to increased 
epithelial-to-mesenchymal transition (EMT) and metastasis in prostate cancer. Xie et 
al. show that DAB2IP knock down increases nuclear β-catenin accumulation and trans-
activation of target genes involved in EMT by inhibiting GSK3β, indicating an inhibitory 
function of DAB2IP in WNT/β-catenin signaling 12. In the context of medulloblastoma 
this seems paradoxical as metastasis is uncommon in the subgroup of human 
medulloblastoma in which WNT signaling is active 4. In our patient series, average 
DAB2IP expression was slightly higher in the group of WNT associated medulloblastomas 
(Fig. 3A), however this difference was non-significant. It would be of interest to 
determine the role of DAB2IP in WNT signaling in the context of medulloblastoma, 
since a major role in medulloblastoma oncogenesis has been attributed to WNT/β-
catenin 48.  Furthermore, it was reported that loss of DAB2IP expression induces the 
activation of Ras and NF-κB in prostate cancer, where Ras is presumed to play an 
essential role in primary tumor growth and NF-κB drives prostate cancer metastasis 
13. Therefore, we investigated the relation between DAB2IP expression and metastatic 
stage. However, we were unable to demonstrate a significant correlation between 
DAB2IP expression and medulloblastoma metastases (Fig. 2E).
In a study of mammalian brain development high levels of DAB2IP expression 
was found in the developing cerebellum, particularly in Purkinje cell precursors 49. 
Although there is no evidence that medulloblastoma arises directly from Purkinje 
cells, these cells play an important part in the development of the normal cerebellum. 
Purkinje cells generate SHH that projects on granule neuron precursor cells and 
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stimulate their proliferation, before the granule neuron precursor cells migrate deeper 
into the forming cerebellum and differentiate further. A subgroup of medulloblastoma 
is believed to be derived form granule neuron precursor cells that fail to stop 
proliferating 3. We showed that DAB2IP knock down in C17.2 neural precursor cells 
significantly reduced TNFα-induced caspase activation suggesting that DAB2IP has a 
pro-apoptotic function in stressed neural precursor cells. However since C17.2 cells 
are immortalized by overexpression of v-myc 31 the role of DAB2IP in altering apoptosis 
responses needs to be established in normal neural precursor cells. 
We found a significant association between poor overall survival in medulloblastoma 
patients and reduced DAB2IP mRNA levels. Interestingly, no significant difference 
in DAB2IP expression was observed between the group of WNT associated 
medulloblastoma - which has the best prognosis - and Group 3 medulloblastoma - 
which has the worse prognosis 4. This association was observed in metastatic as well 
as in non-metastatic medulloblastoma patients, albeit at near significant levels. These 
results demonstrate that DAB2IP expression is a prognostic marker for medulloblastoma 
outcome and suggest that patients with non-metastatic medulloblastoma with low 
DAB2IP expression may benefit from more aggressive treatment strategies. Recent 
studies have shown that medulloblastoma is a heterogeneous disease with diverse 
treatment outcome 23, 50. Currently staging for treatment is based on clinical parameters 
such as age, extent of surgical resection, presence of metastases and histological 
classification 51, 52. Various studies have suggested that this risk stratification could 
be improved by including molecular determinants 23, 50, 53-57. However, it remains to 
be investigated to what extent DAB2IP could contribute to the sub-classification of 
medulloblastoma and whether it can aid as a prognostic factor in clinical practice.
In conclusion, we identified DAB2IP as a potential anti-apoptotic tumor suppressor 
in medulloblastoma. Further research in its use as a potentially important prognostic 
factor and/or therapeutic target may contribute to improvements in the future 
treatment of medulloblastoma patients. 
MATERIALS AND METHODS
Detailed protocols are in the Supplementary Data.
Biologic samples. Original data on tumor samples from two retrospective studies 23, 26 
were used for this study. Survival analysis was based on 108 cases for which expression 
and survival data was available. Patient and tumor characteristics are presented 
in Table 1A. In brief, all samples were snap frozen in the institutional pathology 
departments immediately upon arrival. All samples were reviewed by experienced 
neuropathologists and examined for tumor content. Total RNA was extracted using 
Trizol (Invitrogen). Gene expression profiles were obtained by Affymetrix HG-U133 
Plus 2.0 arrays. Gene expression data were normalized using the GCRMA procedure. 
Informed consent and detailed methods are described elsewhere 23, 26.
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Immunohistochemistry was performed on a largely independent medulloblastoma 
tissue micro array (TMA) cohort with tumors from 87 patients obtained from the files 
of the Department of Neuropathology of the Academic Medical Center (University 
of Amsterdam). Subgroup information was obtained by immunohistochemistry using 
antibodies for the subgroup-specific protein markers β-catenin (WNT), DKK1 (WNT), 
SFRP1 (SHH), NPR3 (Group 3), and KCNA1 (Group 4). Information on gender, age at 
diagnosis, histology, metastatic stage at diagnosis and survival are presented in Table 
1B. The mean follow-up time of survivors in the TMA cohort was 6.2 years (range 0.1 - 
19.4 years). Informed consent was obtained for the use of brain tissue and for access to 
medical records for research purposes. MB1 and MB2 primary human medulloblastoma 
tissues were obtained from surgical specimens after informed consent and approval 
by the Medical Ethical Committee of the VU University Medical Center.
Survival analysis. Overall survival was calculated from the time of diagnosis to the 
patient’s last follow-up or death. Survival of patients was analyzed using Kaplan–Meier 
survival curves, and the log-rank test was used to examine the statistical significance. 
P-values <0.05 were considered significant. Prognostic impact of covariates on survival 
was evaluated on the basis of hazard ratios from Cox’s proportional hazards regression 
model. Multivariate Cox’s proportional hazards regression models were used to 
estimate effects of additional the covariates age, metastatic stage and histology.
Cells. Human D283-med, D556-med (Dr. Darrell Bigner, Duke University), Daoy (ATCC) 
and C17.2 murine cerebellar progenitor cells immortalized by v-myc 31 were cultured 
in DMEM containing 10% FBS and antibiotics.
Acumen proliferation assay. Cells were plated in 96-well plates (Greiner), fixed at 24, 
48, 72 and 96 h after plating using formaldehyde, stained with DAPI and subsequently 
signal intensity was measured using an Acumen eX3 apparatus (TTP LabTech).
Apoptosis assay. Cells were plated in white opaque 96-well plates (Greiner) and treated 
with TNFα (Invitrogen). After 6 h of treatment, caspase activity was measured using 
the Caspase-Glo 3/7 assay (Promega) according to the manufacturer’s instructions. 
Fluorescence and luminescence read-out was performed using a Tecan Infinite F200 
Microplate Reader (Tecan Trading AG, Switzerland). 
Clonogenic assay. Daoy cells were plated in six-well plates at a density of 500-1,000 
cells per well depending on the used dose of irradiation or TNFα concentration. 
Subsequently cells were treated with increasing doses of irradiation or TNFα (10 ng/
ml). After 10-14 days of culturing to allow colony formation, the colonies were fixed 
with 3.7% formaldehyde in PBS and stained with Giemsa solution. Groups consisting 
of 50 cells or more were defined as a colony. The colony counts using light microscopy 
were performed independently by at least two investigators. 
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SUPPLEMENTARY MATERIALS AND METHODS
Meta-ana lys is  of  gene express ion datasets
The NCBI Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) was 
used to identify studies that compared gene expression in mouse medulloblastoma to 
normal mouse cerebellar precursor cells, yielding five different studies (1-5), and a total 
of seven independent tumor/normal datasets. All mouse-related studies employed 
models that mimic the SHH-subgroup medulloblastoma (Supplemental Table S1A). Each 
dataset was log2 transformed, median normalized, and the gene expression patterns 
of individual transcripts were subsequently examined across the individual datasets. 
Transcripts that showed at least a 2-fold down-regulation (p<0.05) in medulloblastoma 
as compared to control samples were selected. Since integrating the results of multiple 
screens can increase the specificity, we ranked the transcripts according to the number 
of datasets in which the particular transcripts was down-regulated. Further, using R2 
algorithms that allow comparison of gene expression between individual datasets (R2: 
microarray analysis and visualization platform (http://r2.amc.nl)), the tumor suppressor 
candidates from the mouse datasets were compared to a human medulloblastoma 
gene expression dataset (GSE 10327) (6) and an independent gene expression dataset 
of normal human cerebellum (GSE 3526) (7). Finally, the list of down-regulated genes 
in mouse and human medulloblastoma was compared to a list of designated tumor 
suppressor genes. The list of tumor suppressor genes was established by interrogating 
the NCBI (http://www.ncbi.nlm.nih.gov/gene) and Amigo (8) Gene Ontology (GO) 
databases (Supplemental Table S1B). Genes that were present in both lists were 
regarded as putative tumor suppressor genes in medulloblastoma.
Lent iv i ra l  express ion vectors
Lentiviral vectors were produced by co-transfecting subconfluent human embryonic 
kidney (HEK) 293T cells with a DAB2IP overexpression construct (kindly provided 
by Dr K. Cichowski, Harvard Medical School, Boston, MA, USA) or a DAB2IP shRNA 
construct (kindly provided by Dr J. T. Hsieh, University of Texas Southwestern Medical 
Center, Dallas, TX, USA) and lentiviral packaging agents (pMD2G, pMD2G pRRE, 
pRSV/REV), using Lipofectamin 2000 (Invitrogen) as a transfection reagent. Lentiviral 
vectors were collected 24 h after transfection. The supernatant was centrifuged to 
remove cell debris and stored at -80 ºC.
Quant i tat ive RT-PCR
Quantitative RT-PCR (qRT-PCR) analysis was used to determine the relative mRNA 
expression levels of DAB2IP, EZH2, and GAPDH mRNA. Total RNA was isolated 
using Trizol (Invitrogen), according to the manufacturer’s protocol. Equal amounts of 
RNA were converted into cDNA using random primers (Invitrogen). Subsequently, 
quantitative PCR was performed using gene-specific primers (Applied Biosystems). 
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The Ct values were used to calculate the relative fold difference in mRNA levels. All 
experiments were performed using biological triplicates and experimental duplicates. 
The data were normalized to GAPDH expression levels.
Western b lot  ana lys is
Cell pellets were re-suspended in RIPA buffer including protease inhibitor. After 1 h the 
re-suspended pellets were centrifuged for 10 min at 10,000 rpm at 4ºC. Supernatant 
was mixed with Laemmli buffer (Bio-RAD) including β- mercaptoethanol and heated 
at 97ºC. A total of 30 μg of protein was loaded on a 10% SDS-polyacrylamide gel 
and separated for 1 h at 100V on an electrophoresis system (Bio-Rad). Next, proteins 
were transferred to PVDF membranes over night at 30V at 4ºC by means of blot buffer 
(TRIS/glycine/methanol). After incubating the PVDF membranes with PBS for 15 min 
they were blocked with 5% milk in PBS-T for 1 h. Membranes were incubated for 1 h 
with mouse anti-EZH2 mAb (BD biosciences) at 1:1,000 dilution in blocking solution 
(1% milk in PBS-T), mouse anti-Actin (Millipore, MAB1501R) at 1:30,000 dilution, and 
overnight with rabbit anti-DAB2IP (1:1,000; Sigma). Membranes were washed with 
PBS-T four times for 15 min. Subsequently, membranes were incubated for 1 h with 
horseradish peroxidise (HRP) antimouse IgG (DAKO) at 1:3,000 dilution in 1% block 
buffer to detect primary anti- EZH2 antibody and anti-Actin antibody or HRP anti-
rabbit IgG (DAKO) at 1:3,000 dilution to detect anti-DAB2IP antibody. Membranes 
were washed again with PBS-T four times for 15 min. ECL detection solution (GE 
Healthcare) was used to detect protein levels. Levels were visualized on X-ray film (GE 
Healthcare) and quantified using ImageJ software (NIH Image). Actin intensities were 
used to normalize DAB2IP and EZH2 levels. Normalized DAB2IP and EZH2 intensities 
were used to calculate the relative expression levels.
Immunohistochemica l  s ta in ing
Paraffin sections of human medulloblastoma tissue and human neocortex were stained 
with monoclonal mouse anti-EZH2 (BD biosciences) diluted 1:300 in antibody solution 
(Immunologic), or with monoclonal rabbit anit-DAB2IP (Sigma) diluted 1:50, for 1 h 
at room temperature. Sections were washed in PBS three times and incubated with 
secondary antibody (EnvisionHRP) for 30 min at room temperature. Following three 
times washing in PBS, positive reactions were visualized by incubating the sections with 
stable 3,3-diaminobenzidine for 10 min. After washing in distilled water, the sections 
were counterstained with hematoxylin for 1 min and analyzed using microscopy.
80
4 D
A
P
2
IP
 IS
 A
 M
E
D
U
LLO
B
LA
S
T
O
M
A
 T
U
M
O
R
 S
U
P
P
R
E
S
S
O
R
1 1. Mao J, Ligon KL, Rakhlin EY, Thayer 
SP, Bronson RT, Rowitch D, et al. A novel 
somatic mouse model to survey tumorigenic 
potential applied to the Hedgehog pathway. 
Cancer Res 2006;66:10171-10178.
2 2. Oliver TG, Read TA, Kessler JD, Mehmeti 
A, Wells JF, Huynh TT, et al. Loss of patched 
and disruption of granule cell development 
in a preneoplastic stage of medulloblastoma. 
Development 2005;132:2425-2439.
3 3. Sasai K, Romer JT, Kimura H, Eberhart 
DE, Rice DS, Curran T. Medulloblastomas 
derived from Cxcr6 mutant mice respond 
to treatment with a smoothened inhibitor. 
Cancer Res 2007;67:3871-3877.
4 4. Schuller U, Heine VM, Mao J, Kho AT, 
Dillon AK, Han YG, et al. Acquisition of 
granule neuron precursor identity is a critical 
determinant of progenitor cell competence 
to form Shh-induced medulloblastoma. 
Cancer Cell 2008;14:123-134.
5 5. Zindy F, Uziel T, Ayrault O, Calabrese 
C, Valentine M, Rehg JE, et al. Genetic 
alterations in mouse medulloblastomas and 
generation of tumors de novo from primary 
cerebellar granule neuron precursors. 
Cancer Res 2007;67:2676-2684.
6 6. Kool M, Koster J, Bunt J, Hasselt NE, 
Lakeman A, van SP, et al. Integrated 
genomics identifies five medulloblastoma 
subtypes with distinct genetic profiles, 
pathway signatures and clinicopathological 
features. PLoS One 2008;3:e3088.
7 7. Roth RB, Hevezi P, Lee J, Willhite 
D, Lechner SM, Foster AC, et al. Gene 
expression analyses reveal molecular 
relationships among 20 regions of the 
human CNS. Neurogenetics 2006;7:67-80.
8 8. Carbon S, Ireland A, Mungall CJ, Shu 
S, Marshall B, Lewis S. AmiGO: online 
access to ontology and annotation data. 
Bioinformatics 2009;25:288-289.
Reference L ist
81
4 D
A
P
2
IP
 IS
 A
 M
E
D
U
LLO
B
LA
S
T
O
M
A
 T
U
M
O
R
 S
U
P
P
R
E
S
S
O
R
Su
p
p
le
m
en
ta
l t
ab
le
 S
1
. M
ic
ro
ar
ra
y 
d
at
as
et
s c
ha
ra
ct
er
is
tic
s
Ti
tl
e
Su
m
m
ar
y
Sa
m
p
le
s
Li
te
ra
tu
re
 r
ef
.
G
E
O
 r
ef
.
A
cq
ui
si
tio
n 
o
f g
ra
nu
le
 n
eu
ro
n 
p
re
cu
rs
o
r 
id
en
tit
y 
 
an
d
 H
ed
g
eh
o
g
-in
d
uc
ed
 m
ed
ul
lo
b
la
st
o
m
a 
in
 m
ic
e.
G
en
e 
ex
p
re
ss
io
n 
p
ro
fil
in
g
 o
f c
er
eb
el
la
r 
tu
m
o
rs
 g
en
er
at
ed
 
fr
o
m
 v
ar
io
us
 e
ar
ly
 a
nd
 la
te
 s
ta
g
e 
C
N
S 
p
ro
g
en
ito
r 
ce
lls
27
(1
)
G
SE
 1
18
59
M
ed
ul
lo
b
la
st
o
m
as
 d
er
iv
ed
 fr
o
m
 C
xc
r6
 m
ut
an
t 
m
ic
e 
re
sp
o
nd
 t
o
 t
re
at
m
en
t 
w
ith
 a
 S
m
o
o
th
en
ed
 in
hi
b
ito
r
St
ud
y 
o
f m
o
us
e 
m
ed
ul
lo
b
la
st
o
m
a 
in
 r
es
p
o
ns
e 
to
 in
hi
b
ito
r 
 
o
f S
m
o
o
th
en
ed
5
(2
)
G
SE
 7
21
2
E
xp
re
ss
io
n 
p
ro
fil
es
 o
f m
o
us
e 
m
ed
ul
lo
b
la
st
o
m
a
Id
en
tifi
ca
tio
n 
o
f d
is
tin
ct
 c
la
ss
es
 o
f u
p
-r
eg
ul
at
ed
 o
r 
d
o
w
n-
 
re
g
ul
at
ed
 g
en
es
 d
ur
in
g
 H
h 
d
ep
en
d
en
t 
tu
m
o
rig
en
es
is
10
(3
)
G
SE
 9
29
9 
33
9 
&
 3
40
G
en
et
ic
 a
lte
ra
tio
ns
 in
 m
o
us
e 
m
ed
ul
lo
b
la
st
o
m
as
 a
nd
 
g
en
er
at
io
n 
o
f t
um
o
rs
 fr
o
m
 c
er
eb
el
la
r 
g
ra
nu
le
 n
eu
ro
n 
p
re
cu
rs
o
rs
Id
en
tifi
ca
tio
n 
o
f d
iff
er
en
tly
 e
xp
re
ss
ed
 g
en
es
 a
m
o
ng
 C
G
N
Ps
 
an
d
 C
G
N
Ps
 t
ra
ns
fe
ct
ed
 w
ith
 r
et
ro
vi
ru
se
s 
th
at
 e
xp
re
ss
 n
m
yc
 
o
r 
cy
cl
in
-d
1
10
(4
)
G
SE
 6
46
3 
33
9 
&
 3
40
Pa
tc
he
d
 h
et
er
o
zy
g
o
us
 m
o
d
el
 o
f m
ed
ul
lo
b
la
st
o
m
a
A
na
ly
si
s 
o
f g
ra
nu
le
 c
el
l p
re
cu
rs
o
rs
, p
re
-n
eo
p
la
st
ic
 c
el
ls
,  
an
d
 t
um
o
r 
ce
lls
14
(5
)
G
SE
 2
42
6 
G
D
S1
11
0
1.
 S
ch
ul
le
r 
U
, H
ei
ne
 V
M
, M
ao
 J
, K
ho
 A
T,
 D
ill
o
n 
A
K
, H
an
 Y
G
, e
t 
al
. A
cq
ui
si
tio
n 
o
f 
g
ra
nu
le
 n
eu
ro
n 
p
re
cu
rs
o
r 
id
en
tit
y 
is
 a
 c
rit
ic
al
 d
et
er
m
in
an
t 
o
f 
p
ro
g
en
ito
r 
ce
ll 
co
m
p
et
en
ce
 t
o
 fo
rm
 S
hh
-in
d
uc
ed
 m
ed
ul
lo
b
la
st
o
m
a.
 C
an
ce
r 
C
el
l 2
00
8;
14
:1
23
-1
34
.
2.
 S
as
ai
 K
, 
R
o
m
er
 J
T,
 K
im
ur
a 
H
, 
E
b
er
ha
rt
 D
E
, 
R
ic
e 
D
S,
 C
ur
ra
n 
T.
 M
ed
ul
lo
b
la
st
o
m
as
 d
er
iv
ed
 f
ro
m
 C
xc
r6
 m
ut
an
t 
m
ic
e 
re
sp
o
nd
 t
o
 t
re
at
m
en
t 
w
ith
 a
 
sm
o
o
th
en
ed
 in
hi
b
ito
r. 
C
an
ce
r 
R
es
 2
00
7;
67
:3
87
1-
38
77
.
3.
 M
ao
 J
, 
Li
g
o
n 
K
L,
 R
ak
hl
in
 E
Y,
 T
ha
ye
r 
SP
, 
B
ro
ns
o
n 
R
T,
 R
o
w
itc
h 
D
, 
et
 a
l. 
A
 n
o
ve
l s
o
m
at
ic
 m
o
us
e 
m
o
d
el
 t
o
 s
ur
ve
y 
tu
m
o
rig
en
ic
 p
o
te
nt
ia
l a
p
p
lie
d
 t
o
 t
he
 
H
ed
g
eh
o
g
 p
at
hw
ay
. C
an
ce
r 
R
es
 2
00
6;
66
:1
01
71
-1
01
78
.
4.
 Z
in
d
y 
F,
 U
zi
el
 T
, A
yr
au
lt 
O
, C
al
ab
re
se
 C
, V
al
en
tin
e 
M
, R
eh
g
 J
E
, e
t 
al
. G
en
et
ic
 a
lte
ra
tio
ns
 in
 m
o
us
e 
m
ed
ul
lo
b
la
st
o
m
as
 a
nd
 g
en
er
at
io
n 
o
f t
um
o
rs
 d
e 
no
vo
 
fr
o
m
 p
rim
ar
y 
ce
re
b
el
la
r 
g
ra
nu
le
 n
eu
ro
n 
p
re
cu
rs
o
rs
. C
an
ce
r 
R
es
 2
00
7;
67
:2
67
6-
26
84
.
5.
 O
liv
er
 T
G
, R
ea
d
 T
A
, K
es
sl
er
 J
D
, M
eh
m
et
i A
, W
el
ls
 J
F,
 H
uy
nh
 T
T,
 e
t 
al
. L
o
ss
 o
f 
p
at
ch
ed
 a
nd
 d
is
ru
p
tio
n 
o
f 
g
ra
nu
le
 c
el
l d
ev
el
o
p
m
en
t 
in
 a
 p
re
-n
eo
p
la
st
ic
 
st
ag
e 
o
f m
ed
ul
lo
b
la
st
o
m
a.
 D
ev
el
o
p
m
en
t 
20
05
;1
32
:2
42
5-
24
39
.
82
4 D
A
P
2
IP
 IS
 A
 M
E
D
U
LLO
B
LA
S
T
O
M
A
 T
U
M
O
R
 S
U
P
P
R
E
S
S
O
R
Supplemental table S2. List of tumor suppressor genes, established by interrogating the Amigo 
and NCBI Gene Ontology (GO) databases
Gene Database Gene Database
Jun AMIGO LRRC3B NCBI
Aatf AMIGO LSAMP NCBI
Abl1 AMIGO LTF NCBI
Adcyap1 AMIGO LZTS1 NCBI
ADPRH NCBI MAD1L1 NCBI
AFUA_2G11990 NCBI Mad2l1 AMIGO
AGTR2 NCBI Mad2l1bp AMIGO
AHRR NCBI MADD AMIGO
Akt1 NCBI MAL NCBI
ALPL NCBI Map3k8 NCBI
An04g06500 NCBI Mapk14 AMIGO
Anapc10 AMIGO MAPRE3 NCBI
ANXA1 NCBI MBD2 NCBI
Apbb1 AMIGO MCC NCBI
Apbb2 AMIGO Mcc_mapped NCBI
Apc AMIGO NCBI MCPH1 NCBI
APITD1 NCBI Mdm2 AMIGO
App AMIGO MGC108388 NCBI
ARHGAP29 NCBI MIR21 NCBI
ARL11 NCBI MIR34A NCBI
ARL14 NCBI MLL NCBI
Atf5 AMIGO Mnt AMIGO
Atm AMIGO Mov10l1 AMIGO
Atr AMIGO MPP3 NCBI
Bak1 AMIGO MRVI1 NCBI
BAP1 NCBI Msh2 AMIGO NCBI
BARD1 NCBI MT1G NCBI
Bax AMIGO NCBI Mtap NCBI
Bccip AMIGO Mtbp AMIGO
Bcl2 AMIGO Mtor NCBI
Bcr AMIGO NCBI MTUS1 NCBI
Becn1 NCBI MXD1 NCBI
BHD NCBI MXI1 NCBI
BLCAP NCBI Mycbp2 AMIGO
Braf NCBI MYO18B NCBI
brc-1 NCBI N NCBI
brc-2 NCBI Nanog AMIGO
BRCA1 NCBI NAP1L4 NCBI
Brca2 AMIGO NCBI Nbn AMIGO
brd-1 NCBI NBR1 NCBI
Brsk1 AMIGO NBR2 NCBI
Btc AMIGO NDRG2 NCBI
BTG2 NCBI NDRG4 NCBI
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Supplemental table S2. Continued
Gene Database Gene Database
Btg3 AMIGO Neurog1 AMIGO
Btg4 AMIGO NCBI NEWENTRY NCBI
Btrc AMIGO NF1 NCBI
Bub1 NCBI NF2 NCBI
Bub3 AMIGO Nfatc1 NCBI
C2orf40 NCBI Nfatc2 NCBI
C3orf51 NCBI NFKB1 NCBI
Cables1 AMIGO NME1 NCBI
Cables2 AMIGO Notch1 NCBI
CADM1 NCBI Npm1 AMIGO
Calr AMIGO Nras AMIGO
CAPG NCBI NUDT2 NCBI
CARS NCBI Nup214 AMIGO
Casp3 AMIGO NUP98 NCBI
CASP8 NCBI Nusap1 AMIGO
Cat NCBI OPCML NCBI
CAV1 NCBI Osm AMIGO
CBFA2T3 NCBI PALB2 NCBI
CCDC136 NCBI PANX2 NCBI
CCNC NCBI PARK2 NCBI
Ccnd1 AMIGO NCBI PAWR NCBI
Ccnd2 AMIGO PDCD4 NCBI
Ccnd3 AMIGO Pde3a AMIGO
Ccne1 AMIGO PF4 NCBI
Ccne2 AMIGO PHB2 NCBI
Ccng2 AMIGO PHLDA2 NCBI
Ccni AMIGO PIG8 NCBI
CD36_72340 NCBI PINX1 NCBI
CD81 NCBI PITX1 NCBI
Cdc23 AMIGO Pkia AMIGO
Cdc42 AMIGO PLAGL1 NCBI
CDH1 NCBI PLCE1 NCBI
Cdh11 NCBI Pml AMIGO NCBI
CDH4 NCBI PPM1A NCBI
Cdk1 AMIGO Ppp2ca AMIGO
Cdk11b AMIGO PPP2R1B NCBI
Cdk2ap2 NCBI PRDM1 NCBI
Cdk4 AMIGO PRDM2 NCBI
Cdk5 AMIGO PRKAR1A NCBI
Cdkn1a AMIGO NCBI PRKCDBP NCBI
Cdkn1b AMIGO NCBI Prox1 AMIGO NCBI
Cdkn2a AMIGO NCBI PRR5 NCBI
CDKN2B NCBI Psmg2 AMIGO
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Supplemental table S2. Continued
Gene Database Gene Database
Cdkn2c NCBI Pten AMIGO NCBI
Cdt1 AMIGO Ptpn11 AMIGO
CEBPA NCBI Ptprc AMIGO
CEBPD NCBI PTPRD NCBI
Cenpe AMIGO PTPRG NCBI
Cenpf AMIGO PTPRJ NCBI
Cep192 AMIGO PTPRK NCBI
CHD5 NCBI Ptprv AMIGO
Chek1 AMIGO Pura AMIGO
CHEK2 NCBI Rad9 AMIGO
Cited2 AMIGO RAF1 NCBI
CLCA2 NCBI RALA NCBI
CLDN23 NCBI Ranbp1 AMIGO
Clspn AMIGO RAP1GAP NCBI
CNOT7 NCBI RARB NCBI
Cops5 AMIGO RASAL1 NCBI
CREBL2 NCBI RASSF1 NCBI
Csk NCBI RASSF2 NCBI
Csnk2a2 AMIGO RASSF5 NCBI
CST5 NCBI Rb1 AMIGO NCBI
CST6 NCBI RB1CC1 NCBI
CTNNB1 NCBI RBBP7 NCBI
Cul7 AMIGO Rbf NCBI
Cul9 AMIGO Recql4 AMIGO
CYGB NCBI Rhob AMIGO NCBI
CYLD NCBI RND3 NCBI
CYP27B1 NCBI Robo1 NCBI
DAB2IP NCBI Rock2 AMIGO
Dazl AMIGO RPL10 NCBI
Dbf4 AMIGO Rpl24 AMIGO
DCC NCBI Rprm AMIGO
Dcn NCBI Rps6 AMIGO
DEC1 NCBI RPS6KA6 NCBI
DEHA0B05984g NCBI RRM1 NCBI
DFNA5 NCBI RUNX1 NCBI
Dicer1 NCBI Runx3 AMIGO NCBI
DIRAS3 NCBI S100A11 NCBI
DKK1 NCBI SASH1 NCBI
DKK3 NCBI sbb NCBI
DLC1 NCBI SEC14L2 NCBI
DLEC1 NCBI SEMA3B NCBI
DUSP6 NCBI SEPT9 NCBI
E2f1 AMIGO SERPINB5 NCBI
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Supplemental table S2. Continued
Gene Database Gene Database
E2f2 AMIGO Sfn AMIGO NCBI
E2f4 AMIGO SFRP1 NCBI
E2f5 AMIGO SFRP5 NCBI
E4f1 AMIGO SHPRH NCBI
Egfr NCBI SIAH1 NCBI
EGR1 NCBI Sik1 AMIGO
EHI_049820 NCBI Sipa1 AMIGO
EHI_098430 NCBI Sirt1 NCBI
EHI_143090 NCBI Skp2 AMIGO
EHI_187800 NCBI SLC22A18 NCBI
Epb4.1l3 NCBI SLC39A1 NCBI
Epgn AMIGO SLC5A8 NCBI
EPHB4 NCBI SLC9A3R1 NCBI
Ereg AMIGO SLIT2 NCBI
ERRFI1 NCBI SMAD2 NCBI
Esr1 AMIGO NCBI SMAD3 NCBI
ETS2 NCBI SMAD4 NCBI
EXT1 NCBI SMAD5 NCBI
EXT2 NCBI SMARCA2 NCBI
EZH2 NCBI SMARCB1 NCBI
FABP3 NCBI SNORD50A NCBI
Fas NCBI SOCS1 NCBI
Fat2 NCBI SOD2 NCBI
Fat3 NCBI Sparc NCBI
FAT4 NCBI Spdya AMIGO
Fbxo5 AMIGO Spdye4 AMIGO
Fgf8 AMIGO SPINT2 NCBI
FHIT NCBI SRPX NCBI
FLCN NCBI ST13 NCBI
Foxg1 AMIGO ST7L NCBI
Foxo4 AMIGO STAT3 NCBI
FOXP1 NCBI Stat5a AMIGO
ft NCBI Stat5b AMIGO
Fzr1 AMIGO STIM1 NCBI
Gadd45a AMIGO Stra8 AMIGO
Gadd45b AMIGO SYNPO2 NCBI
Gadd45g AMIGO SYT13 NCBI
GAK NCBI SYVN1 NCBI
GALR1 NCBI Tacc3 AMIGO
Gas1 AMIGO NCBI NCBI
GAS8 NCBI TCEAL7 NCBI
GJB2 NCBI TCF3 NCBI
Gmnn AMIGO TCF4 NCBI
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Supplemental table S2. Continued
Gene Database Gene Database
GNMT NCBI TCL1A NCBI
GPC3 NCBI TEP1 NCBI
Gpr3 AMIGO TES NCBI
GPX3 NCBI TFAP2A NCBI
GRP NCBI Tgfb2 AMIGO NCBI
GSTP1 NCBI Tgfbr2 NCBI
H2afx AMIGO Thrb NCBI
HACE1 NCBI THSD1 NCBI
Hdac3 AMIGO NCBI THY1 NCBI
Hectd3 AMIGO TIMP3 NCBI
Herc2 AMIGO Tipin AMIGO
HIC1 NCBI TMEFF1 NCBI
HIF1A NCBI TMEFF2 NCBI
Hivep3 NCBI TMEM158 NCBI
Hmgb1 AMIGO TMPRSS11A NCBI
HOPX NCBI TNFAIP3 NCBI
Hoxa13 AMIGO TP53 NCBI
Hspa8 AMIGO TP73 NCBI
Hus1 AMIGO TRIM3 NCBI
ID4 NCBI Trp53 AMIGO NCBI
Ifnz AMIGO Trrap AMIGO
Igf2r NCBI TSC1 NCBI
IGFBP3 NCBI TSC2 NCBI
Ikzf1 NCBI Tsc22d1 NCBI
ING1 NCBI TSG11 NCBI
ING3 NCBI TSPAN32 NCBI
ING4 NCBI TSSC1 NCBI
INTS6 NCBI TSSC4 NCBI
IRF1 NCBI Tubg1 AMIGO
ISOC2 NCBI TUSC3 NCBI
Itgb1 AMIGO TUSC4 NCBI
ITS NCBI Uba3 AMIGO
JDP2 NCBI Uba7 NCBI
JST NCBI Ube2b AMIGO
Junb AMIGO UBE4B NCBI
KCNRG NCBI UCHL1 NCBI
KDM3B NCBI UPP1 NCBI
KIF1B NCBI VHL NCBI
KLF10 NCBI VPS53 NCBI
KLF5 NCBI Vwa5a NCBI
KLF6 NCBI WDR11 NCBI
Kras NCBI WFDC1 NCBI
Krtap16-7 AMIGO Wfdc15a NCBI
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Supplemental table S2. Continued
Gene Database Gene Database
l(2)gl NCBI WIF1 NCBI
LDOC1 NCBI WISP3 NCBI
Lif AMIGO WIT1 NCBI
LIMD1 NCBI WT1 NCBI
LOC100015738 NCBI wt1-B NCBI
LOC100049824 NCBI WTAP NCBI
LOC100089976 NCBI XAF1 NCBI
LOC100156810 NCBI Xpc AMIGO
LOC464013 NCBI Xpo1 AMIGO
LOC472922 NCBI YAP1 NCBI
LOC534968 NCBI Ywhah AMIGO
LOC683581 NCBI ZBTB33 NCBI
LOC706725 NCBI Zfp369 AMIGO
LOX NCBI ZIC1 NCBI
LRIG3 NCBI ZMYND10 NCBI
LRP12 NCBI ZNF224 NCBI
LRP1B NCBI Zzef1 AMIGO
88
4 D
A
P
2
IP
 IS
 A
 M
E
D
U
LLO
B
LA
S
T
O
M
A
 T
U
M
O
R
 S
U
P
P
R
E
S
S
O
R
Supplemental table S3A. Putative tumor suppressor 
genes highly down regulated in medulloblastoma 
versus normal cerebellum datasets
Gene
Atxn7l1
Gad1
Gucy1a3
Aqp4
Kcnd3
Grid2
Tcfap2b
Cacnb2
Calb1
Camk2d
Car8
Elmo1
Elovl7
Gdf10
Gja1
Map2k7
Neurod2
Sema4f
Snrpn
Syt1
Chchd7
Frmd5
Ednrb
Cpeb2
Sema5a
Als2
Slc8a1
Mtch2
Slc1a3
ZNF521
Zfhx4
Unc5c
Limch1
Runx1t1
SPTBN1
Rad23a
Pax3
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Supplemental table S3B. Established (GO) tumor suppressor genes down regulated in 
medulloblastoma (MB) versus normal cerebellum datasets
Gene Reported tumor suppressor in a.o.
Reported tumor 
suppressor in MB (Y/N)
Cables1 Colorectal (1), Ovarian (2) N
Cygb Lung and Breast (3) N
Hopx Endometrial (4), Gastric (5) N
Ptprj Colorectal (6), Meningioma(7) N
Dab2ip Prostate (8), Breast (9), Lung (10) N
Errfi1 Glioblastoma (11) N
Fat2 Squamous Carcinoma (12) N
Gas8 Breast (13) N
Lrp1b Lung (14), Urothelial (15), Thyroid (16) N
Lrrc3b Gastric (17), Colorectal (18) N
Madd Ovarian (19) N
Mal Lung (20), Colorectal (21), Breast (22) N
Mapre3 HNSCC (23) N
Ndrg4 Colorectal (24) N
Opcml Ovarian(25), Glioma & Medulloblastoma (26) Y (26)
Slc9a3r1 Liver (27), Breast (28) N
Spint2 Renal (29), Gastric (30), Medulloblastoma (31) Y (31)
Dlc1 Hepatocellular (32), Breast and Colon and Prostate (33),
Supratentorial Primitive Neuro -Ectoderrmal Tumor (34) N
Lsamp Osteosarcoma(35) N
Sash1 Breast(36), Colorectal(37) N
Id4 Colorectal (38), Leukemia(39), Breast (40), Prostate (41) N
Fabp3 Breast(42) N
Clca2 Breast (43), Colorectal (44) N
Stat5b Hepatocellular(45) N
Runx1 Leukemia (46) N
Cdh1 Gastric
&breast (47), Colorectal (48), Ovarian (49),  Medulloblastoma (50) Y (50)
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5RASAL1 IS A PUTATIVE TUMOR SUPPRESSOR IN NEURAL PROGENITOR CELLS
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ABSTRACT
Glioblastoma (GBM) cells are proposed to arise from neural progenitor cells (NPCs) after 
substantial loss of tumor suppressor gene (TSG) regulation. Mutations of TP53, PTEN 
and NF1 are often correlated with GBM and loss of these genes in NPCs results in 
malignant glioma formation. Our research aimed at identifying novel TSGs that could 
drive oncogenesis in NPCs. We performed an in silico analysis of GBM gene expression 
data and identified 23 genes that were significantly downregulated as putative tumor 
suppressor genes. We investigated the potential oncogenic function of the five most 
significantly deregulated TSGs and TP53 in NPCs, using our epitope-tagged multiplex 
Gaussia luciferase reporter assay. Upon shRNA-mediated knockdown of the tumor 
suppressor candidates in NPCs, we observed a significant growth advantage in vitro 
for RASAL1, YWHAH, SYT13 and CHD5. Intracranial injection in mice of pooled NPCs, 
expressing luciferase reporter enzymes and with confirmed knockdown of the tumor 
suppressor candidates, resulted in tumor formation in vivo in two of 12 mice as measured 
by bioluminescence imaging, whereas mice injected with wild-type NPCs (n=12) 
did not result in detectable tumor growth. Immunohistological analysis of the formed 
tumors revealed that RASAL1, a member of the GAP1 GTPase-activating proteins, was 
responsible for driving the tumor formation in NPCs. Our proof-of-concept results suggest 
that RASAL1 is a tumor suppressor gene that participates in the transformation of NPCs.
Key words: Glioma, glioblastoma, brain cancer, transformation, oncogenesis, neural 
progenitor cells, NPCs, tumor suppressor, multiplex luciferase assay, gaussia luciferase, 
TP53, p53, NF1, PTEN, RASAL1
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INTRODUCTION
Gliomas are the most common primary tumors in the brain. The most malignant form, 
glioblastoma, is one of the most lethal forms of cancer (Maher et al., 2001)(Zhu and 
Parada, 2002). Gliomas are highly inﬁltrative tumors and resistant to conventional 
radiation and chemotherapy, resulting in poor survival, with a median survival of 
approximately 18 months for glioblastoma (Stupp et al., 2005). 
Although the cell of origin remains controversial, gliomas have been considered 
to arise from differentiated glia that undergo a process of dedifferentiation and from 
undifferentiated neural progenitor cells (NPCs) (Sanai et al., 2005)(Sauvageot et al., 
2007)(Alcantara Llaguno et al., 2009)(Friedmann-Morvinski et al., 2012). Analysis of 
early tumor development in mouse models suggests that glioblastomas arise in the 
subventricular zone  (SVZ), the residential area of NPCs (Zhu et al., 2005)(Kwon et al., 
2008)(Alcantara Llaguno et al., 2009)(Friedmann-Morvinski et al., 2012). The SVZ is an 
extensive germinal layer that contains NPCs on the walls of the lateral ventricles of adult 
mammals (Alvarez-Buylla and Lim, 2004). Neurogenesis also occurs in the subgranular 
zone (SGZ) of the dentate gyrus, which produces local neurons that incorporate into 
the granular cell layer (Gage, 2000; Zhao et al.). In humans, the SVZ and SGZ have both 
been shown to harbor neural stem cells (Eriksson et al., 1998)(Sanai et al., 2004). 
Llaguno et al. (Alcantara Llaguno et al., 2009) demonstrated that in NPCs mutations or 
deletions of tumor suppressor (TS) genes that frequently occur in glioblastoma, including 
in the TS genes TP53, NF1, and PTEN, give rise to malignant gliomas in mice. Friedmann-
Morvinski et al. (Friedmann-Morvinski et al., 2012) demonstrated that combinatorial 
knockdown of NF1 and TP53 in differentiated mouse astrocytes and neurons could also 
result in the formation of malignant gliomas, by causing dedifferentiation of astrocytes and 
neurons towards the neural progenitor state. Mice with mutations in the TS genes TP53, 
NF1, and PTEN develop high-grade gliomas with complete penetrance (Alcantara Llaguno 
et al., 2009)(Kwon et al., 2008; Zhu et al., 2005). Moreover, TP53 and PTEN mutations are 
among the most frequent mutations reported in gliomas (Furnari et al., 2007)(Maher et al., 
2001). Neuroﬁbromatosis type 1 patients, with germline mutations in NF1, have increased 
susceptibility to gliomas (Gutmann et al., 2002). The TCGA consortium reported that 
NF1, TP53, and PTEN are among the top-5 most mutated genes in human glioblastoma 
(McLendon, 2008). Moreover, mice with heterozygous germline or conditional somatic 
TP53 mutations in their NPCs, combined with conditional somatic NF1 heterozygosity, 
develop gliomas (Zhu et al., 2005), which is enhanced by additional loss of PTEN (Kwon et 
al., 2008). The tumors formed in these models highly resemble their human equivalents.
RAS proteins are molecular switches for signaling cascades that modulate many 
aspects of cell biology (Wennerberg et al., 2005), which are regulated by RAS 
guanine nucleotide exchange factors (GEFs) and RAS GTPase-activating proteins 
(GAPs) (Bourne et al., 1990; Cherfils and Zeghouf, 2013; Feig, 1994). Interestingly, 
NF1 belongs to the class of RAS-GAPs, that also includes DAB2IP, which we recently 
identified as a novel TS in medulloblastoma (Smits et al., 2012). 
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Here we aimed at the identification of novel glioblastoma TS genes in NPCs. We 
performed expression analysis of 243 glioblastoma and non-neoplastic brain tissue 
samples and identified 23 TS genes significantly downregulated in glioblastoma. We 
functionally analyzed the top-5 of the TS candidates in mouse NPCs in vitro and in 
vivo, using our Gluctag multiplex multi-culture system (van Rijn et al., 2013, 2014). We 
identified the RAS-GAP gene RASAL1 as a novel putative tumor-driving suppressor 
gene in murine NPCs.
RESULTS
Identif ication of tumor suppressor candidates in gl ioblastoma 
We performed an analysis of TCGA expression data (Dong et al., 2010) to identify 
candidate tumor suppressor genes that are downregulated in glioblastoma. The 
mRNA expression data of 243 glioblastoma samples were compared with 11 healthy 
control samples. After statistical analysis 1236 genes were considered significantly 
deregulated, 347 genes were upregulated (28.1%) and 889 genes (71.9%) were 
downregulated (Fig. 1a). We then compared the list of significantly downregulated 
genes with a previously compiled list of tumor suppressor (TS) genes (Smits et al., 2012), 
revealing 23 TS candidates downregulated in glioblastoma (Fig. 1b-c and Table 1). 
We compared the 23 downregulated TS genes in glioblastoma with expression data 
(unpublished data) of other brain tumor types (Fig. 1d). This analysis revealed that 
all 23 glioblastoma TS candidates are also downregulated in medulloblastoma or 
in pediatric high-grade glioma. In addition, we confirmed the TS down-regulation 
in eight independent glioblastoma datasets (Fig. 1e, table 4). Next, we evaluated 
the protein expression of the TS candidates in glioblastoma and non-neoplastic 
brain, demonstrating that also the protein levels of nine TS candidates are clearly 
downregulated in large proportions of glioma tissues, in particular four of the top-5 
significantly downregulated TS candidates MAPRE3, RASAL1, YWHAH, SYT13 (Fig. 
1f). Next, we analyzed the expression of the tumor suppressor candidates in the four 
subtypes of GBM and found that there is a clear distinction of the expression of these 
genes in the mesenchymal, classical, proneural and neural subtypes (Fig. 1g). 
Funct iona l  ana lys is  of  tumor suppressor  candidates  
in  NPCs  in  v i t ro
We decided to take the five most significantly downregulated tumor suppressor 
candidates (Fig. 2a-b) for functional knockdown analysis and we choose TP53 as a control 
gene. To analyze the role of these TS candidates in glioblastoma oncogenesis we used 
NPCs obtained from the SVZ of mice on embryonic day 13.5 (E13.5) after fertilisation and 
stably expressing Firefly luciferase (Fluc) and mCherry (red). These cells were transduced 
with six different reporters, each consisting of cerulean fluorescent protein (blue) and 
the Gaussia luciferase enzyme fused to a unique epitope tag (Gluctag), resulting in six 
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Figure 1. Identification of tumor suppressor candidates in GBM (a) RNA gene expression analysis 
in GBM. RNA of 1236 genes was significantly up- or downregulated in 243 GBM tumor samples. 
Blue lines represent the 40 significantly deregulated putative tumor suppressor genes. (b) 23 of 
the 40 significantly deregulated genes were downregulated. (c) Venn diagram shows the up- and 
downregulated genes and overlap with the putative tumor suppressor genes. (d) RNA of the 23 
significantly downregulated putative tumor suppressor genes in GBM are also frequently found 
to be downregulated in other types of brain tumors such as medulloblastoma (Med) and pediatric 
high-grade glioma (pHGG). (e) When we analyzed other GBM datasets, the 23 putative tumor 
suppressors were often found to be downregulated. Blue colors and numbers represent % of 
normal expression, nd = not determined. (f) Nine putative tumor suppressors show a clear decrease 
(depicted with an *) in protein expression. Blue colors represent low, medium or high expression, 
nd = not determined. (g) RNA expression analysis of the 23 putative tumor suppressor genes 
between the four subtypes of GBM compared to average expression of all subtypes together. MES 
= mesenchymal, CL = classical, NL = neural, PN = proneural and All = all subtypes.
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murine NPC reporter cell lines (NPC-Fluc-Gluctag1-5) (Fig. 2c). Next, we selected the top-5 
TS candidates, i.e. MAPRE3, RASAL1, YWHAH, SYT13 and CHD5, and TP53 and stably 
transduced the six NPC-Fluc-Gluctag cell lines with individual shRNAs directed against 
these TSs (Table 2). We confirmed TS knockdown by qRT-PCR in the five NPC-Fluc-
Gluctag reporter cell lines by direct comparison to their parental control cell lines (Fig. 
2d). The analysis of NPC-Fluc-GlucHA cells, transduced with a shRNA directed against 
MAPRE3, revealed a knockdown of <25% and was omitted from further analysis; all other 
TS shRNAs resulted in a knockdown of >90% (Fig. 2d). Subsequently, we functionally 
compared the proliferation rates of NPC-Fluc-Gluctag cell lines expressing the shRNAs 
against the four remaining TS candidates (RASAL1, YWHAH, SYT13 and CHD5) with 
their parental NPC-Fluc-Gluctag cell lines. We used the NPC-Fluc-Gluctag reporter cell 
lines in a previously developed multiplex bioluminescence-based proliferation assay 
(Van Rijn et al. 2013, 2014), in order to determine the potential proliferative advantage 
as a result of the knockdown of the TSs. Briefly, cells express Gaussia luciferase (Gluc) 
that is fused to an epitope tag (Gluctag) that can bind to an epitope tag-specific antibody. 
Each cell line expresses a specific Gluctag and therefore it is possible to identify the 
Table 1. Significantly downregulated tumor suppressor candidates in GBM. The 23 hits from the 
in silico analysis to identify putative GBM tumor suppressor genes. Gene names and description.
gene description
MAPRE3 microtubule-associated protein, RP/EB family, member 3
RASAL1 RAS protein activator like 1 (GAP1 like)
YWHAH tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta
CHD5 chromodomain helicase DNA binding protein 5
SYT13 synaptotagmin XIII
MYCBP2 MYC binding protein 2, E3 ubiquitin protein ligase
THRB thyroid hormone receptor, beta
MADD MAP-kinase activating death domain
BLCAP bladder cancer associated protein
TRIM3 tripartite motif containing 3
APBB1 amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) 
LDOC1 leucine zipper, down-regulated in cancer 1
UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 
VPS53 vacuolar protein sorting 53 homolog (S. cerevisiae)
PARK2 parkin RBR E3 ubiquitin protein ligase
CDKN2D cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 
CDK5 cyclin-dependent kinase 5
FABP3 fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) 
PTPRK protein tyrosine phosphatase, receptor type, K
ESR1 estrogen receptor 1
BTRC beta-transducin repeat containing E3 ubiquitin protein ligase
ADCYAP1 adenylate cyclase activating polypeptide 1 (pituitary)
RB1CC1 RB1-inducible coiled-coil 1
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Figure 2. Functional analysis of tumor suppressor candidates in NPCs in vitro. (a) Selection of 
putative tumor suppressor genes for in vitro analysis. There is no correlation between RNA expression 
and protein expression. (b) We therefore selected the five most significantly downregulated tumor 
suppressor candidates for functional analysis. As a control we also analysed TP53. (c) Lentiviral 
transduction of Fluc-mCherry (red) and GlucTag-CFP (blue) to construct six cell lines. Each cell line is 
then lentivirally transduced to express a short hairpin against the six tumor suppressor candidates. 
(d) QRT-PCR of short hairpin knockdown of tumor suppressor candidates in NPCs. (e) In vitro growth 
assay using Gluc as a read-out for proliferation of NPC lines. Blue lines represent NPC with tumor 
suppressor knock down, black lines are control NPCs.
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relative expression of each cell line within a co-culture of all the cell lines. Using the 
Gluctag multiplex assay, cell proliferation was monitored of all NPC cell lines within a 
single co-culture over a period of nine days. Of note, knockdown of RASAL1, YWHAH, 
SYT13 and CHD5 resulted in a modest but significant proliferative advantage of the 
NPCs, as compared to the control cell lines (Fig. 2e). 
Funct iona l  ana lys is  of  TS candidates  in  NPCs in  v ivo
Next, we mixed the four RASAL1, YWHAH, SYT13 and CHD5 NPC knockdown cell 
lines and, in parallel, the parental control NPC cells in equal amounts (5 x 104 cells 
per cell line), prior to stereotactic injection of the pooled cells into the mouse striatum 
(n=12). We used Fluc bioluminescence imaging to monitor potential tumor growth in 
vivo (Fig. 3a). None of the injections with wild-type control NPC cells (n=12) resulted in 
a Fluc signal, as measured over a period of 120 days, and confirming the incapacity of 
wild-type NPCs to form tumors after injection of these cells into the striatum of mice. 
Of note, two out of the twelve mice injected with NPCs subjected to TS knockdown did 
give a Fluc signal, indicative of tumor growth by transformation of NPC cells due to TS 
knockdown. We sacrificed the mice and isolated the brains to perform IHC using tag-
specific antibodies (Fig. 3b). Staining with the AcV5 antibody (for RASAL1 identification) 
showed a positive staining of the formed tumor mass, in contrast to the other antibodies 
used and staining of the NPC control brains with the AcV5 antibody. We also stained 
with H&E for histological identification of the tumor (Fig. 3c). These results indicate that 
knockdown of RASAL1 in the NPC-Fluc-GlucAcV5 cells caused the observed tumor growth 
in the striatum of mice, suggesting that RASAL1 is a putative tumor suppressor in NPCs. 
When we analyzed RASAL1 gene expression, we found that low RASAL1 expression 
provides a slight but significant survival advantage in GBM (Fig. 3d, 3 months p<0.05), 
but not in gliomas in general (Fig. 3e). Protein expression analysis in the Human Protein 
Atlas reveals high RASAL1-expression in the hippocampus and the lateral ventricle of 
normal brains, but low or no RASAL1 expression in 73% of gliomas. 
Table 2. NPC cell lines for in vitro and in vivo functional analysis. Mouse neuronal precurs cells were 
lentivirally transduced with Firefly luciferase, co-expressed with mCherry (Fluc-mCherry). Then, 
each cell line was lentivirally transduced with Gaussia luciferase fused to a specific epitope tag 
and co-expressed with Cerulean fluorescent protein (Gluctag-CFP). Finally, short hairpins against 
putative tumor suppressors were transduced. 
NPC cell line TSG short hairpin abbreviation
mNPC-Fluc-mCherry-GlucFlag-CFP YWHAH NPC-FM-GFlagC
mNPC-Fluc-mCherry-GlucHis-CFP P53 NPC-FM-GHisC
mNPC-Fluc-mCherry-GlucHA-CFP MAPRE3 NPC-FM-GHAC
mNPC-Fluc-mCherry-GlucAcV5-CFP RASAL1 NPC-FM-GAcV5C
mNPC-Fluc-mCherry-GlucV5-CFP SYT13 NPC-FM-GV5C
mNPC-Fluc-mCherry-GlucGlu-CFP CHD5 NPC-FM-GGluC
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Figure 3. Functional analysis of tumor suppressor candidates in NPCs in vivo. (a) Intracranial 
injection of the six NPCs with tumor suppressor gene knockdown and control NPCs. Mice were 
followed for 119 days post injection. (b) After sacrifice of the mice, brains were isolated and sliced 
for immunohistochemistry using antibodies against the GlucTag. RASAL1 knockdown cells show 
modest staining. (c) H&E staining of the mouse brain tumor formed after injection of NPCs with 
tumor suppressors knockdown. Bar is 200 µm. (d) Survival data of RASAL1 downregulation in GBM. 
(e) Survival data of RASAL1 downregulation in glioma. (f) RASAL1 staining in GBM tumor tissue and 
in control brain tissues. Nd = not detected.
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DISCUSSION
Here we identified a novel TS candidate in NPCs, RASAL1. Knockdown of RASAL1 in 
NPCs resulted in a proliferative advantage of NPCs in vitro. After intracranial injection of 
NPCs with knockdown of RASAL1 resulted in tumor growth in two out of twelve mice. 
RASAL1, like NF1 and DAB2IP, is a member of the RAS-GAP proteins, tightly 
regulating RAS activity. RASAL1 is downregulated in several solid tumors (Seto et al., 
2011) and loss of RASAL1 activity has been correlated with hyperactive RAS (Calvisi 
et al., 2011; Liu et al., 2013; Ohta et al., 2009). RASAL1 can be downregulated via 
transcriptional regulation by PITX (Kolfschoten et al., 2005), or via epigenetic silencing 
by DNA methylation and histone acetylation - restored by treatment with 5’-AZA 
and TSA, respectively. We investigated whether PITX1 was also downregulated in 
glioblastoma tissues but we did not find any evidence in the TCGA glioblastoma 
dataset (data not shown). Hence, it is not unlikely that the downregulation of RASAL1 
is caused by epigenetic mechanisms. In future studies it would be of interest to 
determine whether RASAL1 downregulation in glioblastoma cells can be restored 
by 5’-AZA and/or TSA, inhibitors of DNA methylation and histone acetylation, 
respectively, although genetic deletion or mutation of the RASAL1 gene may provide 
an alternative explanation. The effect of RASAL1 downregulation on RAS-signaling 
and the cell cycle has been extensively reported by others (Calvisi et al., 2011; Chen 
et al., 2013; Kolfschoten et al., 2005; Liu et al., 2013; Ohta et al., 2009), and may at 
least partly explain the highly proliferative nature of glioblastoma cells.
In this study we compared the expression of the TS candidates in glioblastoma, 
medulloblastoma and pediatric high grade glioma (pHGG) tissues (Fig. 1d). A total of nine 
out of 23 TS genes were downregulated in all three brain tumor types, suggesting a more 
pivotal role of these genes in brain tumors or in tumors in general in comparison to genes 
that are more exclusively deregulated in specific brain tumors. For example, 10 genes 
are more exclusively downregulated in glioblastoma and medulloblastoma, including 
RASAL1, and four genes are more exclusively downregulated in glioblastoma and pHGG. 
It is striking to observe that all TS candidates that are significantly downregulated in 
glioblastoma are also downregulated in either medulloblastoma or pHGG. It may be of 
interest to also further explore these TS genes in medulloblastoma and/or pHGG. 
Glioblastomas, as well as other tumor types, may propagate themselves via a subset 
of cancer stem-like cells (Reya et al., 2001)(Dalerba and Clarke, 2007; Scadden, 2014; 
Singh et al., 2004), which have characteristics in common with NPCs. Future analysis of 
tumors formed by RASAL1-knockdown should therefore include further characterization 
of the tumor subtype and potential glioblastoma stem-like cells. Future experiments may 
also indicate whether downregulation or deletion of RASAL1, solely or in combination 
with combinatorial deletion of TP53, NF1, or PTEN, can also result in transformation of 
differentiated astrocytes and/or neurons, giving rise to glioblastomas.
Llagunoi et al. (Alcantara Llaguno et al., 2009) demonstrate that in contrast to normal 
adult neural stem cells that are strictly conﬁned to the SVZ or SGZ, tumors arising from tumor 
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suppressor-deﬁcient neural stem cells or their progeny are not restricted to these niches 
and actually migrate away from their normal locations, thus accounting for the presence 
of tumors elsewhere in the forebrain, including the cortex, striatum, hippocampus, and 
thalamus. The tumors that formed after injection of neural progenitor cells with knockdown 
of RASAL1 into the striatum of mice showed solid growth, although single infiltrating 
cells were observed as well. However, it remains to be investigated whether RASAL1-
knockdown or deletion in NPCs using endogenous tumor suppressor-based mouse 
models will also result in highly invasive gliomas. Therefore, further characterization of the 
tumors formed after RASAL1-knockdown in NPCs is warranted. 
METHODS
Mouse neuronal precursor cell isolation and culture. Primary mouse neuronal precursors 
were isolated as described previously (Rietze and Reynolds, 2006). Briefly, Primary 
NPCs were isolated from the brain subventricular zone (SVZ) of E13.5 embryos. NPCs 
were maintained in Neurobasal medium (Life Technologies) supplemented with 0.5 
mM stable glutamine (Life Technologies) 1x N2 supplement (Life Technologies), 1x 
Stempro neural supplement (Life Technologies), 20 ng/mL EGF (Sigma) and 10ng/
mL bFGF (Sigma). For passaging, neurospheres were collected and spun down with 
150 x G for 5 minutes and dissociated with Accutase (Life Technologies), diluted to 
the desired concentration and resuspended in Neurobasal medium as described 
previously. For cell culturing and experiments we used ultra low attachment cell 
culture containers (Corning) and cells were kept  at 37˚C and 5% CO2.
Lentivirus transduction. The mouse NPCs were first lentivirally transduced with Firefly 
luciferase (Fluc) reporter for in vivo bioluminescent imaging to detect cell proliferation. 
Then the Gaussia luciferase reporter, fused to an epitope tag, was lentivirally 
transduced for ex vivo bioluminescent blood monitoring of the cells. Finally, a short 
hairpin was expressed against the tumor suppressor gene of interest, using lentiviral 
transduction. To produce the virus, the bioluminescent reporter constructs or the short 
hairpin was co-transfected with a third generation lentiviral packaging mix (pMDLg/
pRRE, pRSV-Rev and pMD2.G, Addgene) in HEK293T cells using Lipofectamine 2000 
(Life Technologies). Virus was harvested two and three days after transfection and 
cell debris was spun down for five minutes at 1,000 × g. U87 cells were transduced 
overnight with lentivirus using a multiplicity of infection of 100 transducing units per 
cell in the presence of 8 μg/ml polybrene in standard culture conditions.
Fluorescence microscopy. Successful transduction was verified by visualizing CFP (co-
expressed with the Gluctag construct) and mCherry fluorescent protein (co-expressed 
with Fluc) using fluorescent microscopy (Leica).
Immunostaining and antibodies. For mouse tissue staining, tumors were removed and 
embedded in paraffin. Microtome sections of 5 µm on glass slides were deparaffinized 
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in xylene and rehydrated in ethanol series of 100%, 96%, and 70% ethanol. 
Endogenous peroxide was blocked with 0.3% H2O2 in methanol for 30 minutes. After 
rinsing with water, antigens were retrieved with citrate buffer (pH 6) with 0.05% Tween 
20 using a microwave (Bosch, five minutes 900 watt, 10 minutes 360 watt). After 
slowly cooling, tissues were washed three times with PBS and incubated with primary 
antibody (10 µg/ml), for one hour at room temperature. After washing three times 
again, tissues were incubated with REAL Envision Rabbit anti-mouse (Dako and REAL 
DAB+ stained (Dako). Nuclei were counterstained with haematoxylin. Tissue sections 
were dehydrated with ethanol series as before and fixed in xylene. Cells and sections 
were imaged and photographed by light microscopy (Leica).
In vivo experiments. All in vivo experiments were subject to ethical committee approval 
and are in accordance with VU University Medical Center and Dutch law on animal 
experimentation (Wet op de dierproeven, WOD). For intracranial tumor implantation, a 
stereotactic frame (Harvard Biosciences) was used to inject cells vertically into the right 
hemisphere. General anesthesia was induced by subcutaneous injection of buprenorphine 
hydrochloride (0.1 mg/kg). The mice were further anesthetized with oxygen containing 
2.5% isofluorane. After skin incision, lidocaine drops (5 mg/ml in PBS) were administered 
topically. A small drill was used to drill a hole into the skull. Coordinates used for injection 
were X = 0.5 mm, Y = 2 mm, Z = -2 mm from the bregma. A mix of 6 x 105 NPCs (1 x 105 
NPCs per tumor suppressor short hairpin knockdown) in 5 µl of Neurobasal medium was 
injected vertically. On indicated days after injection, we performed Fluc bioluminescence 
activity in vivo by injecting D-luciferin (100 mg/kg) intraperitoneally. Imaging was 
performed with an IVIS CCD camera and analyzed with Living Image software (Caliper 
Life Sciences). We collected 100 µl mouse blood aliquots from the tail vein in Microvette 
CB300 EDTA capillary tubes (Sarstedt) for ex vivo whole Gluc.
RT-PCR. NPC RNA was isolated using mirVana (Life Technologies) according to 
manufacturer’s guidelines. cDNA was generated using Omniscript RT kit (Qiagen) and 
PCR was performed in triplo using FastStart SYBR Green Master (Rox) mix (Roche). 
Real time PCR was performed in the ABI 7500 thermal cycler (Life Technologies). 
Primers for tumor suppressor gene amplification are shown in table 3.
Table 3. Primers for gene knockdown RT-qPCR. After transduction with putative tumor suppressor 
gene short hairpin, knockdown was verified using RT-qPCR. 
Gene Gene ID Forward primer 5’-3’ Reverse primer 5’-3’ Product bp.
MAPRE3 100732 ATGGCTGTCAATGTGTACTCCA TCATGGCGACTCAGATTCTCA 56
RASAL1 19415 GGAAGCAGTGACCCCTATTGT AAGGTGAACGGTGTACTCCTC 114
YWHAH 22629 CTTGGCTCTGCTTGACAAGTT GCGGTAGTAATCGCCCTTCAT 97
CHD5 269610 AGCCCGTGAGTCTTCCCAA TGTCTGACATCTCGTCATTGC 105
SYT13 80976 CGGCCCAACAGTTCAACATTA GCCGGGGACCATAGATGTC 87
TP53 22059 CACAGCACATGACGGAGGTC TCCTTCCACCCGGATAAGATG 101
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In silico analysis. TCGA gene expression data was obtained from (Dong et al., 2010). 
We compared the TS candidates with GBM RNA expression data (table 4) in Oncomine 
(www.oncomine.org) and protein expression data in The Human Protein Atlas (www.
proteinatlas.org). We then compared TS candidate expression between the GBM 
classical, mesenchymal, proneural and neural subtypes using R and gene expression 
data from (Verhaak et al., 2010). Survival data for RASAL1 in glioma and GBM was 
obtained from R2: Genomics analysis and visualization platform (r2.amc.nl), using the 
data set Tumor Glioblastoma TCGA 540.
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Table 4. Oncomine gene expression datasets. The datasets used for oncomine GBM gene 
expression analysis, number of samples used and references. 
Number Data set type Data set
# 
Samples reference
1 Glioblastoma vs. Normal Bredel Brain 2 mRNA 54 Cancer Res, 2005
2 Glioblastoma vs. Normal Lee Brain mRNA 101 Cancer Cell, 2006
3 Glioblastoma vs. Normal Liang Brain mRNA 38 Proc Natl Acad Sci U S A, 2005
4 Glioblastoma vs. Normal Murat Brain mRNA 84 J Clin Oncol, 2008
5 Glioblastoma vs. Normal Shai Brain mRNA 42 Oncogene, 2003
6 Glioblastoma vs. Normal Sun Brain mRNA 180 Cancer Cell, 2006
7 Brain Glioblastoma  
vs. Normal
TCGA Brain 1 mRNA 557 No Associated Paper, 2013
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ABSTRACT
Recently, ex vivo three-dimensional organ culture systems have emerged to study the 
physiology and pathophysiology of human organs. These systems also have potential as 
a translational tool in tissue engineering; however, this potential is limited by our ability to 
longitudinally monitor the fate and action of cells used in regenerative therapies Therefore, 
we investigated luciferase-mediated bioluminescence imaging (BLI) as a non-invasive 
technique to continuously monitor cellular behavior in ex vivo whole organ culture. 
Goat adipose-derived stem cells (gADSCs) were transduced with either Firefly 
luciferase (Fluc) or Gaussia luciferase (Gluc) reporter genes and injected in isolated 
goat intervertebral discs (IVD). Luciferase activity was monitored by BLI for at least 
seven days of culture. Additionally, possible confounders specific to avascular organ 
culture were investigated. Gluc imaging proved to be more suitable compared to Fluc 
in monitoring gADSCs in goat IVDs. 
We conclude that BLI is a promising tool to monitor spatial and temporal cellular 
behavior in ex vivo organ culture. Hence, ex vivo organ culture systems allow pre-
screening and pre-validation of novel therapeutic concepts prior to in vivo large animal 
experimentation. Thereby, organ culture systems can reduce animal use, and improve 
the speed of innovation by overcoming technological, ethical and financial challenges.
Key words: Adipose derived stem cells, ex vivo organ cultures, intervertebral discs, 
bioluminescent imaging, loaded disc culture system, Gaussia luciferase, Firefly luciferase
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INTRODUCTION
Recently, ex vivo three-dimensional (3D) whole organ culture systems have emerged as 
means with which to study the physiology and pathophysiology of human organs and 
tissues. Pluripotent human stem cells and their self-organizing capacities have been 
used to develop bowel, kidney, brain, retina and liver-bud organoids1,2. Additionally, 
animal and human tissue explants are used in long-term ex vivo culture. Intestines, 
intervertebral discs, pancreas and skin explants have been cultured to study biological 
and pathological processes2–6. Subsequently, these 3D culture systems are increasingly 
used to study therapies, for instance in prostate cancer7.
In addition to traditional drug-based approaches, tissue engineering aims to 
regenerate damaged or degenerated tissue and organs using cells or regeneration 
inducting factors. However, the fate and action of these cells after implantation are often 
hard to determine, and research will therefore benefit from longitudinal monitoring of 
cellular behavior. Luciferase-mediated bioluminescence imaging (BLI) is a non-invasive 
imaging technique which allows real-time in vivo monitoring of location and proliferation 
of luciferase-expressing cells8,9. BLI is based on the emission of photons produced during 
substrate conversion by luciferase enzymes. These photons can be detected by a cooled 
charged coupled device (CCD) through several millimeters of tissue. The considerable 
penetration depth, including cartilage and bone, and the higher signal-to-noise ratio 
of the BLI technique are marked advantages compared to conventional fluorescent cell 
viability assays which require laser excitation for cell visualization. Different dye methods 
used to determine cell viability require lysis or fixation of cells or tissue. This results in 
termination of the experiment, and therefore impedes longitudinal monitoring of cell 
viability within a single sample. Finally, BLI has been shown to be highly correlated to 
the above mentioned cell viability assays (for both Fluc and Gluc) and is therefore a 
well-established method for cell viability monitoring10,11. These advantages highlight the 
potential of BLI for longitudinal evaluation of cellular therapies in ex vivo tissue culture12. 
In vivo, bioluminescent imaging is only performed in small animal models13–17. Results 
found in small animals are often difficult to extrapolate to the human situation since 
they do not properly reflect the human physiology and/or dimensional conditions18. 
On the other hand, the size of large mammals impedes in vivo bioluminescent imaging 
due to the current penetration depth of BLI. The use of BLI in ex vivo organ culture 
systems offers a potent solution to overcome this problem.
Recently, we developed an ex vivo loaded disc organ culture system (LDCS), to 
study the physiology of intervertebral discs (IVD) and their response to mechanical 
loads4,19. This system allows us to investigate the process of intervertebral disc 
degeneration, identified as an important etiological factor of low back pain20,21. In the 
LDCS goat IVDs are used as they are a representative model for the human IVD22. In 
addition, the LDCS allows for preclinical ex vivo evaluation of therapies aimed at tissue 
regeneration prior to actual in vivo animal experimentation23, without the problems 
related with the translation of small animal research to humans.
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Mesenchymal stem cells (MSCs) are excellent candidates for regenerative therapies 
because of their relatively young age and multi-differentiation potential. Furthermore, 
studies directly comparing young and adult chondrocytes with age-matched MSCs showed 
that - based on aggrecan ultrastructure, ECM composition, and cellular proliferation - 
MSCs produce a superior cartilage-like neo-tissue compared to either young or adult 
chondrocytes24,25. Previous research showed successful luciferase reporter transductions of 
MSCs obtained from humans and animals13,26–28. In vivo, MSCs show promising results when 
transplanted into rat and rabbit IVDs, and these cells survive, differentiate, and increase 
the production of functional extracellular matrix, thereby arresting the degeneration 
process29–31. Furthermore, MSCs are easy to harvest in large quantities from adipose tissue 
and are therefore often used for tissue engineering purposes32.
The aim of the current study has been to evaluate the use of luciferase-mediated 
bioluminescence imaging for longitudinal monitoring of adipose derived mesenchymal 
stem cells injected in large mammal IVDs, cultured in an ex vivo organ culture system. 
We investigated the feasibility of commonly used luciferases: the intracellular Firefly 
luciferase (Fluc) and the naturally secreted Gaussia luciferase (Gluc) which can be 
detected in the cell as well as in the extracellular environment 33. Additionally, possible 
confounders specific to avascular organ culture were investigated.
MATERIAL AND METHODS 
Cell Culture. Mesenchymal stem cells were isolated from subcutaneous adipose tissue, 
collected from skeletally mature Dutch female milk goats (age 3-5 years). Isolation of 
the stem cells was performed as described by Zuk et al34. The research protocol was 
approved by the Scientific Board and the Animal Ethics Committee of the VU University, 
and is in accordance with national guidelines and regulations. In brief, between 50 and 
100 grams of tissue was harvested subcutaneously from the para-vertebral area. Adipose 
tissue was minced, washed in phosphate buffered saline (PBS, Life Technologies), and 
digested using 1 U Liberase TM (Roche) per gram of tissue in PBS for 60 minutes 
at 37°C under gentle shaking conditions. The digested tissue was filtered through a 
100 µm mesh filter to remove residual extracellular matrix and to obtain a single cell 
suspension. The resulting single cell suspension, containing adipose stem cells, was 
diluted in Dulbecco’s modified Eagle’s medium (DMEM, Life technologies) containing 
10% Hyclone fetal bovine serum (FBS, Thermo Scientific),  Penicillin (10,000 units/
ml), streptomycin (10 mg/ml) and amphotericin B (25 μg/ml) (1% PSF; Sigma Aldrich) 
and plated at 1-4 x 106 nucleated cells/cm2. Twenty-four hours after seeding, culture 
medium was refreshed and goat adipose derived stem cells (gADSCs) were obtained 
by expanding the plastic adherent cells. As a positive control, U87 glioblastoma cells 
were cultured in DMEM complemented with 10% FBS and 1% PSF. All cells were grown 
in a humidified incubator at 37°C and 5% CO2. Medium was refreshed twice a week 
and upon reaching near-confluence cells were detached using 0.25% trypsin / 0.1% 
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EDTA (Life Technologies) and diluted for further culture. For all experiments involving 
gADSCs, we used early passage gADSCs (≤ passage 4).
Isolation of intervertebral discs. Spines of skeletally mature 3-to-5-year-old Dutch 
female milk goats were obtained from a local abattoir. Lumbar IVDs were dissected 
within 24 hours after sacrifice, as described by Paul et al4. Briefly, we dissected the 
intervertebral discs (T13-L1 to L5-L6) including the adjacent cartilaginous endplates 
under sterile conditions using an oscillating surgical saw. Excess ligaments and posterior 
elements were removed, and IVDs were cleaned to remove blood, and washed in PBS 
supplemented with 1% PSF. Using these IVDs, we bypassed the technological, ethical 
and financial challenges that are involved with laboratory animal experimentation.
Lentivirus production and transduction. The Gluc and Fluc lentivirus vector reporters 
co-encode the fluorescent genes Cyan Fluorescent Protein (CFP) and mCherry, 
respectively, as described elsewhere (Fig 1a)10,35. To produce lentivirus particles, the 
lentivirus reporters were co-transfected with a third generation lentiviral packaging 
plasmid mix (pMDLg/pRRE, pRSV-Rev and pMD2.G, Addgene) in HEK293T cells 
using Lipofectamine 2000 (Life Technologies), according to manufacturer’s guidelines. 
Lentivirus particles were harvested two and three days after transfection and cell debris 
was spun down for five minutes at 1000 x G. We plated low passage gADSCs and 
U87 cells in 25 cm2 culture flasks and when the cultures reached ~60% confluence we 
transduced them with the Gluc-CFP or the Fluc-mCherry bioluminescent reporter gene 
with a multiplicity of infection 10-20. Transfection was achieved by washing the cells with 
PBS and subsequently adding 3 ml of lentivirus-conditioned medium. After an incubation 
period of four hours for the gADSCs, or overnight for the U87 cells we removed the 
lentivirus conditioned medium and washed the cells with PBS. Finally, we added fresh 
culture medium. We verified transduction efficiency by fluorescence microscopy (Leica) 
of the co-expressed fluorescent reporters. gADSCs expressing Gluc and CFP are further 
mentioned as gADSC-GC. gADSCs expressing Fluc and mCherry are referred to as 
gADSC-FM. For the U87 cells the same terminology is used: U87-GC and U87-FM cells. 
In vitro bioluminescent activity measurements of Gluc and Fluc. To measure Fluc activity, 
we lysed the gADSC-FM with 100 µl Reporter Lysis Buffer (Promega) and three freeze-
thaw cycles. Aliquots of 10 µl lysate were mixed with 40 µl of Luciferase Assay Reagent 
(Promega). Luciferase activity was measured immediately after mixing for two seconds 
using a tube luminometer (Berthold Technologies) and expressed as Relative Light Units 
(RLU). For Gluc activity, the Gluc substrate coelenterazine was prepared freshly by diluting 
the coelenterazine stock (Nanolight, 5 mg/ml in methanol) 1:1000 in PBS + 0.1% Triton 
X-100, to a final concentration of 5 µg/ml. A total of 10 µl of Gluc conditioned medium 
was collected from the cell culture of gADSC-GC cells, 40 µl coelentrazine was added 
and activity was measured as described above. To determine luciferase activity over 
time, 100, 1000 or 10,000 gADSCs were plated in a 24 wells plate (n=3 per condition) 
and luciferase activity was measured 1, 4 and 7 days after initial plating. 
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Ex vivo bioluminescent imaging. A total of 0.5 x 106 gADSC-FM, gADSC-GC, 
U87-FM or U87-GC cells was suspended in 50 µl DMEM. Cells were injected in the 
nucleus pulposus (NP) via the left lateral side, through the annulus fibrosus of the 
IVD using a 29G needle of 1 cm length (Fig. 1c). Pilot experiments to image Gluc 
and Fluc expressing cells in the IVD were performed to determine suitable substrate 
concentration and imaging conditions. We imaged Fluc activity by injecting 50 µl of 30 
mg/ml d-luciferin (Goldbio Technology) dissolved in PBS into the NP prior to each BLI 
measurement. Gluc activity was measured by injecting 50 µl of 1 mg/ml coelenterazine 
substrate in PBS + 0.1% Triton X100 prior to each BLI measurement. For both groups, 
luciferase activity was measured directly after substrate administration using the IVIS 
CCD camera (Perkin Elmer). Exposure times were 10 minutes for IVDs injected with 
Fluc reporter cells, and 30 seconds for IVDs injected with Gluc reporter cells. As a 
negative control we imaged IVDs injected with Fluc or Gluc substrate and as a positive 
control the high Fluc/Gluc expressing U87 glioma tumor cells are run alongside in 
parallel experiments for ex vivo imaging of cells in IVDs. We analyzed the images 
with Living Image software (Perkin Elmer) and activity was defined as the sum of all 
photons/second (p/s) detected within a defined region of interest (ROI). 
Repetitive substrate addition to reporter expressing cells. We conducted the following 
experiments to determine the possible toxic effect of repetitive addition of the luciferase 
substrates on gADSC (i.e. d-luciferin for gADSC-FM and coelenterazine for gADSC-
GC). gADSC-FM were seeded at 5000 cells/cm2 in complete culture medium, and 
bioluminescence activity was assessed after 1 and 4 days. Fluc substrate, d-luciferin, 
was diluted in complete pre-warmed (37°C) culture medium (to a concentration of 150, 
250, 500 and 1000 µg/ml d-luciferin). The concentrations were selected based on the 
by Xenogen36 advised concentration for in vitro use of d-luciferin (150 µg/ml) and the 
amount of d-luciferin we injected in the IVD during the ex vivo experiments (1000 µg/
ml). Directly before imaging, culture medium was aspirated from the cells, and the 
d-luciferin-containing medium was added to the cells. Fluc activity was measured by 
determining photon count using a CCD camera for 30 seconds. Signal intensities were 
defined as the sum of all photons/second detected within a single well and values 
were normalized to the total amount of DNA per well. DNA content was quantified 
using the CyQuant GR (LifeTechnologies) assay according to manufacturer’s protocol. 
Cells were washed with PBS and lysed with 200 µl sterile Milli-Q and a freeze-thaw 
cycle. For the cells receiving the substrate repetitively, medium containing d-luciferin 
was not refreshed after imaging at day 1. This way, we mimicked the ex vivo situation 
where d-luciferin is contained in the avascular IVD and is only partially eliminated 
through diffusion, which is a similar process to the slow nutrient exchange. 
To determine the effect of repeated coelenterazine substrate administration on 
gADSCs, we cultured gADSC-GC at 5000 cells/cm2 and measured Gluc activity for 
4 consecutive days. We added either coelenterazine (1 mg/ml or 5 µg/ml, i.e. ex 
vivo and in vitro concentrations), or methanol (equivalent amount to coelenterazine 1 
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mg/ml), dissolved in complete culture medium. As a negative control we added only 
complete culture medium to the cells. Similar to the Fluc imaging, culture medium 
was aspirated from the cells, coelenterazine-containing medium was added and 
Gluc activity was measured immediately for 30 seconds using CCD imaging. Culture 
medium containing coelenterazine or methanol was left on the cells after imaging. 
Gluc activity was normalized for the total DNA amount of the well, similar to the Fluc 
reporter cells as described above. 
Stability of secreted Gluc. Because the highly charged extracellular matrix and 
avascular nature of the IVD might limit excretion or degradation of secreted Gluc, 
the stability of Gluc in our ex vivo IVD organ was assessed. First, the stability and 
potential binding of secreted Gluc to the negatively charged proteoglycans of the NP 
matrix was determined using isolated NP explants that were obtained from goat IVDs. 
NP explants were isolated by the removal of one IVD endplate and subsequent NP 
resection. The explants were incubated in either 1 ml PBS or 1 ml PBS containing 0.25 
U/ml Chondroitinase ABC (CABC) for 18 hours. CABC is an enzyme that degrades the 
proteoglycans (an extracellular matrix component of the nucleus), thereby mimicking 
the early changes in IVD degeneration37. After three washing steps of 2 hours in PBS, 
NP explants were incubated in complete culture medium. Thereafter, we injected 
NP explants with 50 µl of Gluc-conditioned medium, obtained from 5 x 106 U87-GC 
cells. The initial Gluc activity of the conditioned medium was 6.5 x 106 RLU, measured 
in 50 µl medium. Gluc activity in the NP explants was measured by adding 50 µl 
coelenterazine substrate (1 mg/ml) at various time points for a period of two weeks. 
Culture medium of the NP explants was refreshed at the days of imaging. 
In order to test the possible confinement of secreted Gluc within the complete 
IVD (including the annulus fibrosus and endplates), we injected IVDs either with 50 µl 
of Gluc conditioned medium or 0.5 x 106 U87-GC cells. We cultured the discs in the 
LDCS using the same conditions as described in the section below. Bioluminescence 
activity was measured at 1, 3, 5 and 7 days post Gluc injection, using the same 
imaging protocol as described in the section “ex vivo bioluminescence imaging”. 
Culture medium of the IVDs was refreshed at the days of imaging.
Imaging of gADSCs and U87 control cells in the IVD over time. We injected 0.5 x 106 
U87-GC, U87-FM cells, gADSC-GC or gADSC-FM in the IVDs (n=4 for U87, n=8 for 
gADSC) and assessed BLI at day 1, 3, 5 and 7 after cell injection, as described in the 
section “ex vivo bioluminescence imaging” above. All discs were cultured in individual 
culture chambers in the LDCS (Fig. 1b) in DMEM supplemented with, 10% FBS, 1% 
PFS, 3.5 g/L glucose (Merck, final concentration 4.5 g/L), 25 mMol HEPES buffer (Life 
Technologies) and 50 µg/ml ascorbate-2-phosphate (Sigma Aldrich). Because IVD 
cell viability depends on loading, a simulated physiological loading (SPL) condition, 
consisting of a diurnal dynamical loading (1 Hz sinusoidal) regime as described by Paul 
et al. was applied to each IVD4. Culture medium of IVDs injected with gADSCs-GC 
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and U87-GC was collected and secreted Gluc was measured using the luminometer as 
described in the “in vitro bioluminescence imaging”  section above.
Histological analysis of IVDs. After the ex vivo experiment, we fixed the IVDs in 4% 
formalin for two weeks and decalcified them in Kristensen’s fluid for another two 
weeks. Midsagittal slices (3-5 mm) were cut from the midline of the IVD using a scalpel, 
processed for dehydration and embedded in paraffin. With a microtome, 3 micrometer 
thin sections were cut starting from the midsagittal line, stained with haematoxylin and 
eosin (H&E) and analyzed using light microscopy.
Statistical analysis. Where applicable, data are presented as mean ± standard deviation 
for each experiment. Different experimental groups were compared and analyzed by 
a one-way analysis of variance (ANOVA) using SPSS Statistics software version 22 or 
Graphpad Prism version 6. A p-value <0.05 was considered statistically significant. 
RESULTS 
Transduct ion and character izat ion of  gADSCs
We estimated the lentivirus vector transduction efficiency for both reporters (Fig. 1a) by 
fluorescence microscopy of CFP or mCherry expression to be ~60% for the gADSCs and 
~90% for the U87 cells (Fig. 2a). Expression of the fluorescent proteins in the U87 cells was 
increased compared to the gADSCs; therefore longer exposure times were needed for a 
clear visualization of CFP and mCherry in the gADSCs. In different in vitro experiments 
we characterized the expression of Firefly and Gaussia luciferase by the transduced 
gADSCs. Luciferase activity was found to be proportional to the amount of cells (Fig. 2b). 
In addition, an increase of luciferase activity over time was measured for both gADSC-FM 
and gADSC-GC (Fig. 2c), indicating cell growth. We confirmed this by counting cells. Fluc 
half-life is relatively short (about 4 hours38) compared to the in vitro Gluc half-life (about 
six days39). Since Gluc is also secreted from the cells into the culture medium, it can easily 
accumulate over time (Fig. 2c). Taken together, this results in a cumulative effect for Gluc 
and a subsequent steeper slope for Gluc activity compared to Fluc activity. 
Microscopic analysis showed no significant effect of the lentivirus transduction on 
the morphology of the gADSCs. When we expanded the gADSCs for more than four 
passages, both the transduced and non-transduced cells started to spread out and 
showed increased stress fiber content. Therefore we decided to use only low passage 
gADSCs (P < 4) , not showing any stress fibers, for all experiments. 
Finally, the lentivirus vector transduction did not negatively influence the proliferation 
rate of the gADSCs over time (Fig. 2d), since the proliferation rate of the gADSC-FM 
and gADSC-GC showed a similar increase to non-transduced cells (gADSC-ctrl). 
Comparable results with U87 cells were described earlier40. We conclude that lentivirus 
vector transduction does not alter gADSC morphology or growth properties and we can 
therefore use both Fluc and Gluc as reporters to monitor gADSC viability and proliferation. 
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Figure 1. Methods for goat adipose derived stem cell imaging ex vivo. (A) Schematic depiction of 
the Firefly luciferase (Fluc) reporter co-expressing mCherry and of the Gaussia luciferase reporter 
co-expressing Cerulean fluorescent protein (CFP). (B) Schematic overview of the loaded disc culture 
system (LDCS) that we use to simulate the normal physiological conditions of the intervertebral disc 
(IVD). For details see Paul et al. 20124. (C) Superior and lateral view of the goat IVD. Location of cell 
injection is depicted by “X” and needle track is shown by the black line.
Imaging U87 and gADSC ce l l s  in  IVDs
First, we determined if the bioluminescent signal of the cells could be detected by the 
CCD camera through the IVD endplate. We started by injecting 0.5x106 U87-FM or 
U87-GC reporter cells in IVDs. U87 cells have a high lentivirus vector transduction efficiency 
and explicit expression of the reporters. We therefore expected these cells to be easily 
detectable using BLI. Cell injection was directly followed by injection of the respective 
substrates and bioluminescent signals of both reporter cell lines could be detected in 
intact IVDs (Fig. 2e). BLI activity for Fluc and Gluc signals differed greatly, with Fluc activity 
in the order of 107 photons per second (p/s) and Gluc activity in the order of 5x109 p/s. 
When we injected 0.5x106 gADSCs, we were also able to detect a bioluminescent 
signal in the IVDs (Fig. 2e). The activity of gADSCs was comparable to the U87 cells 
signals, with measured activity in the order of 107 p/s for Fluc and 5x109 p/s for Gluc. 
This experiment demonstrated that it is indeed possible to capture the emitted 
photons externally after passing through the cartilaginous endplate and small part of 
the vertebral body (~3.5mm of tissue).
Cel l  v iab i l i ty  and F luc  and Gluc act iv i ty  af ter  repet i t ive 
substrate addit ion to reporter  express ing ce l l s 
Because the IVD is avascular, excess substrate and reaction products are not readily 
eliminated from the IVD. We therefore tested the effect of repetitive addition of the 
luciferase substrates on gADSCs. For the gADSC-FM no significant differences in 
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Figure 2. Characterization of goat adipose derived stem cell and U87 reporter cells. (A) Fluorescent 
microscopy overlay images of U87 cells and gADSCs expressing Fluc-mCherry (FM) or Gluc-CFP 
(GC). Bars represent 100 µm. (B, C, D) Fluc reporter and Gluc reporter measurements of gADSC 
cells in vitro. Measurements are in triplicate and error bars represent SD. (B) Different amount of 
cells were plated and one day later, Fluc and Gluc activity was measured. (C) Gluc and Fluc activity 
was measured over the time of seven days. (D) gADSC cells were plated and counted over the time 
of seven days to analyze growth rates. (E) Bioluminescence imaging with a CCD camera of an IVD 
injected with U87-GC, U87-FM, gADSC-GC and gADSC-FM. Imaging was performed directly after 
injection of the reporter cells. Scale bar represent bioluminescence in relative light units (RLU).
amount of DNA for all groups were found both on day one and day four (p=0.166 
and p=0.185 respectively), indicating there is no adverse or toxic effect as a result 
of repetitive addition of the substrate to the cells (data not shown). However, we 
did observe a decrease in Fluc activity per cell when the gADSC-FM received 
the substrate repetitively (Fig. 3a). This decrease in activity was also shown to be 
dependent on the dose substrate cells received previously. Cells that received 500 
or 1000 µg/ml substrate on day one showed a significant decrease in Fluc activity on 
day four (p=0.007, p=0.003, respectively, Fig. 3a). We conclude that, while there is a 
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decrease in Fluc activity after repetitive substrate addition to the Fluc reporter cells, 
this decrease in activity cannot be explained by substrate toxicity to the cells.
For the Gluc substrate coelenterazine, we observed a significant decrease in DNA 
content after repeated addition of the high concentration substrate (1 mg/ml) to 
gADSC-GC (p=0.001, Fig. 3b). DNA content of the gADSC-GC that repetitively received 
a low concentration substrate (5 µg/ml) increased over time, although total DNA content 
was lower compared to the cells that only received a single dose of substrate on day 4. The 
decrease in DNA content cannot be due to the dissolvent (methanol), since cells receiving 
an equal amount of methanol but without coelenterazine did not show a decrease in DNA 
content (Fig. 3b). The total Gluc activity per cell remained constant (data not shown). 
These results indicate a dose-dependent toxic effect of the Gluc substrate coelenterazine, 
mainly due to coelenterazine rather than the methanol dissolvent. 
Figure 3. Repeated Fluc and Gluc substrate addition to goat adipose derived stem cell. (A) Fluc 
substrate was repeatedly added to gADSC-FM cells and bioluminescent activity was measured 1 
and 4 days after initial plating, with different concentrations of Fluc substrate on day 1 and the 
same concentration on day 4. Measured activity was normalized for the amount of DNA per well. 
(B) Gluc substrate in two different concentrations (high substrate: coelenterazine 1 mg/ml and low 
substrate: coelenterazine 5 µg/ml) or methanol was added to gADSC-GC cells. Bioluminescent 
activity was measured 1 and 4 days after initial plating. DNA contents of all groups were measured. 
(A, B) Experiments were performed in triplicate, data are represented as mean ± SD, * statistically 
significant different (p<0.05), ** (p<0.01).
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Gluc does not  b ind to the extrace l lu lar  matr ix  of  the NP 
and is  not  conf ined with in  the IVD
Because secreted Gluc is not removed by circulation in the avascular IVD and is only 
eliminated by diffusion, knowledge of its stability in our ex vivo IVD organ is necessary 
to correlate Gluc expression to cell viability. To study potential binding of Gluc to the 
negatively charged proteoglycans in the NP matrix, we injected medium containing 
secreted Gluc to NP explants and followed Gluc activity for 15 days. When measuring 
Gluc activity over time, we could not observe a significant difference between the 
CABC degenerated NPs and the control NPs (Fig. 4a). During the first three days, there 
was a trend towards higher Gluc activity in the control NPs over the CABC treated 
NPs, but this non-significant difference was diminished after day three. Therefore we 
conclude that the possible binding of Gluc to the negatively charged proteoglycans of 
the nucleus pulposus forms no significant problem in Gluc imaging in IVDs.
To investigate if secreted Gluc is stable and confined within the intact IVDs, we 
compared IVDs injected with a single dose of medium containing secreted Gluc with 
IVDs injected with Gluc secreting U87-GC cells. Near background Gluc activity could 
be observed in the IVDs injected with Gluc conditioned medium for at least seven 
days (Fig. 4b, c) whereas in the isolated NP explants, activity could be monitored for 
barely three days (observed on BLI images, data not shown). The Gluc activity of IVDs 
injected with U87-GC cells clearly remained higher compared to the IVDs injected 
with medium containing secreted Gluc for the first seven days post-injection (Fig. 
4b, c). Gluc expressing cells in IVDs displayed a detectable and quantifiable dynamic 
range of Gluc activity while the Gluc activity of conditioned medium remained stable 
but low over time. This result suggests that changes in Gluc activity can be monitored 
over time and is not significantly hampered by residual Gluc stability. 
Imaging of  gADSCs and U87 ce l l s  in  the IVD over  t ime
For longitudinal monitoring of luciferase expressing cells injected in the IVD, we 
initially imaged the U87 reporter cells. The U87-GC cells injected in IVDs and cultured 
in the LDCS showed a strong bioluminescent signal that could be monitored up to the 
seventh day after cell injection (Fig. 5a). The U87-FM cells injected in the IVD showed 
a very low (near background) signal that was scattered over the entire disc (Fig. 5a). 
As with the U87 cells, a strong bioluminescent signal was found for the gADSC-GC 
whereas the gADSC-FM showed a low background signal (Fig. 5a). The initial signal of 
the gADSC-GC was lower compared to the U87-GC, however, it was more stable over 
time (Fig. 5a, b). Gluc could not be detected in the 50 ml culture medium obtained 
from the individual culture chambers of the LDCS, either for U87-GC cells nor for 
gADSC-GC injected IVDs. This might be due to the relative large volume of the culture 
medium compared to the amount of Gluc produced by the luciferase positive cells.
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Figure 4. Stability of Gluc in the IVD (A) Gluc containing medium was injected and imaged in NP explants 
with or without pre-treatment with proteoglycan degrading Chondroitinase ABC. (B) IVD injection of 
medium containing secreted Gluc or Gluc expressing U87-GC cells. Gluc activity was determined on 
specified time points. (C) Representative BLI pictures of Gluc activity over time. Scale bars represent 
bioluminescence (RLU). Experiments were performed in triplicate, data are represented as mean ± SD.
Clusters  of  ce l l s  can be observed in  IVDs in jected  
with  gADSC-GC,  gADSC-FM, U87-GC and U87-FM cel l s
We processed the IVDs injected with gADSC-GC, gADSC-FM, U87-GC and U87-FM 
cells for histological viewing after a culture period of seven days and bioluminescent 
imaging. We could clearly observe a void within the nucleus pulposus of injected 
IVDs. No such voids were observed in sections of control discs. Therefore, we consider 
these voids to be due to injections of cells and substrate in the NP. Inside these voids 
we could clearly identify clusters of cells that were not found in control IVDs (Fig. 5c, 
d). Moreover, the gADSCs showed a more organized pattern and intact morphology 
compared to the scattered distribution for U87 cells, suggesting an increased cell loss 
within the clusters in the U87 cells (Fig. 5c, d). This corresponds to the reduction of BLI 
signal for the U87-GC cells. 
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Figure 5. Injection of U87-FM, U87-GC, gADSC-FM and Gluc-GC reporter cells in intervertebral discs 
ex vivo. (A) Representative BLI images of luciferase activity of IVDs injected with U87-GC, U87-FM, 
gADSC-GC or gADSC-FM. Imaging was performed 3, 5 and 7 days after injection of the reporter cells. 
Scale bars represent bioluminescence (RLU). (B) Quantification of bioluminescent signals. Data are 
represented as mean ± SD, n=4 for U87 cells and n=8 for gADSCs. (C) Bright field microscopy of H&E 
staining of IVDs injected with U87-GC, U87-FM, gADSC-GC and gADSC-FM reporter cells. Controls 
are IVDs without injected cells. Bars represent 100 µm. (D) Magnification of selected images from (C) 
showing a more organized pattern and healthy appearance for the gADSCs. Bars represent 100 µm.
DISCUSSION 
In this manuscript we aimed to determine the feasibility of using bioluminescent imaging 
of adipose derived stem cells to monitor and evaluate cell fate and distribution in ex vivo 
culture. In this study the IVD serves as an example of an ex vivo organ culture. We evaluated 
the use of two different luciferases - the intracellular sequestered Firefly luciferase (Fluc) 
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and the naturally secreted Gaussia luciferase (Gluc) - for longitudinal cellular imaging 
within a single sample. We conclude that the Gluc reporter is more suitable for imaging 
gADSCs in the IVD, as it shows a stable signal for up to seven days. After at least seven 
days of culture, histological analysis verified the presence of intact cells inside the IVD.
On the cellular level, we observed a lower bioluminescent signal in gADSCs 
compared to the U87 cell line. This can be expected since tumor cells have a much 
higher metabolism and activity compared to gADSCs. Also the higher transduction 
efficiency of U87 cells compared to gADSCs is reflected in the increased BLI signal. 
On the reporter level, we found lower BLI signals for the Fluc than for the Gluc 
reporter in our in vitro assays. This could possibly be explained by the differences in 
gene sensitivity as the Gaussia luciferase produces a 2,000-fold higher bioluminescent 
signal compared to the Fluc reporter39. Moreover, the long half-life of Gluc in culture 
medium results in a cumulative effect39 (Fig 2c). 
A striking observation was the finding that luciferase activity of Fluc-expressing 
gADSCs decreased significantly after repeated administration of substrate in vitro. This 
decrease in activity could not be explained by a toxic effect of the substrate on the cells. 
We can only speculate about the exact mechanism that causes this decrease, although 
a change in cell membrane permeability for d-luciferin after initial contact could be a 
possible cause. Another hypothesis is a negative effect due to a possible accumulation 
of the residual oxyluciferin after the luciferase oxidation reaction. In contrast to Fluc, a 
dose-dependent toxic effect was observed for the Gluc substrate coelenterazine in vitro. 
The in vitro experiments, nevertheless, appear to be an aggravated simulation of 
the ex vivo IVD culture. Diffusion in the NP upon injection will lower the local substrate 
concentration over time, enhanced by mechanical loading of the IVD. The limited effect 
of Gluc substrate toxicity is supported particularly by the healthy appearance of the 
gADSCs cells in the IVD (Fig. 5c, d). The decreased viable appearance and morphology 
of the U87 tumor cells, which have a much higher metabolism and anabolic activity 
compared to gADSCs, may be the result of a “transition shock” after injection in the 
hostile environment of low nutrition and oxygenation within the IVD. These harsh 
conditions may also explain the observed lower BLI signals for the Fluc reporter 
compared to the Gluc reporter ex vivo (Fig 5a). Both the Fluc and Gluc reporters need 
O2 for substrate conversion, but Fluc is also dependent on ATP and Mg
2+, elements 
likely scarce in the avascular IVD due to the minimal exchange of nutrients and other 
substances41,42. Furthermore, the intracellular localization of Fluc might also impair photon 
conversion. For in vitro assays, cells are usually lysed before Fluc activity is determined, 
thus interaction of the enzyme with the substrate may be considered optimal, while in 
the case of intact cells, either in vitro or in the IVD, the substrate-Fluc interaction may 
be hampered. In contrast, when Gluc is synthesized, it is also secreted into the external 
milieu, and thus likely enhancing substrate conversion and higher BLI signals.
Possible confounders in our study could be the containment of secreted Gluc in 
the IVD through binding to the extracellular matrix or entrapment within the intact 
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IVD. We were able to show that Gluc is not efficiently bound in the nucleus pulposus 
(NP) by the proteoglycans (Fig. 4a). When comparing Gluc expressing cells with Gluc 
conditioned medium, an increase in BLI signal is observed for the U87-GC cells injected 
in the IVD (Fig 4b). Although a direct comparison between Gluc expressing cells and 
Gluc conditioned medium is difficult, a stable Gluc production by the injected cells 
is indicated by two results: First, only intracellular Gluc could be present in the cells 
at the moment of injection, while a clear and high BLI signal could be observed after 
one day in situ, indicating Gluc production by the cells. Secondly, even though the 
injected Gluc expressing cells represent a relatively larger volume of cells compared 
to injected amount of Gluc conditioned medium this could not explain the whole 
150-fold increase in BLI signal. While the BLI signal of the injected Gluc-conditioned 
medium remains essentially unchanged and low over time (Fig. 4d), the BLI signal of 
the Gluc expressing cells decreases. This decrease indicates that dynamic Gluc activity 
can readily be detected in the IVD and can be the result of a reduction in cell viability. 
Reduction of BLI signal is predominantly observed in U87 cells, gADSCs showed a 
far more stable albeit lower Gluc signal (Fig. 5b). This is in line with the decreased 
cell quality observed in the histological evaluations (Fig 5c, d). Together, these data 
indicate that that gADSCs are more able to cope with the hostile IVD environment, 
and that Gluc can be used as a reporter for stem cell imaging in large animal IVDs. 
Although the described method in the current study shows great potential and 
many alternative applications, some limitations have to be considered concerning the 
current set-up of this system. The adipose derived stem cells receive the luciferase 
reporters via transduction by a lentivirus vector. The use of lentivirus vector is an 
unspecific approach with viral integration in multiple genomic loci and could therefore 
result in unpredictable genetic modifications and subsequent off-target genetic 
aberrations and phenotypes of the host cells. However, in multiple lentivirus vector 
transductions we did not find any signs of differences in cell viability, proliferative 
capacity or differences in experimental outcomes, implying that this undesired 
genetic modification is unlikely to occur. Nevertheless, only a complete genomic 
analysis will provide certainty. Also, the loaded disc culture system is a model system 
for the intervertebral disc, and although demonstrated to maintain the IVD native 
properties for over three weeks, it is limited in experimental duration and immune 
competency compared to the in vivo situation. The complexity of the assembly of the 
loaded disc culture system entails the risk of bacterial contamination after consecutive 
measurements. Despite these limitations we suggest that the use of an ex vivo organ 
culture allows longitudinal non-invasive real-time monitoring of (stem) cells in organs 
and complex tissues located in the deeper areas of the body. 
 Two previous studies reported on the use of bioluminescence imaging for cellular 
therapies for the intervertebral disc. Omlor et al.43 used Fluc to monitor cellular activity 
of autologous mesenchymal stem cells injected in the porcine IVD. Three days after cell 
injection, Fluc activity was measured by pulverizing the NP and subsequent lysis of the 
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cells. Fluc activity was largely reduced, as shown similarly in the current study. In contrast 
to our study, lysis of the cells in the study of Omlor et al. did not allow further monitoring 
of cell activity within a single sample. Francisco et al.17 transduced porcine NP cells with 
Fluc. These labeled porcine cells were injected in rat IVD explants and Fluc activity was 
monitored for 14 days. After in vivo injection of Fluc expressing porcine cells in the rat 
IVD, BLI signal was only assessed after 15 hours, without longitudinal follow-up. Not only 
is a different cell type used (NP cells versus gADSCs in the present study), but the rat 
IVD used in the study by Francisco et al. is also not comparable to the human IVD. The 
small size of the rat IVD favors nutrient diffusion and BLI signal detection. Furthermore, 
murine IVDs have different biomechanical properties and also retain their notochordal 
cells in adult life44. These cells are considered stem cell-like NP precursor cells and could 
therefore create a more suitable microenvironment for the injected reporter cells. Thus, 
although ex vivo BLI imaging in the IVD is not new, the current study is the first to show 
longitudinal monitoring of gADSCs in large animal IVDs.
The application of ex vivo imaging of cells, in particular ADSCs and tumor cells, 
is of interest for the all organ culture models, as it gives insight in the physiology, 
pathophysiology and therapeutic response. However, the demonstrated cell imaging 
in intervertebral discs can be interpreted as a worst-case scenario compared to other 
tissues because of the a-vascularity and subsequent physiological scarcity of nutrients. 
Therefore, extrapolation of feasibility to highly vascularized organs such as bowel wall, 
prostate and liver seems highly plausible. However, use of BLI ex vivo is influenced 
by containment of luciferase and toxicity of substrate that should be investigated and 
considered for every specific tissue. 
CONCLUSION
In this manuscript we propose live stem cell bioluminescent imaging as a promising tool 
for the understanding of cellular behavior of large animal organs, studied in 3D organ 
cultures. We were able to image luciferase-expressing U87 glioma cells and primary 
gADSCs transplanted in an ex vivo organ culture i.e. the goat IVD. The Gluc expressing 
gADSCs show a stable BLI signal over time after injection in the IVD. Furthermore, we 
investigated a range of possible confounders that could interfere with the bioluminescent 
imaging of gADSCs in IVDs. Table 1 gives a comprehensive overview of the advantages 
and disadvantages of Gluc and Fluc bioluminescent reporters. We aim to use this 
imaging method for longitudinal investigation of the fate and behavior of gADSCs in 
the IVD, in order to gain a better understanding of their behavior in, and interactions 
with the native cells and matrix in the IVD and ultimately optimize their regenerative 
capacities. Also, using this setup one is able to circumvent the technological, ethical 
and financial challenges that are involved with life animal experimentation and imaging. 
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Table 1. Overview of the advantages and disadvantages of Firefly and Gaussia luciferase
Advantages Disadvantages
Gaussia luciferase
Luciferase oxidation reaction does  
not require ATP or Mg2+
Luciferase oxidation reaction requires O2
Requires short photon measure time Long stability of secreted Gluc in vitro
Photons emitted have a shorter wavelength  
= more energy and longer penetration depth
Coelenterazine substrate toxicity
Advantages Disadvantages 
Firefly luciferase
Contained within the cells Substrate needs to enter the cells
d-luciferin substrate not toxic Luciferase oxidation reaction requires  
O2, ATP and Mg
2+
Short half-life Requires long photon measure time
Photons emitted have a larger wavelength  
= less energy and penetration depth
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In this thesis we aimed to develop and apply functional bioluminescent reporter systems 
in order to study complex pathologies and therapeutic modalities of the nervous system. 
Patients harboring brain tumors suffer not only on a physiological level but also on a 
cognitive level, and this poses a tremendous burden on not only their own well-being, 
but also on that of their relatives. Brain tumors are thought to arise from aberrant neural 
stem cells and while stem cells can be the origin of pathologies, they can also play a role 
in regaining health. Spinal pathologies, such as disc herniation and chronic lower back 
pain, occur frequently and affect many people, with a high economic and social impact 
as a consequence. More insight into the molecular mechanisms of these diseases could 
provide us with novel treatment opportunities, while a better understanding of current 
and emerging therapeutic strategies could improve the clinical outcome of these 
patients, reducing the burden of both patients and society.
Bra in  tumors
Brain tumors are complex diseases requiring complex therapeutic options, which are 
often still limited. With almost 1,000 new glioma patients (of which 60% is a WHO 
grade IV glioblastoma multiforme) in The Netherlands every year, it forms the most 
prevalent brain tumor in adults. The current treatment of surgical resection, irradiation 
and temozolomide chemotherapy results in a modest survival benefit of 18 months 
(1). GBMs are derived from cells with astrocytic origin and may have risen from, or 
give rise to, neural stem cells (3, 4). Despite their reciprocal origin and features, recent 
studies have shown the existence of four subtypes of GBM (classical, mesenchymal, 
pro-neural and neural) with variable genetic background (5). In addition, all four 
subtypes have been shown to be present within a single tumor (6). 
While GBMs mostly arise in adults, medulloblastoma is the most common brain tumor 
in children, with about 50-60 new cases per year in The Netherlands (IKNL, 0-14 years, www.
cijfersoverkanker.nl). While 70-80% survive for more than five years, all treatment options 
carry an inherent risk for neurological deficits and cognitive impairment in a majority of 
patients (2). In medulloblastoma, also four subgroups (Wnt, Shh, group 3 and 4) can be 
distinguished and these correlate with differential outcome of patients (7). This makes the 
genetic profile of brain tumors significantly complex, whereas the therapeutic strategy of 
brain tumors is more or less equal for all subtypes. Current therapeutic strategies for brain 
tumors are therefore, quite insufficient and thus eligible for extensive research. 
The complexity and sensitivity of the brain makes treatment of brain tumors a 
formidable challenge. On one side, surgery and irradiation may result in brain damage, 
which has large implications for the patients’ functioning. A conservative approach on the 
other hand, with limited surgical resection and irradiation, may lead to residual disease 
and rapid recurrent tumor growth. Chemotherapy, and other therapeutic approaches, 
are usually very limited since most compounds fail to cross the blood-brain-barrier (BBB) 
(8). To improve, and especially personalize, brain tumor treatment, novel and targeted 
therapeutic approaches are required. In order to be able to obtain the most advantage of 
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these targeted treatment modalities, a functional molecular profile of individual tumors is 
needed to complement the current histological and radiological imaging approaches (9). 
Low back pa in  and t issue regenerat ion
While low back pain in itself is not life-threatening, it poses a major social and 
economic burden in developed countries (10). In The Netherlands, prevalence is 
around 58-84%, meaning that many people suffer from low back pain resulting in work 
and social disability. When chronic low back pain is caused by intervertebral disc (IVD) 
degeneration, and conservative therapies and standard surgical approaches fail, it 
might be beneficial to induce disc regeneration by implantation of mesenchymal stem 
cells (11). The use of adipose tissue-derived mesenchymal stem cells may provide a 
good choice, since these cells are easy to obtain. This is in contrast with bone marrow-
derived mesenchymal stem cells, which are also often studied for their regenerative 
capacities (12, 13). Currently, preclinical models of intervertebral disc degeneration 
and regeneration are insufficient. Most studies use rodent models, which differ 
significantly in physiology and IVD cellular content compared to human IVDs (14). 
Also, these models require live animals to inflict IVD degeneration and to inject stem 
cells for tissue regeneration studies (15)(13). For our research we set up an ex vivo 
IVD culture system based on caprine IVDs, since they show the best resemblance 
to human discs when comparing size, vascularization and chondrocyte content (16). 
These surplus IVDs were derived from consumption goats and therefore, did not 
require experimental animals, greatly reducing economical as well as ethical impact. 
Funct iona l  molecular  imaging
To study brain tumor biology and stem cell tissue regeneration biology, molecular 
imaging tools can provide more functional and molecular insight. A multiplex approach 
for functional molecular imaging might make large-scale functional screening strategies 
available to the scientific community, greatly boosting functional biology output. 
Bioluminescent imaging using luciferases has several advantages over alternative 
imaging, such as a high signal-to-background ratio, deeper tissue penetration and low 
cost reagents and equipment. Despite earlier efforts to combine multiple luciferases in 
a multiplex assay (17), a real multiplex approach was not yet available and in this light 
our work filled in a gap in the toolbox. Gaussia luciferase (Gluc) is naturally secreted 
from cells and this makes ex vivo detection possible. Secretion of the reporter makes it 
available outside of the cell and we used this property to fuse Gluc with an epitope tag 
to be able to use tag-specific antibodies to specifically isolate Gluc-tag. The epitope 
tag is a viral, or bacterial, peptide and the sequence of epitope tags is virtually infinite. 
This allowed us to construct a virtually infinite number of Gluc-tag reporters, allowing 
large-scale screening and quantification of functional bioluminescent reporters. The 
multiplex functional reporter assay heavily depends on tag-antibody binding efficiency. 
Every tag requires an appropriate antibody with high affinity for the tag in order to be 
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able to effectively bind Gluc-tag from animal blood or cell culture medium. Currently, 
the amount of efficient tag-antibody binding is still fairly limited, reducing the large-
scale capacities of our assay, but optimization and tag-antibody affinity might overcome 
this issue. Another drawback of this assay is the need to genetically modify cells in order 
to make them express the desired reporters, which requires lentiviral, or retroviral, 
transduction of cells with possibly undesired genetic aberrations as a consequence. 
The genetic hazards of current gene editing techniques make it inappropriate for 
clinical imaging in patients, and the benefits still remain in the preclinical research 
setting. Recent developments in gene editing methods such as CRISPR-Cas9 (18) 
might prove to be much more specific, with reduced off-target effects, paving the 
way for gene editing in patients. Despite these emerging technologies, large-scale 
functional screening in patients is still far away since introduction of a large amount of 
reporters in cells requires major gene editing in patients’ cells.  
Stem ce l l s  and tumor heterogeneity
We developed the Gluc-tag assay as a quantitative method to study tumor heterogeneity 
or cellular interactions. The Gluc-tag assay makes it possible to equip different 
cells with a cell-specific functional bioluminescent reporter. In complex tissues or 
heterogeneous tumors, different cells have different origins, or have a variety of genetic 
modifications. The Gluc-tag assay allows us to study gene functions, or to study other 
cellular modifications such as exposure to compounds, irradiation and environmental 
challenges. Other applications would be to study cancer and healthy cell interactions, 
or to study stem cells in complex, mixed tissues and follow their fate and differentiation. 
Since stem cell progeny differentiate and change cellular shape, it could be beneficial 
to identify progeny cells in complex mixtures of cells. When the different cells are mixed 
in culture, it would be possible to determine the functional read-out of every cell in the 
cell culture mixture. In this way it might be possible to determine specific cell viability, 
gene promoter activity or any other functional bioluminescent application. Currently, 
fluorescence is often used to study different cells in co-culture, but the method is limited 
due to overlap of emission spectra and it also requires complex optics and detection 
equipment (19, 20). The benefit of functional fluorescent reporters is the ability to 
actually identify the different cells under a fluorescent microscope, whereas functional 
multiplex bioluminescence is based on enzyme activity and light production. While 
different luciferases can produce light of different wavelengths, it requires sophisticated 
equipment to separate multiple light wavelengths. By using epitope tags, fused to 
luciferases enzyme, and tag antibody immunobinding assays there is a potentially large 
amount of reporters and no need for special equipment. Cell identification and spatial 
resolution can be performed by immunohistochemical staining for epitope tags of 
tissues. In live cell functional molecular imaging, a trade-off has to be made between 
the large amount of multiplex bioluminescent reporters without spatial resolution or a 
limited amount of fluorescent reporters with spatial resolution. 
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In  s i l i co  gene express ion ana lys is  of  tumor suppressors
Currently, the online depository of gene expression data is rapidly increasing, making 
large amounts of data of various origins available to the scientific community. While this 
enables scientists to compare their own tumor data with data from others, or with data 
from other tumors, it is often challenging to compare data between gene expression 
experiments since all experiments are essentially comparable but in details very 
different. This interexperimental variation might result in false positive or false negative 
hits. DNA/RNA sequencing or other gene expression methods should be primarily 
used for screening purposes and hits should be validated in more detail to provide 
detailed information about gene expression and function. In our effort to determine 
driving tumor suppressors in medulloblastoma and glioblastoma we analyzed gene 
expression data to identify down-regulated putative tumor suppressor genes. We 
identified putative tumor suppressor genes using the publicly available Amigo gene 
ontology database (21) and decided that putative tumor suppressor genes are genes 
that have been associated with tumor suppression in the literature. Unfortunately, 
the current database does not support the GO term “tumor suppressor” anymore 
since it considers this term no longer a normal cell feature but more a pathological 
phenomenon and refers to regulation of cell cycle as an alternative. While this choice 
makes sense, it makes it hard to update our current list of tumor suppressors. The 
database Genecards (22) provides a search function that allows a search for tumor 
suppressor in the genes function, or in the publications, but we recommend verification 
of putative tumor suppressor hits with the database and literature for confirmation. 
Tumor suppressors  in  the RAS pathway
The RAS oncogene is considered to be one of the most powerful cancer drivers (23) and is 
often affected in many types of tumor (24)(25). While the RAS gene can be mutated itself, 
the RAS pathway may also be affected by aberrations in RAS-interacting genes and thereby, 
enhance tumor growth and apoptosis evasion. In malignant brain tumors, mutations in the 
RAS gene are not frequently observed although the RAS pathway is activated in 88% of 
GBMs (26). Frequently inactivated genes in GBM are the RAS-inactivating NF1 and the 
PI(3)K-inactivating PTEN, resulting in activation of the RAS-pathway. In this light, it is not 
very surprising that we identified RAS-interacting genes to be involved in brain tumors. 
RAS GTPases are a class of proteins that inactivate RAS and loss of these genes may have 
substantial effects on tumor progression. The loss of DAB2IP-activity has been associated 
with the activity of EZH2, a methylation enhancer that is also associated with other cancer-
related genes. EZH2 can methylate genes, in order to decrease their expression, and 
therefore, it is considered a promising target in cancer treatment (27). While targeting 
EZH2 opens treatment possibilities, reactivation of DAB2IP is less likely to be achieved but 
we did show that it has prognostic value in medulloblastoma patients. 
RASAL1 is a GTPase that we associated with GBM oncogenesis. The gene is 
significantly down-regulated in GBM and it caught our interest since it is the second RAS 
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GTPase that popped up in our research, underlining the importance of RAS GTPases 
and the RAS-pathway in brain cancers. Moreover, RASAL1 has also been associated with 
other tumors (28, 29). The expression of RASAL1 is, as with DAB2IP, also found to be 
epigenetically silenced (30) but a relation with EZH2 has yet to be determined. When 
knocked down, the gene might have a role in GBM formation from neural stem cells. 
We tested this using mouse neural precursor cells injected into mouse brains. While our 
results cannot be extrapolated to human cells in the human brain, it still poses a significant 
indication for human oncogenesis. Past research attempted to interfere with the RAS 
oncogene itself but since RAS is not easily susceptible to small molecule inhibitors, 
it has not led to any significant treatment modalities that improve patient outcome. 
While the interest in RAS-interference has diminished after these disappointing results, 
recent advances and improvements in drug design methods and interaction analysis 
methods has led to a RAS renaissance (23). While RAS has gained interest as a drugable 
target again, it remains a huge challenge and therefore, there might be opportunities 
in interfering with RAS-interacting genes and other genes involved in the RAS-pathway. 
This approach could open up RAS-associated treatment modalities.
Future d i rect ions
The functional multiplex bioluminescence assay we described in chapters two and three 
was a proof-of-principle to determine the feasibility of multiplexing Gluc reporters fused to 
epitope tags. In our study we initially created 14 Gluc-tag reporters, but we had to discard 
four Gluc-tag reporters after in vitro validation of the Gluc-tag immunobinding assay since 
we were not able to obtain tag-specific antibodies that efficiently bind these reporters. Of 
the 10 remaining reporters, we were able to detect only six Gluc-tag reporters efficiently 
after immunobinding experiments in vitro, as well as in vivo. Future optimization and 
development of the assay could increase the number of tag-antibody combinations. This 
can be done by assay optimization, antibody development or tag development. 
Another limiting factor of the multiplex bioluminescence approach is the current 
need for a relatively large volume of cell culture medium, or animal liquid such as 
blood, to use in the immunobinding assay. Currently, the assay is developed at 
96-well format, requiring at least 30 microliter of sample per immunobinding assay. 
In order to improve multiplex capacities of the assay, it is necessary to downscale the 
immunobinding assay to antibody chip array format on glass slides, or within a small 
chamber. This might be done by development of array printing to print tag-specific 
antibodies on a chip (31) and to perform the immunobinding assay on this printed 
chip. The use of antibody arrays requires considerably less samples for a significantly 
larger amount of reporters, greatly improving multiplex capacities of the assay. 
Another application for the Gluc-tag assay would be the development of a Gluc-tag-
based recombination-induced tag exchange (RITE) (32). This would allow the conditional 
expression of a gene of interest in target reporter cells, in combination with expression of 
a recombinase gene. Using a recombinase-expressing lentiviral vector, we would be able 
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to activate a gene of interest and combine this event with the exchange of the epitope 
tag fused to the Gluc-reporter. This would allow for temporal bioluminescent imaging 
of cells that successfully express the gene of interest, since these cells would obtain a 
different Gluc-tag than the original cell line. This approach could enhance tissue- and 
tumor heterogeneity studies by providing multiculture bioluminescent imaging.
In chapter four we conducted a meta-analysis of medulloblastoma and glioblastoma 
gene expression using publicly available, online gene expression databases. We identified 
DAB2IP as a RAS GTPase tumor suppressor gene that is repressed in medulloblastoma 
and thereby inhibits apoptosis of cancer cells. Also, we found that DAB2IP-expression 
is repressed epigenetically by EZH2-trimethylation (33).  While we were able to use 
DAB2IP-expression as a diagnostic marker for medulloblastoma survival, it might be 
more challenging to regain DAB2IP-activity in cancer cells in order to normalize them. 
Gene therapy is an option for DAB2IP-normalization, however, this approach is currently 
considered too risky. A therapeutic approach where EZH2 is inhibited to prevent 
DAB2IP down-regulation might prove to be more realistic. Efforts to silence EZH2 are 
ongoing since this gene is more frequently associated with other tumors. EZH2 activity 
can be silenced by miRNAs (34) or drug compounds (35)(27). It would be interesting 
to specifically study EZH2- and DAB2IP-modulation in medulloblastoma by compound 
screen, and also  to develop a special bioluminescent EZH2-methylation reporter, since 
read-out is cheap and easy to perform. Another option would be to develop a DAB2IP-
promoter activity reporter to study EZH2- and DAB2IP-activity. 
In chapter five we identified 23 significantly down-regulated genes as putative 
tumor suppressors in GBM. When we decreased the expression of five of the most 
significantly down-regulated genes in mouse neural stem cells, and injected cell 
mixtures into the mouse brain, we detected cell growth in two mice. We used the 
Gluc-tag system to identify each cell line but were unable to detect any Gluc after 
immunobinding. IHC revealed that the tumors might have been positive for the 
reporter correlating with RASAL1 down-regulation. We will use CRISPR/Cas9 (36) to 
knock out putative tumor suppressor gene expression in neural stem cells in an effort 
to validate our previous results and to determine putative tumor suppressor pathways 
involved in GBM-oncogenesis. When we identify GBM-oncogenesis pathways to 
therapeutically interact on, we could then perform drug screens on these cells to 
specifically target GBM subsets that depend on tumor suppressor inactivity. 
In chapter six we set up an ex vivo system to image adipose-derived mesenchymal 
stem cells in large animal IVDs. We showed that the use of secreted Gluc is more 
effective than the use of Fluc. We might be able to use our system to study stem cell 
regeneration in IVD degeneration. Questions such as stem cell fate and their mode of 
action still need to be addressed in order to understand IVD regeneration. Insight into 
regenerative stem cell biology possibly allows for optimization and stimulation of stem 
cell transplantation in order to increase regenerative efficacy for intervertebral disc 
degenerative diseases and/or to improve current treatment strategies for patients. 
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FUNCTIONAL MOLECULAR IMAGING OF CANCER 
DEVELOPMENT AND STEM CELL REGENERATION  
IN THE NERVOUS SYSTEM
Brain tumors are devastating diseases that have a great impact on patients. Glioblastomas 
are high-grade gliomas with poor prognosis while medulloblastoma patients have a 
better outcome. Despite this, cognitive effects as a consequence of the treatment 
significantly reduce medulloblastoma patient quality of life. While lower back pain is 
considered a pathology that has significantly less impact on patients compared to brain 
tumors, a relatively high incidence makes it a disease with great socio-economic impact. 
It is hypothesized that brain tumors may arise from aberrant stem cells and clonal 
selection, resulting in heterogeneous tumor development. Tumor heterogeneity and 
clonal selection remains to be one of the foremost challenges in developing adequate 
therapies. While in brain tumors, stem cells may prove to be the cause of progressive 
disease, stem cell transplantation might also be beneficial in tissue regeneration in, for 
example, degenerated intervertebral disc.
In an effort to develop a method to study tumor heterogeneity we developed a 
series of functional bioluminescent reporters that can be used in multiplex. Therefore, 
we fused epitope tags to the naturally secreted functional bioluminescent reporter 
Gaussia luciferase. We then used a tag-specific antibody binding assay to separately 
measure each secreted reporter from cell culture medium or blood. We showed that 
by using this method we were able to follow multiple brain tumor cell lines, each 
expressing a reporter with different tag, in co-culture in vitro and in vivo. We then used 
this method to study the function of putative tumor suppressors in glioblastomas. 
First, we compiled a comprehensive list of putative tumor suppressor genes and 
compared this list with gene expression data of medulloblastoma to identify putative 
tumor suppressor genes that are down regulated. Here we identified DAB2IP, a RAS-
GTPase activating protein that is suppressed by EZH2-induced methylation. We also 
showed that DAP2IP expression in medulloblastoma is a positive marker for patient 
survival. We then used this list to identify down regulated putative tumor suppressor 
genes in glioblastoma. We then created neural precursor cell lines expressing short 
hairpin RNA against selected putative tumor suppressor genes and expressing a 
specific tagged reporter. We then co-injected these cells in the mouse striatum and 
analyzed tumor development. We found that RASAL1 might act as a tumor suppressor 
in neural precursor cells and that knock down can possibly result in tumor induction. 
Then, we used luciferase reporters to image adipose derived mesenchymal stem 
cells over prolonged periods of time inside large mammal intervertebral discs to 
study stem cell regeneration. We therefore injected luciferase-expressing adipose 
derived mesenchymal stem cells in intervertebral discs and cultured them over time 
under simulated loading conditions to mimic physical load.  We were able to do 
bioluminescent imaging of stem cells in goat intervertebral discs, despite confounding 
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factors that might induce interference. We also found that Gaussia luciferase is more 
suited to image cells in intervertebral discs compared to Firefly luciferase.
This research may provide new insights into brain tumor development and heterogeneity 
and in stem cell biology, providing novel approaches for therapeutic modalities.
150


9NEDERLANDSE SAMENVATTING LIST OF PUBLICATIONS CURRICULUM VITAE DANKWOORD

9N
E
D
E
R
LA
N
D
S
E
 S
A
M
E
N
V
A
T
T
IN
G
FUNCTIONELE MOLECULAIRE BEELDVORMING  
VAN DE ONTWIKKELING VAN KANKER  
EN REGENERATIE DOOR STAMCELLEN  
IN HET CENTRAAL ZENUWSTELSEL
Een hersentumor is een ernstige ziekte die een grote impact heeft op patiënten. Een 
glioblastoom is een hooggradig glioom met een uiterst slechte prognose, terwijl 
patiënten met een medulloblastoom een beter vooruitzicht hebben. Desondanks 
zijn cognitieve effecten als gevolg van de behandeling aanzienlijk en vermindert de 
kwaliteit van leven van een patiënt met een medulloblastoom aanzienlijk. Terwijl de 
pijn in de onderrug (lumbago) wordt beschouwd als een ziekte die aanzienlijk minder 
invloed heeft op patiënten in vergelijking met hersentumoren, maakt de relatief hoge 
incidentie het een ziekte met grote sociaaleconomische gevolgen.
Er wordt verondersteld dat hersentumoren kunnen voortvloeien uit afwijkende 
stamcellen en klonale selectie, wat resulteert in heterogene tumorontwikkeling. Tumor 
heterogeniteit en klonale selectie blijft een van de belangrijkste uitdagingen bij het 
ontwikkelen van geschikte therapieën. Terwijl in hersentumoren de stamcellen de oorzaak 
van ziekte progressieve kunnen zijn, is stamceltransplantatie een mogelijke oplossing 
voor weefselregeneratie in bijvoorbeeld gedegenereerde tussenwervelschijven.
Om een  methode te ontwikkelen om tumor heterogeniteit te bestuderen hebben 
we een serie functionele bioluminescente reporters gemaakt die gebruikt kunnen 
worden in een multiplex analyse. Daarom hebben we de van nature gesecreteerde 
Gaussia luciferase reporter gefuseerd met epitoop labels. Vervolgens hebben we 
gebruik gemaakt van een immuun-bindingsassay waarmee we met label-specifieke 
antilichamen elke uitgescheiden reporter van cel medium of bloed afzonderlijk 
kunnen meten. We hebben aangetoond dat we met deze methode meerdere 
hersentumorcellijnen konden volgen, elk met expressie van een ander gelabelde 
reporter in co-culture in vitro en in vivo. Vervolgens hebben we deze methode gebruikt 
om de functie van potentiële tumor suppressorgenen in glioblastomen te bestuderen.
Eerst hebben we een uitgebreide lijst samengesteld met mogelijke tumor 
suppressor genen en deze vergeleken met genexpressiedata van medulloblastomen 
om vermeende tumor suppressor genen te identificeren die lager tot expressie 
worden gebracht. Op deze manier hebben we DAB2IP geïdentificeerd, een RAS-
GTPase activerend eiwit dat wordt onderdrukt door EZH2-geïnduceerde methylatie. 
We hebben ook aangetoond dat DAP2IP expressie in medulloblastomen een positieve 
marker is voor overleving van de patiënt. Vervolgens hebben we deze lijst gebruikt 
om in glioblastomen naar beneden gereguleerde, vermeende, tumor suppressor 
genen te identificeren. We hebben vervolgens neurale voorloper cellijnen gemaakt 
die short hairpin RNA tegen geselecteerde vermeende tumor suppressor genen en 
een specifieke gelabelde reporter tot expressie brachten. Vervolgens hebben we deze 
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cellen samen geïnjecteerd in het striatum van de muis en hebben we de ontwikkeling 
van tumoren geanalyseerd. We vonden dat RASAL1 mogelijk kan fungeren als een 
tumor suppressor in neurale voorloper cellen en dat het verminderen van de expressie 
ervan mogelijk kan leiden tot tumorinductie.
Vervolgens hebben we luciferase reporters gebruikt om uit vetweefsel geïsoleerde 
mesenchymale stamcellen over langere tijd te imagen in tussenwervelschijven van grote 
zoogdieren om stamcelregeneratie te bestuderen. We hebben daarom uit vetweefsel 
geïsoleerde mesenchymale stamcellen een luciferase reporter tot expressie laten 
brengen en geïnjecteerd in tussenwervelschijven van de geit en ze gekweekt onder 
gesimuleerde beladingscondities om fysieke belasting na te bootsen. We waren in staat 
om bioluminescente beeldvorming van stamcellen in geit tussenwervelschijven toe te 
passen, ondanks bijkomende factoren die hierin verstoringen kunnen veroorzaken. 
We vonden ook dat Gaussia luciferase beter geschikt is voor bioluminescente 
beeldvorming van cellen in tussenwervelschijven in vergelijking met Firefly luciferase.
Dit onderzoek kan nieuwe inzichten in de ontwikkeling van hersentumoren en 
tumorheterogeniteit en in stamcelbiologie geven, waarmee het aanknopingspunten 
zou kunnen geven voor nieuwe mogelijkheden voor therapeutische toepassingen.
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Sjoerd van Rijn was born in the city of Leiden on March 14, 1981. He lived his early life 
in the coastal town of Noordwijk and did his primary education at De Witte School and 
pre-university secondary education at Northgo College in this town. After a brief detour 
at Delft University of Technology and the Amsterdam University of Applied Sciences, 
Sjoerd started with the bachelor’s program in Biomedical Sciences at VU University in 
Amsterdam. There, he also did his first scientific internship with Dr. Joen Luirink and 
Dr. Edwin van Bloois in the department of molecular microbiology of VU University, 
working on the elucidation of Sec and YidC dependent membrane protein integration. 
He obtained his bachelor’s degree in 2005. After a year of working and travelling to 
New Zealand, Australia and Indonesia he commenced with the master’s program in 
Oncology at the VU University Medical Center. He then completed his first master’s 
program scientific internship in the laboratory of professor Victor van Beusechem at the 
genetherapy unit of the VU University Medical Center department of Medical Oncology. 
He there worked on the enhancement of oncolytic potency of conditionally replicative 
adenoviruses. The last scientific internship was accomplished in Massachusetts General 
Hospital in Boston, were he joined the Breakefield lab to work together with Dr. Johan 
Skog on the development of microvesicle biology and diagnostics. He then returned to 
Amsterdam to start a PhD training in the newly established Neuro-oncology Research 
Group of the Department of Neurosurgery at the VU University Medical Center Cancer 
Center Amsterdam. He worked there together with professor Thomas Würdinger and 
Dr. David Noske on the development and application of functional molecular imaging 
tools in tumors and regenerative stem cells in the central nervous system. Sjoerd has 
now accepted a postdoc position at the DKFZ in Heidelberg, in the Pediatric Neuro-
oncology group of Professor Stefan Pfister and Dr. Marcel Kool.
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Ik hou het kort…
Mijn promotietraject is me best zwaar gevallen. Ik begon heel ambitieus aan mijn 
projecten en werkte hard om zo snel mogelijk data te krijgen. Het nadeel van een, 
toen nog, jong lab met over de breedte en de diepte weinig ervaring is dat de 
onderzoeksinfrastructuur nog opgebouwd moet worden. Hierdoor ging er veel tijd 
zitten in het opzetten van methoden in plaats van het genereren van data, hetgeen zo 
belangrijk is om publicaties te maken. Dit kwam bovenop het gebrek aan mijn eigen 
onderzoekservaring, de reden waarom je een promotietraject doorloopt. 
Zeker de laatste twee jaren zijn me zwaar gevallen. Door tegenvallende vorderingen 
in mijn onderzoek kreeg ik steeds meer het gevoel heel veel in mijn onderzoek te 
stoppen maar er steeds minder uit terug te krijgen. Mijn motivatie was bij tijd en 
wijle tanende naar niveau Marianentrog. Maar zonder dalen geen pieken. Het zit er 
op! Ik heb met hangen en wurgen en een hoop getreuzel toch een proefschrift bij 
elkaar weten te schrijven en het resultaat ligt hier voor je. Waar mijn onderzoek mij 
menigmaal op het randje van wanhoop heeft gedreven, zijn jullie het die mij net zo 
vaak weer van die rand weggehaald hebben. Mijn promotie heb ik daarom vooral 
aan jullie te danken. Met het risico om mensen tekort te doen ga ik toch een aantal 
mensen in het bijzonder noemen.
Beste Tom, ik zal het nooit vergeten toen ik je voor het eerst ontmoette bij de koffiemachine 
in het CCA, waarna je me naar Mass General in Boston hebt gehaald voor een stage 
bij Xandra en Johan. Een avontuur dat ik voor geen goud had willen missen! Nadat jij 
in Amsterdam de NRG met David hebt opgezet, heb jij mij de kans gegeven om mijn 
promotie bij jullie te doen. Wat hebben we veel meegemaakt en wat zijn we in de loop 
van de tijd veranderd! Gegroeid, kan ik wel zeggen. Onderzoek doen is zoveel meer dan 
alleen maar pipetteren. Het is onderhandelen met partners, het is je resultaten verkopen, 
het is je zaak verdedigen, het is politiek bedrijven. Jij snapt dat spel als geen ander en, 
hoewel sommige elementen misschien niet mijn tweede natuur zijn, ik heb enorm veel van 
je geleerd. Ook heb je nooit je vertrouwen in mij verloren, zelfs niet toen daar misschien 
alle reden voor was. Jij hebt mij uiteindelijk alle kansen gegeven om mijn promotie tot een 
mooi einde te brengen en zelfs daarna nog steek je je hand voor mij in het vuur. Ik ben je 
daar zo dankbaar voor. Ik zal je niet teleurstellen in Heidelberg! 
Beste David, jij bent de laconieke vaste rots in de branding van de NRG. Als “Onze man 
in de Kliniek” ben je achter de schermen waarschijnlijk de reden dat de organisatie 
draaiende bleef. Ook wij hebben samen het hele NRG avontuur meegemaakt en ik 
vind het knap dat je altijd zo ontspannen en goedlachs bleef, ook als er soms wat 
kreukels gladgestreken moesten worden. Volgens mij heb ik je nog nooit uit je slof 
zien schieten. Je relativisme kon ik goed hebben en je had toch altijd een aardig 
woordje over als ik er even doorheen zat met mijn motivatie. 
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Ook jij hebt het vertrouwen in mij nooit verloren en mede dankzij jou is mijn promotie 
alsnog tot een goed einde gekomen. Veel dank voor alles wat je voor me gedaan hebt!
Beste professor Vandertop, hoewel onze concrete samenwerking zich voornamelijk de 
laatste tijd, rond mijn promotie, heeft afgespeeld wil ik u ook graag bedanken voor 
de kans die u mij heeft gegeven om deze promotie bij neurochirurgie succesvol af 
te ronden. Ik hou van uw efficiëntie, zowel in uw woorden als uw daden. De snelheid 
waarmee u altijd handelt met revisies van manuscripten en dergelijke is alom geroemd! 
Als u bij gelegenheden de hele club toesprak, bleek wel degelijk dat u op de hoogte 
was van het reilen en zeilen binnen de NRG en u wist dat toch altijd subtiel maar 
raak aan te stippen. Ongetwijfeld is uw rol achter de schermen groter dan ik kan 
vermoeden en ik dank u daarvoor hartelijk.
Hoog- en Zeergeleerde opponenten van de leescommissie, Ik dank u hartelijk dat u 
mijn proefschrift op wetenschappelijke waarde heeft willen beoordelen en met mij 
van gedachten wilt wisselen over mijn werk. Professor Van Beusechem, beste Victor, 
ook aan jou heb ik veel te danken. Ik heb mijn eerste masterstage bij je mogen lopen 
en jij hebt me bij Tom voorgedragen om naar Boston te gaan. Het verloop van mijn 
wetenschappelijke carrière heb ik dus in eerste instantie aan jou te danken. Ik waardeer 
je nuchtere kijk op de zaken en dank je voor alles wat je voor me hebt betekend.
Ik bedank stichting STOPhersentumoren.nl en stichting VUMC CCA voor het financieel 
mogelijk maken van mijn onderzoek en hun onaflatende inzet om onderzoek naar 
kanker, en hersentumoren in het bijzonder, op alle mogelijke fronten te steunen. 
Jullie hulp is onontbeerlijk voor ons onderzoek. Klaske en Nico, de energie en het 
enthousiasme waarmee jullie stichting STOPhersentumoren.nl en alle gerelateerde 
evenementen vorm geven is werkelijk ongelofelijk!
Beste Esther, Bart, Daniëla, Xi Wen, Postdocs zijn de pijler waar het onderzoek op 
bouwt. Nu ben ik zelf ook aan de beurt om een serieuze duit in het zakje van de 
wetenschap te doen. Ik heb veel van jullie geleerd en had nog meer willen leren maar 
nu kan ik jullie alleen nog maar bedanken voor jullie hulp en samenwerking. Jullie zijn 
mijn voorbeeld. Esther, we zijn nu meer in elkaars onderzoeksrichting gevaren. Ik hoop 
dat we in de toekomst nog eens een leuk project met elkaar kunnen gaan opzetten! 
Beste Laurine, jij bent de labmoeder. Dat dekt, denk ik, de gehele lading wel. Ida, 
als Laurine de labmoeder is, ben jij onze tante. Zonder jullie zou er van onderzoeken 
weinig terecht komen. Niemand zou weten waar ‘ie wat moest vinden. Jullie staan 
altijd klaar voor iedereen met raad en daad en ik kan jullie niet genoeg bedanken voor 
alle hulp die jullie me in al die jaren hebben gegeven. 
Tjabba Jonas! Jij hebt mij op sleeptouw genomen in de eerste anderhalf jaar van 
mijn promotie. Door jou weet ik hoe gek je moet zijn voor de wetenschap. Elke 
nacht had je weer een nieuw, gek plan in je ideeënboek gekrabbeld en ik moest dan 
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uit jouw verhaal een soort eenvoudig destillaat hiervan zien te ontcijferen. Ik heb 
veel van je geleerd, en jouw creativiteit heeft een blijvende invloed gehad op mijn 
wetenschappelijke denkraam. Naast werk zijn we ook bevriend geraakt en hebben we 
vele avonturen beleefd, waarvan ik onze tocht op de Kungsleden en het bezoek aan 
de sauna’s aldaar het meeste herinner. Je bent een man van weinig woorden maar 
met een groot hart en hoewel je nu weer ver weg woont, hoop ik dat we elkaar bij 
gelegenheden blijven zien. 
Beste Chris, Ciao Viola! jullie waren mijn eerste collega PhD-lotgenoten en ik ben 
blij dat ik jullie heb mogen leren kennen. Jullie hebben mij laten zien hoe je een 
goede PhD student wordt en daarmee een goede postdoc. Ik heb natuurlijk ook van 
jullie veel geleerd op werk maar misschien nog meer daarbuiten. Dank voor jullie 
vriendschap en ik hoop jullie nog veel te zien in de toekomst. Het gaat jullie goed en 
ik wen jullie natuurlijk heel veel geluk met jullie kids (nee, niet van elkaar)! 
Beste collega’s in Boston e.o., Xandra, Bakhos, Johan, Casey, Jon en Flavia, dank voor 
een onvergetelijke en leerzame tijd in Boston. Hopelijk tot snel weer! 
Beste Myron, Susanna, Nik, Tonny, Ellen, Jasmina, Heleen, Edward, Francois, Piotr 
en Sjors. Met jullie is het altijd en overal gezellig en jullie hebben me vaak door een 
dalletje heengetrokken. Fijn dat jullie mijn collega’s wilden zijn!
Hey Ravi, Olà Jordi, Rogier, Topper! Joe Pep, Goedemiddag Hans. Ciao Rubina! Hai 
Maxime, vrienden. Jullie zijn zoveel meer dan collega’s. Zonder jullie had ik deze 
promotie nooit gered. Gelukkig (of misschien wel niet) konden we altijd op elkaar 
bouwen om onze ellende te verdrinken en weg te lachen. We hebben veel beleefd 
samen en ik ben blij dat ik jullie tot mijn vrienden mag beschouwen. Jullie zijn de besten! 
Beste Michiel, ze noemen ons Waldorf en Statler. Laten we het opnemen als een 
compliment. Desalniettemin, ik heb enorm met je kunnen lachen en ben blij dat we elkaar 
nog vaak zien en spreken. Zijn we toch nog goed terecht gekomen! Fijn dat we goede 
vrienden zijn geworden! Dank voor alle wijze lessen en mooie uitdrukkingen (tanende).
Beste Majid, Christiane, Paul, Kelly, Juriaan, Priya, Jeroen, Leonoor, Jeroen, Marjella, 
Arthur, Rifka, Kevin, Marieke, Matthijs, Elske. Vrienden van de peuterspeelzaal tot en 
met de middelbare school, enkelen erna pas. Jullie zijn mijn beste vrienden en hoewel 
we langzaamaan allemaal uitwaaien is onze vriendschap blijvend en, zoals ik het laatst 
aan Majid omschreef, heeft weinig onderhoud nodig. Als we elkaar weer zien na een 
lange tijd is het alsof de tijd heeft stilgestaan. Ouwe-jongens-krentenbrood!
Lieve Tomas en Marloes, mijn enige, echte broer en zus. Wat zijn we verschillend, 
maar wat lijken we verdomd veel op elkaar! Ik kan me mijn leven zonder jullie niet 
voorstellen. Hoewel we op onze eigen manier met elkaar omgaan, weet ik dat jullie 
er altijd voor me zijn en vergeet niet dat ik er ook altijd voor jullie zal zijn. Suzanne en 
Marc, jullie zijn ook leuk! Ik ben heel blij met jullie allemaal! 
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Lieve Oma, wat gaat het goed met u! Al 92 jaar, of was het alweer 93 jaar? En nog in zulke 
goede doen. Ik ben blij dat u hier in goede gezondheid bij ons bent en dat we nog zo 
goed kunnen praten en leuke dingen kunnen doen. U en opa hebben ons hele leven voor 
ons klaar gestaan en ik ben net zo blij met u, als u met ons. Dank voor alle steun en liefde!
Lieve Pappa, zouden de meesten zeggen. Ik zeg Henk. Dat heb ik altijd gedaan. Jij hebt 
ons altijd onvoorwaardelijk gesteund met alles wat we deden en doen. Je staat altijd 
klaar, komt altijd helpen met vanalles en doet altijd je best voor ons. We mopperen 
wel op je als je misschien wat onbehouwen bent, maar uiteindelijk mogen we in onze 
handen knijpen met jou als vader. Ik zal ook wel moeten, want ik lijk toch veel op je! 
Carla, ik ben blij dat Henk en jij elkaar hebben gevonden. Ook jij zet je onvoorwaardelijk 
voor mij en mijn broer en zus in en ook voor Henk ben je de enige juiste. Ik wens dat 
jullie nog lang gelukkig zijn met elkaar en lekker genieten van het leven als volleerde 
pensionado’s. Ok, nog net niet helemaal voor jou dan, Carla. Dank voor al jullie steun. 
Lieve Mamma, zouden de meesten zeggen. Ik zei Mieke. Dat heb ik altijd gedaan. Ik 
denk niet elke dag meer aan je. Zo gaat dat, alles slijt met de tijd. Toch blijf je altijd 
bij me en ben ik je dankbaar omdat ik door Henk en jou ben geworden wie ik ben. Ik 
denk ook dat ik door jou gefascineerd ben geraakt van de verwoestende gevolgen 
van kanker. Door jou sta ik hier nu. Wat zou je trots geweest zijn.
Lieve Lotte, jij bent het beste wat ik aan mijn promotie heb overgehouden! Ik geloof 
in jou en mij!
Is het toch nog een lang verhaal geworden… 
Sjoerd
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